CA3066317A1 - Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor - Google Patents
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor Download PDFInfo
- Publication number
- CA3066317A1 CA3066317A1 CA3066317A CA3066317A CA3066317A1 CA 3066317 A1 CA3066317 A1 CA 3066317A1 CA 3066317 A CA3066317 A CA 3066317A CA 3066317 A CA3066317 A CA 3066317A CA 3066317 A1 CA3066317 A1 CA 3066317A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- antibody
- antigen
- binding fragment
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 305
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 63
- 229940122392 PCSK9 inhibitor Drugs 0.000 title description 43
- 208000031226 Hyperlipidaemia Diseases 0.000 title description 6
- 239000000427 antigen Substances 0.000 claims abstract description 295
- 108091007433 antigens Proteins 0.000 claims abstract description 295
- 102000036639 antigens Human genes 0.000 claims abstract description 295
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 279
- 239000012634 fragment Substances 0.000 claims abstract description 276
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 209
- 102000004877 Insulin Human genes 0.000 claims abstract description 146
- 108090001061 Insulin Proteins 0.000 claims abstract description 146
- 229940125396 insulin Drugs 0.000 claims abstract description 141
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 105
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 65
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 46
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 40
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 168
- 238000011282 treatment Methods 0.000 claims description 159
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 147
- 229960004539 alirocumab Drugs 0.000 claims description 121
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 106
- 239000003112 inhibitor Substances 0.000 claims description 78
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 58
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 58
- 239000000556 agonist Substances 0.000 claims description 52
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 47
- 201000001320 Atherosclerosis Diseases 0.000 claims description 37
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 35
- 208000029078 coronary artery disease Diseases 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 32
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 31
- 230000003178 anti-diabetic effect Effects 0.000 claims description 26
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 25
- 239000003472 antidiabetic agent Substances 0.000 claims description 25
- 102100030970 Apolipoprotein C-III Human genes 0.000 claims description 23
- 102000004895 Lipoproteins Human genes 0.000 claims description 23
- 108090001030 Lipoproteins Proteins 0.000 claims description 23
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 21
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 21
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 21
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 20
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 20
- 239000005557 antagonist Substances 0.000 claims description 20
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 19
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 19
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims description 19
- 101710163236 Glucose-dependent insulinotropic receptor Proteins 0.000 claims description 19
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims description 19
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 19
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 claims description 19
- 108010057186 Insulin Glargine Proteins 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 17
- 229960002869 insulin glargine Drugs 0.000 claims description 17
- 229940125753 fibrate Drugs 0.000 claims description 16
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 16
- 229960003512 nicotinic acid Drugs 0.000 claims description 16
- 235000001968 nicotinic acid Nutrition 0.000 claims description 16
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 15
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 15
- 229960005370 atorvastatin Drugs 0.000 claims description 15
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 15
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 14
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 14
- 229960002027 evolocumab Drugs 0.000 claims description 14
- 229960000815 ezetimibe Drugs 0.000 claims description 14
- 229960002965 pravastatin Drugs 0.000 claims description 14
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 14
- 229960000672 rosuvastatin Drugs 0.000 claims description 14
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 14
- 229960002855 simvastatin Drugs 0.000 claims description 14
- 230000009885 systemic effect Effects 0.000 claims description 14
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 13
- 229960003765 fluvastatin Drugs 0.000 claims description 13
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 13
- 229960002797 pitavastatin Drugs 0.000 claims description 13
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 13
- 229940044601 receptor agonist Drugs 0.000 claims description 13
- 239000000018 receptor agonist Substances 0.000 claims description 13
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 claims description 12
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 12
- 229950011350 bococizumab Drugs 0.000 claims description 12
- 229960005110 cerivastatin Drugs 0.000 claims description 12
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 12
- 229950006208 lodelcizumab Drugs 0.000 claims description 12
- 229960004844 lovastatin Drugs 0.000 claims description 12
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 12
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 12
- 229950009885 ralpancizumab Drugs 0.000 claims description 12
- 229940044551 receptor antagonist Drugs 0.000 claims description 12
- 239000002464 receptor antagonist Substances 0.000 claims description 12
- 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 claims description 11
- 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 claims description 11
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 claims description 11
- 108010073961 Insulin Aspart Proteins 0.000 claims description 11
- 108010089308 Insulin Detemir Proteins 0.000 claims description 11
- 108010065920 Insulin Lispro Proteins 0.000 claims description 11
- 239000003524 antilipemic agent Substances 0.000 claims description 11
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 11
- 229960004717 insulin aspart Drugs 0.000 claims description 11
- 229960002068 insulin lispro Drugs 0.000 claims description 11
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims description 11
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims description 10
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims description 10
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 10
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 10
- 229940123208 Biguanide Drugs 0.000 claims description 10
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims description 10
- 101800001586 Ghrelin Proteins 0.000 claims description 10
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 10
- 102000030595 Glucokinase Human genes 0.000 claims description 10
- 108010021582 Glucokinase Proteins 0.000 claims description 10
- 102000001554 Hemoglobins Human genes 0.000 claims description 10
- 108010054147 Hemoglobins Proteins 0.000 claims description 10
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 10
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 10
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 10
- 108091006299 SLC2A2 Proteins 0.000 claims description 10
- 108091006300 SLC2A4 Proteins 0.000 claims description 10
- 229940100389 Sulfonylurea Drugs 0.000 claims description 10
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 10
- 102400000752 Xenin Human genes 0.000 claims description 10
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 10
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 10
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 10
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 10
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 claims description 10
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 10
- 108010050259 insulin degludec Proteins 0.000 claims description 10
- 229960004225 insulin degludec Drugs 0.000 claims description 10
- 229960003948 insulin detemir Drugs 0.000 claims description 10
- 108700039926 insulin glulisine Proteins 0.000 claims description 10
- 229960000696 insulin glulisine Drugs 0.000 claims description 10
- 229950004994 meglitinide Drugs 0.000 claims description 10
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 108010006643 xenin 25 Proteins 0.000 claims description 10
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 9
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940125827 GPR40 agonist Drugs 0.000 claims description 9
- 229940123232 Glucagon receptor agonist Drugs 0.000 claims description 9
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims description 9
- 229940123451 Somatostatin receptor 3 agonist Drugs 0.000 claims description 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 9
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 9
- 239000003626 gastrointestinal polypeptide Substances 0.000 claims description 9
- 229940125425 inverse agonist Drugs 0.000 claims description 9
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 9
- 206010002388 Angina unstable Diseases 0.000 claims description 8
- 208000007814 Unstable Angina Diseases 0.000 claims description 8
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 8
- 229940123483 GPR142 agonist Drugs 0.000 claims description 7
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 7
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 7
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 7
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 6
- 206010049768 Silent myocardial infarction Diseases 0.000 claims description 5
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims description 4
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 claims 6
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 claims 6
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 3
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 3
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 23
- 239000000902 placebo Substances 0.000 description 83
- 229940068196 placebo Drugs 0.000 description 83
- -1 bovine Chemical compound 0.000 description 63
- 238000012216 screening Methods 0.000 description 55
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 54
- 229940126602 investigational medicinal product Drugs 0.000 description 53
- 238000002347 injection Methods 0.000 description 52
- 239000007924 injection Substances 0.000 description 52
- 230000008859 change Effects 0.000 description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 38
- 150000002632 lipids Chemical class 0.000 description 34
- 230000009467 reduction Effects 0.000 description 33
- 210000004602 germ cell Anatomy 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 16
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 208000010668 atopic eczema Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 12
- 150000003626 triacylglycerols Chemical class 0.000 description 12
- 101710095342 Apolipoprotein B Proteins 0.000 description 11
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 11
- 230000009977 dual effect Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 10
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 10
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 10
- AIRYAONNMGRCGJ-FHFVDXKLSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC AIRYAONNMGRCGJ-FHFVDXKLSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000020832 chronic kidney disease Diseases 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 238000012549 training Methods 0.000 description 10
- WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000172 allergic effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 9
- 239000004026 insulin derivative Substances 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000009850 completed effect Effects 0.000 description 8
- 102000053786 human PCSK9 Human genes 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 7
- 108010042126 Creatine kinase Proteins 0.000 description 7
- 108010033266 Lipoprotein(a) Proteins 0.000 description 7
- 102000057248 Lipoprotein(a) Human genes 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 102000025171 antigen binding proteins Human genes 0.000 description 7
- 108091000831 antigen binding proteins Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000001982 diacylglycerols Chemical class 0.000 description 7
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 206010022095 Injection Site reaction Diseases 0.000 description 6
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 5
- 108010011459 Exenatide Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 229940090047 auto-injector Drugs 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229960001093 lixisenatide Drugs 0.000 description 5
- 108010004367 lixisenatide Proteins 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000009597 pregnancy test Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 108010029667 pramlintide Proteins 0.000 description 4
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 230000001906 cholesterol absorption Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XFJAMQQAAMJFGB-ZQGJOIPISA-N (2s,3r,4r,5s,6r)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=C(CC=2C=C3OCCOC3=CC=2)C(CC)=CC=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XFJAMQQAAMJFGB-ZQGJOIPISA-N 0.000 description 2
- GCERFBKFVDLDKD-NRYJBHHQSA-N (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;3-(diaminomethylidene)-1,1-dimethylguanidine;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CN(C)C(=N)N=C(N)N.C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F GCERFBKFVDLDKD-NRYJBHHQSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 2
- PTIFVLOBVCIMKL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)cyclopropyl]-[1,2,4]triazolo[4,3-a]pyridin-8-yl]propan-2-ol Chemical compound N=1N=C2C(C(C)(O)C)=CC=CN2C=1C1(C=2C=CC(Cl)=CC=2)CC1 PTIFVLOBVCIMKL-UHFFFAOYSA-N 0.000 description 2
- CZGVOBIGEBDYTP-VSGBNLITSA-N 3-[[(3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2h-1$l^{6},4-benzothiazepin-8-yl]methylamino]pentanedioic acid Chemical compound C1([C@@H]2C3=CC(OC)=C(CNC(CC(O)=O)CC(O)=O)C=C3S(=O)(=O)C[C@@](N2)(CC)CCCC)=CC=CC=C1 CZGVOBIGEBDYTP-VSGBNLITSA-N 0.000 description 2
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 2
- 108010006229 Acetyl-CoA C-acetyltransferase Proteins 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 102000054930 Agouti-Related Human genes 0.000 description 2
- 101710127426 Agouti-related protein Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002905 Colesevelam Polymers 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 108010063919 Glucagon Receptors Proteins 0.000 description 2
- 102100040890 Glucagon receptor Human genes 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 102000005561 Human Isophane Insulin Human genes 0.000 description 2
- 108010084048 Human Isophane Insulin Proteins 0.000 description 2
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- 206010027525 Microalbuminuria Diseases 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101800001672 Peptide YY(3-36) Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- QNAZTOHXCZPOSA-UHFFFAOYSA-N Sobetirome Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OCC(O)=O)=CC=2C)C)=C1 QNAZTOHXCZPOSA-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 229940127104 WYE-155189 Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229960004733 albiglutide Drugs 0.000 description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 2
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 229960001152 colesevelam Drugs 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DBOBAIHRZONIPT-GHCHSQRSSA-N decanedioic acid;2,2-dimethyl-3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide Chemical compound OC(=O)CCCCCCCCC(O)=O.C=1C=C(OCCCNCC(C)(C)C(N)=O)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.C=1C=C(OCCCNCC(C)(C)C(N)=O)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DBOBAIHRZONIPT-GHCHSQRSSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940074619 diovan Drugs 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical group CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 description 2
- 229950011259 evogliptin Drugs 0.000 description 2
- 235000020937 fasting conditions Nutrition 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 150000002410 histidine derivatives Chemical class 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960003566 lomitapide Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 238000012633 nuclear imaging Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 2
- 229940125395 oral insulin Drugs 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 2
- 108010033693 saxagliptin Proteins 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229940099093 symlin Drugs 0.000 description 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 2
- 229950000034 teneligliptin Drugs 0.000 description 2
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 2
- 229950009970 tesofensine Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QUKZWYNGKYRRKE-RIKNOMPASA-N (1r,3r)-2-[(2r)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.C1C(C2)CC(C3)CC2(O)CC13[C@@H](N)C(=O)N1[C@@H](C#N)CC2C[C@H]21 QUKZWYNGKYRRKE-RIKNOMPASA-N 0.000 description 1
- PCOMIRCNMMNOAP-CQSZACIVSA-N (1s)-1-[5-[[3-(2-methylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol Chemical compound CC1=NC=CC=C1OC1=CC(SC=2N=CC=CC=2)=CN=C1NC1=NC([C@H](O)CO)=NS1 PCOMIRCNMMNOAP-CQSZACIVSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ZWASRJHIEFYJGL-BFUOFWGJSA-N (2r)-1,1,1-trifluoro-2-[3-[(2r)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl]sulfonylphenyl]propan-2-ol Chemical compound C([C@H]1C)N(C=2C(=CC(F)=CC=2)C(F)(F)F)CCN1S(=O)(=O)C1=CC=CC([C@@](C)(O)C(F)(F)F)=C1 ZWASRJHIEFYJGL-BFUOFWGJSA-N 0.000 description 1
- MSFZPBXAGPYVFD-NFBCFJMWSA-N (2r)-2-amino-3-[1-[3-[2-[2-[2-[4-[[(5s)-5,6-diamino-6-oxohexyl]amino]butylamino]-2-oxoethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound NC(=O)[C@@H](N)CCCCNCCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O MSFZPBXAGPYVFD-NFBCFJMWSA-N 0.000 description 1
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- BTCRKOKVYTVOLU-SJSRKZJXSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(OCCOC3CC3)=CC=2)=C1 BTCRKOKVYTVOLU-SJSRKZJXSA-N 0.000 description 1
- NPBCMXATLRCCLF-IRRLEISYSA-N (2s,4r)-4-[(3r,5s,6r,7r,8r,9s,10s,12s,13r,14s,17r)-6-ethyl-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2C[C@H](O)[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 NPBCMXATLRCCLF-IRRLEISYSA-N 0.000 description 1
- GQPYTJVDPQTBQC-KLQYNRQASA-N (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F GQPYTJVDPQTBQC-KLQYNRQASA-N 0.000 description 1
- JJKOQZHWYLMASZ-FJWDNACWSA-N (3s,7r,8r,9s,10r,13s,14s,17r)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3[C@@H](O)C=C21 JJKOQZHWYLMASZ-FJWDNACWSA-N 0.000 description 1
- MZZLGJHLQGUVPN-PVPMGCCUSA-N (4R,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one Chemical compound COC1=C(C=C(C(C)C)C(F)=C1)C1=C(CN2[C@H](C)[C@@H](OC2=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C(C=C1)C(F)(F)F MZZLGJHLQGUVPN-PVPMGCCUSA-N 0.000 description 1
- QIQSYARFOIKJJR-LUTWCBITSA-N (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoic acid;(4z,7z,10z,13z,16z)-docosa-4,7,10,13,16-pentaenoic acid;(7z,10z,13z,16z,19z)-docosa-7,10,13,16,19-pentaenoic acid;(6z,9z,12z,15z,18z)-henicosa-6,9,12,15,18-pentaenoic acid;(5z,8z,11z,14z,17z)-i Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O.CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O QIQSYARFOIKJJR-LUTWCBITSA-N 0.000 description 1
- TXNPQZGSVXLGGP-MMTVBGGISA-N (6s)-6-(2-hydroxy-2-methylpropyl)-3-[(1s)-1-[4-(1-methyl-2-oxopyridin-4-yl)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC(C)(C)O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C2=CC(=O)N(C)C=C2)=CC=CC=C1 TXNPQZGSVXLGGP-MMTVBGGISA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- OAAZMUGLOXGVNH-UHFFFAOYSA-N 1-(3-hydroxyazetidin-1-yl)-2-(6-hydroxy-2-phenyl-2-adamantyl)ethanone Chemical compound C1C(O)CN1C(=O)CC1(C=2C=CC=CC=2)C2CC(C3O)CC1CC3C2 OAAZMUGLOXGVNH-UHFFFAOYSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- VOGXDRFFBBLZBT-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O VOGXDRFFBBLZBT-AAQCHOMXSA-N 0.000 description 1
- NFTMKHWBOINJGM-UHFFFAOYSA-N 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole Chemical compound N1=CC(CC)=CN=C1N1CCC(C=2SC=C(COC=3C=CC(=CC=3)N3N=NN=C3)N=2)CC1 NFTMKHWBOINJGM-UHFFFAOYSA-N 0.000 description 1
- NNBGCSGCRSCFEA-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 NNBGCSGCRSCFEA-UHFFFAOYSA-N 0.000 description 1
- GXALXAKNHIROPE-UHFFFAOYSA-N 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid Chemical compound C1CC(CC(=O)O)CCC1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-UHFFFAOYSA-N 0.000 description 1
- AYKLXGCULGWUJX-UHFFFAOYSA-N 2-[5-chloro-2-[[1-[(3,4-difluorophenyl)methyl]-4-[(4-methylsulfonylphenyl)methyl]pyrrole-2-carbonyl]amino]-1,3-thiazol-4-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC1=CN(CC=2C=C(F)C(F)=CC=2)C(C(=O)NC=2SC(Cl)=C(CC(O)=O)N=2)=C1 AYKLXGCULGWUJX-UHFFFAOYSA-N 0.000 description 1
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- RZPAXNJLEKLXNO-UKNNTIGFSA-N 22-Hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C(O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-UKNNTIGFSA-N 0.000 description 1
- VPCSYAVXDAUHLT-UHFFFAOYSA-N 3-[3,5-dibromo-4-(4-hydroxy-3-propan-2-ylphenoxy)anilino]-3-oxopropanoic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(NC(=O)CC(O)=O)=CC=2Br)Br)=C1 VPCSYAVXDAUHLT-UHFFFAOYSA-N 0.000 description 1
- FODHWOBAQBTTFS-UHFFFAOYSA-N 3-[4-[2-(2-methylphenyl)ethynyl]phenyl]propanoic acid Chemical compound CC1=CC=CC=C1C#CC1=CC=C(CCC(O)=O)C=C1 FODHWOBAQBTTFS-UHFFFAOYSA-N 0.000 description 1
- OCNBSSLDAIWTKS-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-n,n-bis(cyclopropylmethyl)-8-methylquinolin-2-amine Chemical compound C1CC1CN(CC1CC1)C=1N=C2C(C)=CC=CC2=CC=1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OCNBSSLDAIWTKS-UHFFFAOYSA-N 0.000 description 1
- VUUUHLIHQHVLLE-UHFFFAOYSA-N 4-[(5-fluoropyridin-2-yl)methoxy]-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one Chemical compound C1=C2N(C)C=3CCNCC=3C2=CC=C1N(C(C=1)=O)C=CC=1OCC1=CC=C(F)C=N1 VUUUHLIHQHVLLE-UHFFFAOYSA-N 0.000 description 1
- XWBXJBSVYVJAMZ-UHFFFAOYSA-N 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic acid Chemical compound CC(C)(C)C1=C(C(=O)NC2C3CC4CC(C3)CC2C4)C=NN1C1=CC=C(C(O)=O)C=C1 XWBXJBSVYVJAMZ-UHFFFAOYSA-N 0.000 description 1
- RRZVGDGTWNQAPW-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile Chemical compound C1=NN(C)C=C1CCN1C(C=2C=CC(=CC=2)C#N)=C(C2=CN(C)N=C2)N=C1 RRZVGDGTWNQAPW-UHFFFAOYSA-N 0.000 description 1
- LGGPZDRLTDGYSQ-JADSYQMUSA-N 4-[[4-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OC[P@]3(=O)O[C@@H](CCO3)C=3C=C(Cl)C=CC=3)=CC=2C)C)=C1 LGGPZDRLTDGYSQ-JADSYQMUSA-N 0.000 description 1
- LUUMLYXKTPBTQR-UHFFFAOYSA-N 4-chloro-n-[5-methyl-2-(7h-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C(C)=CN=C(C(=O)C=2C=3C=CNC=3N=CN=2)C=1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical class C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- AYJRTVVIBJSSKN-UHFFFAOYSA-N 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(COC=3C=NC(=CC=3)C=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 AYJRTVVIBJSSKN-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-M 6,8-dioxo-6,7,8,9-tetrahydro-1H-purin-2-olate Chemical compound [N-]1C(=O)N=C2NC(=O)NC2=C1O LEHOTFFKMJEONL-UHFFFAOYSA-M 0.000 description 1
- CGAMDQCXAAOFSR-UHFFFAOYSA-N 8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1NC(Cl)=N2 CGAMDQCXAAOFSR-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 239000008498 ALS-L1023 Substances 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 description 1
- 108700041144 Angiopoietin-Like Protein 8 Proteins 0.000 description 1
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 description 1
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 1
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 description 1
- 101710085845 Angiopoietin-related protein 4 Proteins 0.000 description 1
- VWVKUNOPTJGDOB-BDHVOXNPSA-N Anhydrous tofogliflozin Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100460776 Arabidopsis thaliana NPY2 gene Proteins 0.000 description 1
- 101100460782 Arabidopsis thaliana NPY4 gene Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- 108010067611 BMS-962476 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- HEYVINCGKDONRU-UHFFFAOYSA-N Bupropion hydrochloride Chemical compound Cl.CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 HEYVINCGKDONRU-UHFFFAOYSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 1
- GFEUVUBEKDDAHT-QNDXFWAVSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CCOCCOCCOCCOC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CCOCCOCCOCCOC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC GFEUVUBEKDDAHT-QNDXFWAVSA-N 0.000 description 1
- 108010002025 CER-001 Proteins 0.000 description 1
- 108010055448 CJC 1131 Proteins 0.000 description 1
- 108010007056 CKGGRAKDC-GG-D(KLAKLAK)2 Proteins 0.000 description 1
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010043222 Exubera Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101710154531 G-protein coupled bile acid receptor 1 Proteins 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 208000035451 General disorders and administration site conditions Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010058940 Glutamyl Aminopeptidase Proteins 0.000 description 1
- 102000006485 Glutamyl Aminopeptidase Human genes 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 1
- 101000887427 Homo sapiens Probable G-protein coupled receptor 142 Proteins 0.000 description 1
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 description 1
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010083928 MDCO-216 Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- FLOSMHQXBMRNHR-QPJJXVBHSA-N Methazolamide Chemical compound CC(=O)\N=C1\SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-QPJJXVBHSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 108010036875 ORMD-0801 Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108700005984 PP 1420 Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100039861 Probable G-protein coupled receptor 142 Human genes 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 1
- 102000013272 Renalase Human genes 0.000 description 1
- 108010090629 Renalase Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 101150055528 SPAM1 gene Proteins 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102000004117 Somatostatin receptor 3 Human genes 0.000 description 1
- 108090000674 Somatostatin receptor 3 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 208000034786 Suspected transmission of an infectious agent via product Diseases 0.000 description 1
- 229940127103 TKS-1225 Drugs 0.000 description 1
- 229940127105 TT-401 Drugs 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 102100033121 Transcription factor 21 Human genes 0.000 description 1
- 101710119687 Transcription factor 21 Proteins 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- YDTUJCNTIMWHPJ-NRFANRHFSA-N [(1r)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3-yl]-2-methoxyphenoxy]-1-cyclopropylethyl] dihydrogen phosphate Chemical compound C1([C@@H](OP(O)(O)=O)COC2=CC=C(C=C2OC)N2C(C=3SC(=CC=3N=C2)C=2C=CC(Cl)=CC=2)=O)CC1 YDTUJCNTIMWHPJ-NRFANRHFSA-N 0.000 description 1
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 1
- WNWXXAPGHTVCDL-OKDJMAGBSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 WNWXXAPGHTVCDL-OKDJMAGBSA-N 0.000 description 1
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940023375 adipex-p Drugs 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940034653 advicor Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229940078883 afrezza Drugs 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940074323 antara Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003705 antithrombocytic agent Substances 0.000 description 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940058087 atacand Drugs 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 229940034406 atorvastatin / ezetimibe Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- ZEZFKUBILQRZCK-MJSCXXSSSA-N beloranib Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=2C=CC(OCCN(C)C)=CC=2)C[C@@]21CO2 ZEZFKUBILQRZCK-MJSCXXSSSA-N 0.000 description 1
- 229950009345 beloranib Drugs 0.000 description 1
- 229940120049 belviq Drugs 0.000 description 1
- HYHMLYSLQUKXKP-UHFFFAOYSA-N bempedoic acid Chemical compound OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O HYHMLYSLQUKXKP-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229940014641 bydureon Drugs 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- WGEWUYACXPEFPO-AULYBMBSSA-N chembl2016681 Chemical compound C1C[C@@H](NS(=O)(=O)C(C)(C)C)CC[C@@H]1C(=O)NC1=CC=C(C(F)(F)F)C=N1 WGEWUYACXPEFPO-AULYBMBSSA-N 0.000 description 1
- GXALXAKNHIROPE-QAQDUYKDSA-N chembl2364624 Chemical compound C1C[C@@H](CC(=O)O)CC[C@@H]1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-QAQDUYKDSA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229960005049 clofibride Drugs 0.000 description 1
- CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical compound CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940012193 contrave Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940015838 cycloset Drugs 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229950004181 dalcetrapib Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229950004456 darapladib Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPUQGCOBYOXAED-UHFFFAOYSA-N diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)(C(=O)OCC)COC(=O)CC(C=C1C(=O)N(C)C)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 FPUQGCOBYOXAED-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- ICFXZZFWRWNZMA-UHFFFAOYSA-N diethylpropion hydrochloride Chemical compound [Cl-].CC[NH+](CC)C(C)C(=O)C1=CC=CC=C1 ICFXZZFWRWNZMA-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 229940035000 epanova Drugs 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- AKFNKZFJBFQFAA-DIOPXHOYSA-N ethyl 4-[[2-[(2s,4s)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]bicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC(C(=O)OCC)(CC2)CCC12NCC(=O)N1C[C@@H](F)C[C@H]1C#N AKFNKZFJBFQFAA-DIOPXHOYSA-N 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 229950000005 evacetrapib Drugs 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940012151 exubera Drugs 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229940004151 fluvastatin 80 mg Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- AIWAEWBZDJARBJ-PXUUZXDZSA-N fz7co35x2s Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(C=CC1=O)=O)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 AIWAEWBZDJARBJ-PXUUZXDZSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229950005743 granotapide Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 229940062714 humalog mix Drugs 0.000 description 1
- 229940084776 humulin n Drugs 0.000 description 1
- 229940084769 humulin r Drugs 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- GFICWFZTBXUVIG-SCSAIBSYSA-N imeglimin Chemical compound C[C@H]1NC(N(C)C)=NC(N)=N1 GFICWFZTBXUVIG-SCSAIBSYSA-N 0.000 description 1
- 229950005411 imeglimin Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229950010567 insulin tregopil Drugs 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZIPLFLRGHZAXSJ-UHFFFAOYSA-N isoquinoline-5-carboxylic acid Chemical compound N1=CC=C2C(C(=O)O)=CC=CC2=C1 ZIPLFLRGHZAXSJ-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940103445 janumet Drugs 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940103465 juvisync Drugs 0.000 description 1
- 229940103513 kazano Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 108010000849 leukocyte esterase Proteins 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 229940044185 lipofen Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940034394 liptruzet Drugs 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 1
- 229950007685 lobeglitazone Drugs 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229940080794 lovastatin 20 mg Drugs 0.000 description 1
- 229940080803 lovastatin 40 mg Drugs 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108700008455 metreleptin Proteins 0.000 description 1
- 229960000668 metreleptin Drugs 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 229940101564 micardis Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WDPFJWLDPVQCAJ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5h-cyclopenta[d]pyrimidin-1-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=2CCCC=2C(=O)N=C(SCC=2C=CC(F)=CC=2)N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 WDPFJWLDPVQCAJ-UHFFFAOYSA-N 0.000 description 1
- CFKBNYUHQSQBSX-UHFFFAOYSA-N n-[2-[[1-[4-hydroxy-4-(1,3-thiazol-5-yl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound C1CC(O)(C=2SC=NC=2)CCC1N(C1)CC1NC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 CFKBNYUHQSQBSX-UHFFFAOYSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 230000001607 nephroprotective effect Effects 0.000 description 1
- 229940117337 nesina Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 229940098815 novolin n Drugs 0.000 description 1
- 229940098893 novolin r Drugs 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 229960001199 olmesartan medoxomil Drugs 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 229940001450 onglyza Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229940000596 parlodel Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 229940083256 peripheral vasodilators nicotinic acid and derivative Drugs 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- AZUIUVJESCFSLJ-UHFFFAOYSA-N phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C(C(F)(F)F)C=CC=1C=1C(OC)=CC=CC=1C(=O)NC(C=C1CC2)=CC=C1CN2C(=O)OC1=CC=CC=C1 AZUIUVJESCFSLJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229940092966 pitavastatin 1 mg Drugs 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical group [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- CJMKTEIIPMBTJB-DXFHJFHKSA-M potassium;[(2r,3r,4s,5r,6r)-6-[[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-5-yl]phenyl]carbamoylamino]-3,5-dihydroxy-4-phenylmethoxyoxan-2-yl]methyl sulfate Chemical compound [K+].O([C@H]1[C@H](O)[C@@H](COS([O-])(=O)=O)O[C@H]([C@@H]1O)NC(=O)NC=1C=CC=C(C=1)[C@@H]1C2=CC(=CC=C2S(=O)(=O)C[C@@]([C@@H]1O)(CC)CCCC)N(C)C)CC1=CC=CC=C1 CJMKTEIIPMBTJB-DXFHJFHKSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229950002887 pradigastat Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000016670 prohibitin Human genes 0.000 description 1
- 108010028138 prohibitin Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- WPDCHTSXOPUOII-UHFFFAOYSA-N propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC2CCN(CC2)C(=O)OC(C)C)C(OC)=C1NC1=CC=C(S(C)(=O)=O)N=C1C WPDCHTSXOPUOII-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 229940126844 remogliflozin Drugs 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 229950004360 rilapladib Drugs 0.000 description 1
- 229960000804 ronifibrate Drugs 0.000 description 1
- AYJVGKWCGIYEAK-UHFFFAOYSA-N ronifibrate Chemical compound C=1C=CN=CC=1C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 AYJVGKWCGIYEAK-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 1
- 229950006544 saroglitazar Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940126842 sergliflozin Drugs 0.000 description 1
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229940103449 simcor Drugs 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950007873 sobetirome Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940034887 tenuate Drugs 0.000 description 1
- 229940078806 teveten Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940049667 tradjenta Drugs 0.000 description 1
- 229940127279 trajenta Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- WUJVPODXELZABP-FWJXURDUSA-N trodusquemine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 description 1
- 229950004499 trodusquemine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- BHLXTPHDSZUFHR-UHFFFAOYSA-N varespladib Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1 BHLXTPHDSZUFHR-UHFFFAOYSA-N 0.000 description 1
- 229950006583 varespladib Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229950006508 velneperit Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229940009349 vytorin Drugs 0.000 description 1
- PNAMDJVUJCJOIX-XVZWKFLSSA-N vytorin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-XVZWKFLSSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
- 229940061639 zonegran Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229940018503 zyban Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provided are methods for treating high cardiovascular risk patients with hypercholesterolemia and type 1 or type 2 diabetes mellitus receiving insulin therapy. These methods generally comprise administering to a patient a pharmaceutical composition comprising an antibody or antigen binding fragment, thereof, which specifically binds hPCSK9 antibody, in combination with insulin therapy.
Description
METHODS FOR TREATING HYPERLIPIDEMIA
RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/517,672, filed June 9,2017, U.S. Provisional Patent Application No.
62/532,162, filed July 13, 2017, and European Patent Application No. 18305565.6, filed May 4, 2018. The contents of each of these related applications are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/517,672, filed June 9,2017, U.S. Provisional Patent Application No.
62/532,162, filed July 13, 2017, and European Patent Application No. 18305565.6, filed May 4, 2018. The contents of each of these related applications are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of therapeutic treatments of diseases and disorders which are associated with elevated levels of lipids and lipoproteins. More specifically, the invention relates to the use of PCSK9 inhibitors to treat diabetic patients with hyperlipidemia, including hypercholesterolemia.
BACKGROUND
BACKGROUND
[0003] Hyperlipidemia is a general term that encompasses diseases and disorders characterized by or associated with elevated levels of lipids and/or lipoproteins in the blood.
Hyperlipidemias include hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia, and elevated lipoprotein a (Lp(a)). A particular prevalent form of hyperlipidemia in many populations is hypercholesterolemia.
Hyperlipidemias include hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia, and elevated lipoprotein a (Lp(a)). A particular prevalent form of hyperlipidemia in many populations is hypercholesterolemia.
[0004] Hypercholesterolemia, particularly an increase in low-density lipoprotein (LDL) cholesterol (LDL-C) levels, constitutes a major risk for the development of atherosclerosis and coronary heart disease (CHD) (Sharrett et al., 2001, Circulation 104:1108-1113). Low-density lipoprotein cholesterol is identified as the primary target of cholesterol lowering therapy and is accepted as a valid surrogate therapeutic endpoint. Numerous studies have demonstrated that reducing LDL-C levels reduces the risk of CHD with a strong direct relationship between LDL-C levels and CHD events; for each 1 mmol/L (-40 mg/dL) reduction in LDL-C, cardiovascular disease (CVD) mortality and morbidity is lowered by 22%. Greater reductions in LDL-C produce greater reduction in CHD events, and comparative data of intensive versus standard statin treatment suggest that the lower the LDL-C level, the greater the benefit in patients at very high cardiovascular (CV) risk.
[0005] Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with type 1 (Ti) or type 2 (T2) diabetes mellitus (DM), and insulin-treated diabetic patients have an even higher CV risk. Furthermore, the presence of comorbid DM
among those who have atherosclerotic CVD (ASCVD) significantly increases the risk of CV events.
Several studies and meta-analyses have shown that lowering LDL-C using statins leads to significant reductions in CV events in DM patients, with further CV risk reduction associated with additional LDL-C-lowering using concomitant ezetimibe. However, even with the currently available treatments, many patients with DM continue to have persistent lipid abnormalities and are therefore exposed to a residual risk of CV events.
among those who have atherosclerotic CVD (ASCVD) significantly increases the risk of CV events.
Several studies and meta-analyses have shown that lowering LDL-C using statins leads to significant reductions in CV events in DM patients, with further CV risk reduction associated with additional LDL-C-lowering using concomitant ezetimibe. However, even with the currently available treatments, many patients with DM continue to have persistent lipid abnormalities and are therefore exposed to a residual risk of CV events.
[0006] Current LDL-C-lowering medications include proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as anti-PCSK9 antibodies. Although anti-PCSK9 antibodies have undergone extensive clinical investigation, the efficacy and safety of alirocumab in the diabetic population are not fully understood. Thus, there is a need in the art to identify treatment regimens for anti-PCSK9 antibodies that provide optimal efficacy and safety for the treatment of hypercholesterolemia in diabetic patients receiving insulin therapy who are at high CV risk.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0007] The instant disclosure provides methods for treating hypercholesterolemia in a patient with diabetes mellitus (DM) receiving insulin therapy. In certain embodiments, the methods comprise administering one or more doses of an antibody or an antigen-binding fragment thereof which specifically binds human PCSK9 to a patient with hypercholesterolemia and diabetes. In certain embodiments, the patient has a high cardiovascular risk. In certain embodiments, the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
[0008] According to one aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM , and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg, or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM , and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg, or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[0009] In certain embodiments, 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[0010] In certain embodiments, the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1/6. In certain embodiments, the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof competes for binding with an antibody or antigen-binding fragment thereof that comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO:
6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof competes for binding with an antibody or antigen-binding fragment thereof that comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO:
6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
[0011] In certain embodiments, the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:
86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99%
identical to the amino acid sequence set forth in SEQ ID NO:85, and an LCVR
having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99%
identical to the amino acid sequence set forth in SEQ ID NO:85, and an LCVR
having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
[0012] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014. In certain embodiments, the antibody or antigen-binding fragment thereof is alirocumab.
[0013] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0014] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0015] In certain embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0016] In certain embodiments, the patient further receives a concomitant lipid-modifying therapy (LMT). In certain embodiments, the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant. In certain embodiments, the LMT is a statin therapy. In certain embodiments, the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin. In certain embodiments, the statin therapy is a maximally tolerated dose statin therapy.
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.ln certain embodiments, the patient is intolerant to a statin.
.. [0017] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin,In certain embodiments, the patient further receives a further concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of a .. glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0018] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 25%, 30%, 35%, or 40%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient (e.g., by at least about 6.0%, about 6.5%, about 7.0% or about 7.5% after 12 or 24 weeks of treatment). In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number of lipoprotein particles in the patient (e.g., by at least 5 about 20%, about 30%, about 40% or about 50%% after 12 or 24 weeks of treatment). In other embodiments, the antibody or antigen-binding fragment thereof reduces the size of lipoprotein particles in the patient (e.g., by at least about 1.5%, about 2%, about 2.5%, or about 3% after 12 0r24 weeks of treatment).
[0019] In certain embodiments, the antibody or antigen-binding fragment thereof (a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0020] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9);
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0021] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every four weeks to the patient 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, after 8 weeks, the LDL-C level in the patient is higher than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, after 8 weeks, the LDL-C level in the patient is lower than or equal to the threshold level, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
In one embodiment, the threshold level is 15 mg/dL. In another embodiment, the threshold level is 25 mg/dL.
[0022] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM) , the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg, or 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[0023] In certain embodiments, 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[0024] In certain embodiments, the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1/6. In certain embodiments, the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof competes for binding with an antibody or antigen-binding fragment thereof that comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO:
6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
[0025] In certain embodiments, the antibody or antigen binding fragment thereof comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising the amino acid sequences set forth in SEQ ID NOs: 85 and 89, respectively. In certain embodiments, the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ
ID NO:85, and an LCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
[0026] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014. In certain embodiments, the antibody or antigen-binding fragment thereof is alirocumab.
[0027] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0028] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0029] In certain embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0030] In certain embodiments, the patient further receives a concomitant lipid-modifying therapy (LMT). In certain embodiments, the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant. In certain embodiments, the LMT is a statin therapy. In certain embodiments, the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin. In certain embodiments, the statin therapy is a maximally tolerated dose statin therapy.
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.
[0031] In certain embodiments, the patient is intolerant to a statin.
[0032] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin, [0033] In certain embodiments, the patient further receives a concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0034] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 20%, 25%, 30%, or 35%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient (e.g., by at least about 6.0%, about 6.5%, about 7.0% or about 7.5% after 12 or 24 weeks of treatment). In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number of lipoprotein particles in the patient (e.g., by at least about 20%, about 30%, about 40% or about 50%% after 12 or 24 weeks of treatment). In other embodiments, the antibody or antigen-binding fragment thereof reduces the size of lipoprotein particles in the patient (e.g., by at least about 1.5%, about 2%, about 2.5%, or about 3% after 12 0r24 weeks of treatment).
[0035] In certain embodiments, the antibody or antigen-binding fragment thereof: (a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0036] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9);
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0037] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every four weeks to the patient 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, after 8 weeks, the LDL-C level in the patient is higher than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, after 8 weeks, the LDL-C level in the patient is lower than or equal to the threshold level, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
In one embodiment, the threshold level is 15 mg/dL. In another embodiment, the threshold level is 5 25 mg/dL.
[0038] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with T2DM and atherosclerotic cardiovascular disease (ASCVD), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) 10 ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[0039] In certain embodiments, the ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease. In certain embodiments, the CHD comprises acute myocardial infarction, silent myocardial infarction, and unstable angina.
[0040] In certain embodiments, the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In certain embodiments, the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In certain embodiments, the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[0041] In certain embodiments, the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1/6. In certain embodiments, the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID
NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
[0042] In certain embodiments, the antibody or antigen binding fragment thereof comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising the amino acid sequences set forth in SEQ ID NOs: 85 and 89, respectively. In certain embodiments, the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ
ID NO:85, and an LCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
[0043] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014. In certain embodiments, the antibody or antigen-binding fragment thereof is alirocumab.
[0044] In certain embodiments, the method further comprises:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[0045] In certain embodiments, the method further comprises:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[0046] In certain embodiments, the threshold level is 70 mg/dL.
[0047] In certain embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0048] In certain embodiments, the patient further receives a concomitant lipid-modifying therapy (LMT). In certain embodiments, the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant. In certain embodiments, the LMT is a statin therapy. In certain embodiments, the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin. In certain embodiments, the statin therapy is a maximally tolerated dose statin therapy.
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.
[0049] In certain embodiments, the patient is intolerant to a statin.
[0050] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin. In certain embodiments, the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0051] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 20%, 25%, 30%, 35%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient. In certain embodiments, the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0052] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with T2DM and ASCVD, the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or .. antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0053] Other embodiments will become apparent from a review of the ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES
[0054] Figure 1 is a diagram illustrating the overall design of the main phase of the study described in Example 2 herein. The study includes a screening period, a double-blinded treatment period, and a safety observation period.
[0055] Figure 2 is a graph showing the LS means (+/-SE) of percent change of calculated LDL-C levels from baseline in the ITT population of patients with Type 1 Diabetes as per IVRS. Least-squares (LS) means and standard errors (SE) were taken from mixed-effect model with repeated measures (MMRM) analysis. The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline-by-time point interaction. MMRM
model was run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
[0056] Figure 3 is a graph showing the LS means (+/-SE) of percent change of calculated LDL-C levels from baseline in the ITT population of patients with Type 2 Diabetes as per IVRS. Least-squares (LS) means and standard errors (SE) were taken from mixed-effect model with repeated measures (MMRM) analysis. The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline-by-time point interaction. MMRM
model was run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
[0057] Figure 4 is a graph showing the percentage changes from baseline to Week 24 in non-HDL-C, LDL-C, ApoB, and LDL-PN in the ITT population with Type 2 Diabetes and ASCVD.
[0058] Figure 5 is a graph showing the percentages of individuals achieving non-HDL-C <
100 mg/dL, LDL-C < 70 mg/dL, and ApoB < 80 mg/dL at Week 24 in the ITT
population with Type 2 Diabetes and ASCVD.
DETAILED DESCRIPTION
[0059] The methods are not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present methods will be limited only by the appended claims.
[0060] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0061] Although any methods and materials similar or equivalent to those described herein can be used, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to describe in their entirety.
Methods for Treating a Patient with Hypercholesterolemia and Diabetes on Insulin Therapy [0062] Provided are methods and compositions for treating diabetic patients with hypercholesterolemia on insulin therapy. According to certain embodiments, these methods result in a reduction of lipoprotein levels (e.g., LDL-C and/or Lp(a)) in the serum of such patients.
[0063] The present disclosure also provides a PCSK9 inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PCSK9 (e.g., human PCSK9) or a composition comprising the PCSK9 inhibitor for use in treating a diabetic patients with hypercholesterolemia on insulin therapy. In certain embodiments, the PCSK9 inhibitor or composition is useful in reducing the levels of lipoprotein (e.g., LDL-C
and/or Lp(a)) in the serum of such patients.
[0064] As used herein, the term "lipoprotein" means a biomolecular particle containing both protein and lipid. Examples of lipoproteins include, e.g., low density lipoprotein (LDL), very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and lipoprotein (a) (Lp(a)).
[0065] Diabetes mellitus, often simply called diabetes, is a group of metabolic diseases in which a person has high blood sugar levels, either because the body does not produce 5 enough insulin, or because cells do not respond to the insulin that is produced. The most common types of diabetes are: (1) type 1 diabetes, where the body fails to produce insulin;
(2) type 2 diabetes, where the body fails to use insulin properly, combined with an increase in insulin deficiency over time; and (3) gestational diabetes, where women develop diabetes due to their pregnancy. All forms of diabetes increase the risk of long-term complications, 10 which typically develop after many years. Most of these long-term complications are based on damage to blood vessels and can be divided into the two categories "macrovascular"
disease, arising from atherosclerosis of larger blood vessels and "microvascular" disease, arising from damage of small blood vessels. Examples for macrovascular disease conditions are ischemic heart disease, myocardial infarction, stroke and peripheral vascular 15 disease. Examples for microvascular diseases are diabetic retinopathy, diabetic nephropathy, as well as diabetic neuropathy.
[0066] According to certain embodiments, the patient to be treated has type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) and is receiving insulin therapy. In certain embodiments, the patient has been diagnosed with Ti DM or T2DM for at least one year. In certain embodiments, the patient was diagnosed with Ti DM prior to the age of 30 years. In certain embodiments, the T1DM patient has a C-peptide level lower than 0.2 pmol/mL. . In certain embodiments, the patient has a glycosylated hemoglobin (HbA1c) level lower than 10%.
[0067] According to certain embodiments, the patient to be treated has hypercholesterolemia not adequately controlled by a lipid modifying therapy (LMT).
Hypercholesterolemia is considered not to be adequately controlled by an LMT
if serum LDL-C concentrations in patient are not reduced to a recognized, medically-acceptable level, e.g., less than 70 mg/dL, (taking into account the patient's relative risk of coronary heart disease) after at least 4 weeks on the LMT. In certain embodiments, the LMT is a maximally tolerated statin therapy. As used herein, "maximally tolerated statin therapy"
means the highest dose of statin that can be administered to a patient without causing unacceptable adverse side effects in that patient. For example, the methods disclosed herein include treating a patient with Ti DM or T2DM who has hypercholesterolemia that is not adequately controlled by a daily dose of a statin selected from the group consisting of atorvastatin (including atorvastatin + ezetimibe), rosuvastatin, cerivastatin, pitavastatin, fluvastatin, lovastatin, simvastatin (including simvastatin + ezetimibe), pravastatin, and combinations thereof. In certain embodiments, a patient does not receive a concomitant statin therapy if the patient is intolerant to this therapy. Statin intolerant patients may have, for example, skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that begin or increase during statin therapy and stopped when statin therapy is discontinued.
Patient Selection [0068] The present methods and compositions are useful for treating patients who have hypercholesterolemia and diabetes and are receiving insulin therapy. The patient to be treated may also exhibit one or more of additional selection criteria. For example, a patient may be selected for treatment if the patient has a calculated LDL-C level greater than or equal to 70 mg/dL, 100 mg/dL, or 130 mg/dL. The patient may be treated with an maximally tolerated dose of statin, optionally in combination with at least one other lipid modifying therapy (LMT) for at least 4 weeks, or wherein the patient has been treated with optimal dose of at least one non-statin LMT for at least 4 weeks if the patient is statin intolerant. The maximally tolerated dose of statin can be defined, for example, as the dose prescribed based on regional practice or local guidelines or is the dose that is maximally tolerated due to adverse effects on higher doses as specified in the local prescribing information for pediatric patients. Statin intolerance can be defined, for example, as inability to tolerate at least 2 statins: one statin at the lowest daily starting dose, and another statin at any dose, due to skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that began or increased during statin therapy and stopped when statin therapy was discontinued. Patients not receiving a daily regimen of a statin (e.g., 1 to 3 times weekly) are also considered as not able to tolerate a daily dose.
[0069] Additionally, a patient may be selected for treatment if the patient has a high cardiovascular (CV) risk. In certain embodiments, the high CV risk patient has a documented history of cardiovascular disease (CVD) and/or at least one additional CV risk factor. CVD includes without limitation coronary heart disease (CHD) and CHD
risk equivalents. CHD includes without limitation acute myocardial infarction (MI), silent MI, unstable angina, coronary revascularization procedure (e.g., percutaneuous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)), and clinically significant CHD (e.g., diagnosed by invasive or noninvasive testing, such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging). CHD
risk equivalents include without limitation peripheral arterial disease (e.g., as described in the inclusion criteria of Example 2) and previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, of atherothrombotic origin. CV risk factors include without limitation hypertension, current cigarette smoking, age 45 years for
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.ln certain embodiments, the patient is intolerant to a statin.
.. [0017] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin,In certain embodiments, the patient further receives a further concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of a .. glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0018] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 25%, 30%, 35%, or 40%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient (e.g., by at least about 6.0%, about 6.5%, about 7.0% or about 7.5% after 12 or 24 weeks of treatment). In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number of lipoprotein particles in the patient (e.g., by at least 5 about 20%, about 30%, about 40% or about 50%% after 12 or 24 weeks of treatment). In other embodiments, the antibody or antigen-binding fragment thereof reduces the size of lipoprotein particles in the patient (e.g., by at least about 1.5%, about 2%, about 2.5%, or about 3% after 12 0r24 weeks of treatment).
[0019] In certain embodiments, the antibody or antigen-binding fragment thereof (a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0020] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9);
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0021] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) Ti DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every four weeks to the patient 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, after 8 weeks, the LDL-C level in the patient is higher than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, after 8 weeks, the LDL-C level in the patient is lower than or equal to the threshold level, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
In one embodiment, the threshold level is 15 mg/dL. In another embodiment, the threshold level is 25 mg/dL.
[0022] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM) , the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg, or 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[0023] In certain embodiments, 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In other embodiments, 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[0024] In certain embodiments, the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1/6. In certain embodiments, the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof competes for binding with an antibody or antigen-binding fragment thereof that comprises an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID
NO:
6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
[0025] In certain embodiments, the antibody or antigen binding fragment thereof comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising the amino acid sequences set forth in SEQ ID NOs: 85 and 89, respectively. In certain embodiments, the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ
ID NO:85, and an LCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
[0026] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014. In certain embodiments, the antibody or antigen-binding fragment thereof is alirocumab.
[0027] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0028] In certain embodiments, the method disclosed herein further comprises (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to the threshold level. In certain embodiments, the threshold level is 70 mg/dL.
[0029] In certain embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0030] In certain embodiments, the patient further receives a concomitant lipid-modifying therapy (LMT). In certain embodiments, the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant. In certain embodiments, the LMT is a statin therapy. In certain embodiments, the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin. In certain embodiments, the statin therapy is a maximally tolerated dose statin therapy.
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.
[0031] In certain embodiments, the patient is intolerant to a statin.
[0032] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin, [0033] In certain embodiments, the patient further receives a concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0034] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 20%, 25%, 30%, or 35%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient (e.g., by at least about 6.0%, about 6.5%, about 7.0% or about 7.5% after 12 or 24 weeks of treatment). In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number of lipoprotein particles in the patient (e.g., by at least about 20%, about 30%, about 40% or about 50%% after 12 or 24 weeks of treatment). In other embodiments, the antibody or antigen-binding fragment thereof reduces the size of lipoprotein particles in the patient (e.g., by at least about 1.5%, about 2%, about 2.5%, or about 3% after 12 0r24 weeks of treatment).
[0035] In certain embodiments, the antibody or antigen-binding fragment thereof: (a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0036] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9);
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C
level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, e.g., after 8 weeks, the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0037] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every four weeks to the patient 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if, after 8 weeks, the LDL-C level in the patient is higher than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if, after 8 weeks, the LDL-C level in the patient is lower than or equal to the threshold level, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
In one embodiment, the threshold level is 15 mg/dL. In another embodiment, the threshold level is 5 25 mg/dL.
[0038] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with T2DM and atherosclerotic cardiovascular disease (ASCVD), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) 10 ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[0039] In certain embodiments, the ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease. In certain embodiments, the CHD comprises acute myocardial infarction, silent myocardial infarction, and unstable angina.
[0040] In certain embodiments, the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In certain embodiments, the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks. In certain embodiments, the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[0041] In certain embodiments, the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1/6. In certain embodiments, the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising an HCVR having the amino acid sequence of SEQ ID
NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the antibody or antigen-binding fragment thereof binds to an epitope on PCSK9 that overlaps with the epitope of an antibody comprising an HCVR having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6.
[0042] In certain embodiments, the antibody or antigen binding fragment thereof comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising the amino acid sequences set forth in SEQ ID NOs: 85 and 89, respectively. In certain embodiments, the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs: 86, 87, 88, 90, 91, and 92. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ
ID NO:85, and an LCVR having an amino acid sequence at least 90%, 95%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:89.
[0043] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014. In certain embodiments, the antibody or antigen-binding fragment thereof is alirocumab.
[0044] In certain embodiments, the method further comprises:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[0045] In certain embodiments, the method further comprises:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[0046] In certain embodiments, the threshold level is 70 mg/dL.
[0047] In certain embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously.
[0048] In certain embodiments, the patient further receives a concomitant lipid-modifying therapy (LMT). In certain embodiments, the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant. In certain embodiments, the LMT is a statin therapy. In certain embodiments, the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin. In certain embodiments, the statin therapy is a maximally tolerated dose statin therapy.
In certain embodiments, the cholesterol absorption inhibitor is ezetimibe.
[0049] In certain embodiments, the patient is intolerant to a statin.
[0050] In certain embodiments, the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin. In certain embodiments, the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy. In certain embodiments, the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[0051] In certain embodiments, the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient, e.g., by at least 30%, 35%, 40%, or 45%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the non-HDL-C
level of the patient, e.g., by at least 20%, 25%, 30%, 35%. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient. In certain embodiments, the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient. In certain embodiments, the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[0052] According to another aspect, the methods comprise a method for treating hypercholesterolemia in a patient with T2DM and ASCVD, the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or .. antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[0053] Other embodiments will become apparent from a review of the ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES
[0054] Figure 1 is a diagram illustrating the overall design of the main phase of the study described in Example 2 herein. The study includes a screening period, a double-blinded treatment period, and a safety observation period.
[0055] Figure 2 is a graph showing the LS means (+/-SE) of percent change of calculated LDL-C levels from baseline in the ITT population of patients with Type 1 Diabetes as per IVRS. Least-squares (LS) means and standard errors (SE) were taken from mixed-effect model with repeated measures (MMRM) analysis. The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline-by-time point interaction. MMRM
model was run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
[0056] Figure 3 is a graph showing the LS means (+/-SE) of percent change of calculated LDL-C levels from baseline in the ITT population of patients with Type 2 Diabetes as per IVRS. Least-squares (LS) means and standard errors (SE) were taken from mixed-effect model with repeated measures (MMRM) analysis. The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline-by-time point interaction. MMRM
model was run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
[0057] Figure 4 is a graph showing the percentage changes from baseline to Week 24 in non-HDL-C, LDL-C, ApoB, and LDL-PN in the ITT population with Type 2 Diabetes and ASCVD.
[0058] Figure 5 is a graph showing the percentages of individuals achieving non-HDL-C <
100 mg/dL, LDL-C < 70 mg/dL, and ApoB < 80 mg/dL at Week 24 in the ITT
population with Type 2 Diabetes and ASCVD.
DETAILED DESCRIPTION
[0059] The methods are not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present methods will be limited only by the appended claims.
[0060] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0061] Although any methods and materials similar or equivalent to those described herein can be used, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to describe in their entirety.
Methods for Treating a Patient with Hypercholesterolemia and Diabetes on Insulin Therapy [0062] Provided are methods and compositions for treating diabetic patients with hypercholesterolemia on insulin therapy. According to certain embodiments, these methods result in a reduction of lipoprotein levels (e.g., LDL-C and/or Lp(a)) in the serum of such patients.
[0063] The present disclosure also provides a PCSK9 inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PCSK9 (e.g., human PCSK9) or a composition comprising the PCSK9 inhibitor for use in treating a diabetic patients with hypercholesterolemia on insulin therapy. In certain embodiments, the PCSK9 inhibitor or composition is useful in reducing the levels of lipoprotein (e.g., LDL-C
and/or Lp(a)) in the serum of such patients.
[0064] As used herein, the term "lipoprotein" means a biomolecular particle containing both protein and lipid. Examples of lipoproteins include, e.g., low density lipoprotein (LDL), very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and lipoprotein (a) (Lp(a)).
[0065] Diabetes mellitus, often simply called diabetes, is a group of metabolic diseases in which a person has high blood sugar levels, either because the body does not produce 5 enough insulin, or because cells do not respond to the insulin that is produced. The most common types of diabetes are: (1) type 1 diabetes, where the body fails to produce insulin;
(2) type 2 diabetes, where the body fails to use insulin properly, combined with an increase in insulin deficiency over time; and (3) gestational diabetes, where women develop diabetes due to their pregnancy. All forms of diabetes increase the risk of long-term complications, 10 which typically develop after many years. Most of these long-term complications are based on damage to blood vessels and can be divided into the two categories "macrovascular"
disease, arising from atherosclerosis of larger blood vessels and "microvascular" disease, arising from damage of small blood vessels. Examples for macrovascular disease conditions are ischemic heart disease, myocardial infarction, stroke and peripheral vascular 15 disease. Examples for microvascular diseases are diabetic retinopathy, diabetic nephropathy, as well as diabetic neuropathy.
[0066] According to certain embodiments, the patient to be treated has type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) and is receiving insulin therapy. In certain embodiments, the patient has been diagnosed with Ti DM or T2DM for at least one year. In certain embodiments, the patient was diagnosed with Ti DM prior to the age of 30 years. In certain embodiments, the T1DM patient has a C-peptide level lower than 0.2 pmol/mL. . In certain embodiments, the patient has a glycosylated hemoglobin (HbA1c) level lower than 10%.
[0067] According to certain embodiments, the patient to be treated has hypercholesterolemia not adequately controlled by a lipid modifying therapy (LMT).
Hypercholesterolemia is considered not to be adequately controlled by an LMT
if serum LDL-C concentrations in patient are not reduced to a recognized, medically-acceptable level, e.g., less than 70 mg/dL, (taking into account the patient's relative risk of coronary heart disease) after at least 4 weeks on the LMT. In certain embodiments, the LMT is a maximally tolerated statin therapy. As used herein, "maximally tolerated statin therapy"
means the highest dose of statin that can be administered to a patient without causing unacceptable adverse side effects in that patient. For example, the methods disclosed herein include treating a patient with Ti DM or T2DM who has hypercholesterolemia that is not adequately controlled by a daily dose of a statin selected from the group consisting of atorvastatin (including atorvastatin + ezetimibe), rosuvastatin, cerivastatin, pitavastatin, fluvastatin, lovastatin, simvastatin (including simvastatin + ezetimibe), pravastatin, and combinations thereof. In certain embodiments, a patient does not receive a concomitant statin therapy if the patient is intolerant to this therapy. Statin intolerant patients may have, for example, skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that begin or increase during statin therapy and stopped when statin therapy is discontinued.
Patient Selection [0068] The present methods and compositions are useful for treating patients who have hypercholesterolemia and diabetes and are receiving insulin therapy. The patient to be treated may also exhibit one or more of additional selection criteria. For example, a patient may be selected for treatment if the patient has a calculated LDL-C level greater than or equal to 70 mg/dL, 100 mg/dL, or 130 mg/dL. The patient may be treated with an maximally tolerated dose of statin, optionally in combination with at least one other lipid modifying therapy (LMT) for at least 4 weeks, or wherein the patient has been treated with optimal dose of at least one non-statin LMT for at least 4 weeks if the patient is statin intolerant. The maximally tolerated dose of statin can be defined, for example, as the dose prescribed based on regional practice or local guidelines or is the dose that is maximally tolerated due to adverse effects on higher doses as specified in the local prescribing information for pediatric patients. Statin intolerance can be defined, for example, as inability to tolerate at least 2 statins: one statin at the lowest daily starting dose, and another statin at any dose, due to skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that began or increased during statin therapy and stopped when statin therapy was discontinued. Patients not receiving a daily regimen of a statin (e.g., 1 to 3 times weekly) are also considered as not able to tolerate a daily dose.
[0069] Additionally, a patient may be selected for treatment if the patient has a high cardiovascular (CV) risk. In certain embodiments, the high CV risk patient has a documented history of cardiovascular disease (CVD) and/or at least one additional CV risk factor. CVD includes without limitation coronary heart disease (CHD) and CHD
risk equivalents. CHD includes without limitation acute myocardial infarction (MI), silent MI, unstable angina, coronary revascularization procedure (e.g., percutaneuous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)), and clinically significant CHD (e.g., diagnosed by invasive or noninvasive testing, such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging). CHD
risk equivalents include without limitation peripheral arterial disease (e.g., as described in the inclusion criteria of Example 2) and previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, of atherothrombotic origin. CV risk factors include without limitation hypertension, current cigarette smoking, age 45 years for
17 men and 55 years for women, history of micro/macroalbuminuria, history of diabetic retinopathy, family history of premature CHD (in father or brother before 55 years of age; in mother or sister before 65 years of age), low HDL-C (male <40 mg/dL [1.0 mmol/L] and female <50 mg/dL [1.3 mmol/L]), and documented chronic kidney disease (CKD) (e.g., as defined in the inclusion criteria of Example 2).
[0070] In certain embodiments, the high CV risk patient has atherosclerotic cardiovascular disease (ASCVD). In certain embodiments, ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease. In certain embodiments, the CHD
comprises acute myocardial infarction, silent myocardial infarction, and unstable angina. In certain embodiments, the CHD is defined as acute myocardial infarction, silent myocardial infarction, or unstable angina.
Insulin Therapy [0071] As indicated herein, diabetic patients selected for treatment with the methods of the invention have received, and continue to receive, insulin therapy comprising insulin or its derivatives. Insulins on the market differ in the origin of the insulin (e.g., bovine, porcine, human insulin) and also in their composition, whereby the profile of action (onset of action and duration of action) can be influenced. By combining different insulin products it is possible to obtain a wide variety of profiles of action and to set blood sugar levels which are as close as possible to physiological. Exemplary insulin therapies may include naturally-occurring insulin, such as human insulin, as well as modified insulins with an extended duration of action, such as insulin glargine (Gly(A21)-Arg(B31)-Arg(B32) human insulin, e.g., Lantus ). Insulin glargine is injected as an acidic, clear solution and, on account of its solution properties in the physiological pH range of the subcutaneous tissue, is precipitated as a stable hexamer associate. Insulin glargine is injected once daily and is notable over .. other long-activity insulins for its flat serum profile and the associated reduction in the risk of nocturnal hypoglycemias (Schubert-Zsilavecz et al., 2:125-130 (2001)). Insulin glargine may be administered at concentrations higher than 100U/mL, e.g. 270 - 330U/mL
of insulin glargine or 300U/mL of insulin glargine (as disclosed in EP 2387989), Other exemplary insulin therapies include: insulin glulisine (e.g. Apidre), insulin detemir (e.g. Levemir ), insulin lispro (e.g. Humalog , Liproloe), insulin degludec (e.g. DegludecPlus , IdegLira (NN9068)), insulin aspart and aspart formulations (e.g. NovoLog ), basal insulin and analogues (e.g. LY2605541, LY2963016, NN1436), PEGylated insulin lispro (e.g.
LY-275585), long-acting insulins (e.g. NN1436, Insumera (PE0139), AB-101, AB-102, Sensulin LLC), intermediate-acting insulins (e.g. Humulin N, Novolin N), fast-acting and short-acting insulins (e.g. Humulin R, Novolin R, Linjeta (VIAjece), PH20 insulin, NN1218, HinsBet ),
[0070] In certain embodiments, the high CV risk patient has atherosclerotic cardiovascular disease (ASCVD). In certain embodiments, ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease. In certain embodiments, the CHD
comprises acute myocardial infarction, silent myocardial infarction, and unstable angina. In certain embodiments, the CHD is defined as acute myocardial infarction, silent myocardial infarction, or unstable angina.
Insulin Therapy [0071] As indicated herein, diabetic patients selected for treatment with the methods of the invention have received, and continue to receive, insulin therapy comprising insulin or its derivatives. Insulins on the market differ in the origin of the insulin (e.g., bovine, porcine, human insulin) and also in their composition, whereby the profile of action (onset of action and duration of action) can be influenced. By combining different insulin products it is possible to obtain a wide variety of profiles of action and to set blood sugar levels which are as close as possible to physiological. Exemplary insulin therapies may include naturally-occurring insulin, such as human insulin, as well as modified insulins with an extended duration of action, such as insulin glargine (Gly(A21)-Arg(B31)-Arg(B32) human insulin, e.g., Lantus ). Insulin glargine is injected as an acidic, clear solution and, on account of its solution properties in the physiological pH range of the subcutaneous tissue, is precipitated as a stable hexamer associate. Insulin glargine is injected once daily and is notable over .. other long-activity insulins for its flat serum profile and the associated reduction in the risk of nocturnal hypoglycemias (Schubert-Zsilavecz et al., 2:125-130 (2001)). Insulin glargine may be administered at concentrations higher than 100U/mL, e.g. 270 - 330U/mL
of insulin glargine or 300U/mL of insulin glargine (as disclosed in EP 2387989), Other exemplary insulin therapies include: insulin glulisine (e.g. Apidre), insulin detemir (e.g. Levemir ), insulin lispro (e.g. Humalog , Liproloe), insulin degludec (e.g. DegludecPlus , IdegLira (NN9068)), insulin aspart and aspart formulations (e.g. NovoLog ), basal insulin and analogues (e.g. LY2605541, LY2963016, NN1436), PEGylated insulin lispro (e.g.
LY-275585), long-acting insulins (e.g. NN1436, Insumera (PE0139), AB-101, AB-102, Sensulin LLC), intermediate-acting insulins (e.g. Humulin N, Novolin N), fast-acting and short-acting insulins (e.g. Humulin R, Novolin R, Linjeta (VIAjece), PH20 insulin, NN1218, HinsBet ),
18 premixed insulins, SuliXen , NN1045, insulin plus Symlin , PE-0139, ACP-002 hydrogel insulin, and oral, inhalable, transdermal and buccal or sublingual insulins (e.g. Exubera , Nasulin , Afrezza , insulin tregopil, TPM-02 insulin, Capsulin , Cobalamin oral insulin, ORMD-0801, Oshadi oral insulin, NN1953, NN1954, NN1956, VIAtab ).
Also suitable are those insulin derivatives which are bonded to albumin or another protein by a bifunctional linker.
PCSK9 Inhibitors [0072] The methods comprise administering to a patient a therapeutic composition comprising a PCSK9 inhibitor. As used herein, a "PCSK9 inhibitor" is any agent which binds to or interacts with human PCSK9 and inhibits the normal biological function of PCSK9 in vitro or in vivo. Non-limiting examples of categories of PCSK9 inhibitors include small molecule PCSK9 antagonists, nucleic acid-based inhibitors of PCSK9 expression or activity (e.g., siRNA or antisense), peptide-based molecules that specifically interact with PCSK9 (e.g., peptibodies), receptor molecules that specifically interact with PCSK9, proteins comprising a ligand-binding portion of an LDL receptor, PCSK9-binding scaffold molecules (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, fibronectin-based scaffold constructs, and other scaffolds based on naturally occurring repeat proteins, etc., [see, e.g., Boersma and Pluckthun, 2011, CUM
Opin. Biotechnol. 22:849-857, and references cited therein]), and anti-PCSK9 aptamers or portions thereof. According to certain embodiments, PCSK9 inhibitors that can be used in the context of the present methods are anti-PCSK9 antibodies or antigen-binding fragments of antibodies that specifically bind human PCSK9.
[0073] The term "human proprotein convertase subtilisin/kexin type 9" or "human PCSK9"
or "hPCSK9", as used herein, refers to PCSK9 having the nucleic acid sequence shown in SEQ ID NO:197 and the amino acid sequence of SEQ ID NO:198, or a biologically active fragment thereof.
[0074] The term "antibody", as used herein, is intended to refer to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions
Also suitable are those insulin derivatives which are bonded to albumin or another protein by a bifunctional linker.
PCSK9 Inhibitors [0072] The methods comprise administering to a patient a therapeutic composition comprising a PCSK9 inhibitor. As used herein, a "PCSK9 inhibitor" is any agent which binds to or interacts with human PCSK9 and inhibits the normal biological function of PCSK9 in vitro or in vivo. Non-limiting examples of categories of PCSK9 inhibitors include small molecule PCSK9 antagonists, nucleic acid-based inhibitors of PCSK9 expression or activity (e.g., siRNA or antisense), peptide-based molecules that specifically interact with PCSK9 (e.g., peptibodies), receptor molecules that specifically interact with PCSK9, proteins comprising a ligand-binding portion of an LDL receptor, PCSK9-binding scaffold molecules (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, fibronectin-based scaffold constructs, and other scaffolds based on naturally occurring repeat proteins, etc., [see, e.g., Boersma and Pluckthun, 2011, CUM
Opin. Biotechnol. 22:849-857, and references cited therein]), and anti-PCSK9 aptamers or portions thereof. According to certain embodiments, PCSK9 inhibitors that can be used in the context of the present methods are anti-PCSK9 antibodies or antigen-binding fragments of antibodies that specifically bind human PCSK9.
[0073] The term "human proprotein convertase subtilisin/kexin type 9" or "human PCSK9"
or "hPCSK9", as used herein, refers to PCSK9 having the nucleic acid sequence shown in SEQ ID NO:197 and the amino acid sequence of SEQ ID NO:198, or a biologically active fragment thereof.
[0074] The term "antibody", as used herein, is intended to refer to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions
19 (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments, the FRs of the anti-PCSK9 antibody (or antigen-binding portion thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0075] The term "antibody," as used herein, also includes antigen-binding fragments of full antibody molecules. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA
encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
[0076] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g.
monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.
[0077] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a VH domain associated with a VL domain, the VH and VL domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
[0078] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
Non-limiting, 5 exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody include: (i) VH-CH1; (ii) VH-CH2;
(iii) VH-CH3; (iv) VH-CH1-CH2, (V) VH-CH1-CH2-CH3, VH-CH2-CH3, (Vii) VH-CL, (Viii) VL-CH1, (ix) VL-CH2, (X) VL-CH3; (Xi) VcCH1-CH2; (Xii) VL-CH1-CH2-CH3; VcCH2-CH3; and (xiv) VL-CL. In any configuration of variable and constant domains, including any of the exemplary 10 configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A
hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody may 15 comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric VH or VL domain (e.g., by disulfide bond(s)).
[0079] As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will
[0075] The term "antibody," as used herein, also includes antigen-binding fragments of full antibody molecules. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA
encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
[0076] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g.
monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.
[0077] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a VH domain associated with a VL domain, the VH and VL domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
[0078] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
Non-limiting, 5 exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody include: (i) VH-CH1; (ii) VH-CH2;
(iii) VH-CH3; (iv) VH-CH1-CH2, (V) VH-CH1-CH2-CH3, VH-CH2-CH3, (Vii) VH-CL, (Viii) VL-CH1, (ix) VL-CH2, (X) VL-CH3; (Xi) VcCH1-CH2; (Xii) VL-CH1-CH2-CH3; VcCH2-CH3; and (xiv) VL-CL. In any configuration of variable and constant domains, including any of the exemplary 10 configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A
hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody may 15 comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric VH or VL domain (e.g., by disulfide bond(s)).
[0079] As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will
20 typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present methods using routine techniques available in the art.
[0080] The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.
[0081] The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
[0080] The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.
[0081] The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
21 [0082] The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL
sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0083] Human antibodies can exist in two forms that are associated with hinge heterogeneity. In one form, an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond. In a second form, the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody). These forms have been extremely difficult to separate, even after affinity purification.
[0084] The frequency of appearance of the second form in various intact IgG
isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form (Angal et al.
(1993) Molecular Immunology 30:105) to levels typically observed using a human IgG1 hinge. The instant methods encompass antibodies having one or more mutations in the hinge, CH2 or region which may be desirable, for example, in production, to improve the yield of the desired antibody form.
[0085] An "isolated antibody," as used herein, means an antibody that has been identified and separated and/or recovered from at least one component of its natural environment.
For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an "isolated antibody" for purposes of the present methods. An isolated antibody also includes an antibody in situ within a recombinant cell.
Isolated antibodies are antibodies that have been subjected to at least one purification or isolation
sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0083] Human antibodies can exist in two forms that are associated with hinge heterogeneity. In one form, an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond. In a second form, the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody). These forms have been extremely difficult to separate, even after affinity purification.
[0084] The frequency of appearance of the second form in various intact IgG
isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form (Angal et al.
(1993) Molecular Immunology 30:105) to levels typically observed using a human IgG1 hinge. The instant methods encompass antibodies having one or more mutations in the hinge, CH2 or region which may be desirable, for example, in production, to improve the yield of the desired antibody form.
[0085] An "isolated antibody," as used herein, means an antibody that has been identified and separated and/or recovered from at least one component of its natural environment.
For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an "isolated antibody" for purposes of the present methods. An isolated antibody also includes an antibody in situ within a recombinant cell.
Isolated antibodies are antibodies that have been subjected to at least one purification or isolation
22 step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and/or chemicals.
[0086] The term "specifically binds," or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that "specifically binds"
PCSK9, as used in the context of the present methods, includes antibodies that bind PCSK9 or portion thereof with a KD of less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon resonance assay. An isolated antibody that specifically binds human PCSK9, however, has cross-reactivity to other antigens, such as PCSK9 molecules from other (non-human) species.
[0087] The anti-PCSK9 antibodies useful for the present methods may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR
regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The methods include the use of antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are .. referred to herein collectively as "germline mutations"). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the VH and/or VL domains are mutated back to the residues found in the original germline sequence from which the antibody was derived.
In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or
[0086] The term "specifically binds," or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that "specifically binds"
PCSK9, as used in the context of the present methods, includes antibodies that bind PCSK9 or portion thereof with a KD of less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon resonance assay. An isolated antibody that specifically binds human PCSK9, however, has cross-reactivity to other antigens, such as PCSK9 molecules from other (non-human) species.
[0087] The anti-PCSK9 antibodies useful for the present methods may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR
regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The methods include the use of antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are .. referred to herein collectively as "germline mutations"). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the VH and/or VL domains are mutated back to the residues found in the original germline sequence from which the antibody was derived.
In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or
23 within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and/or CDR
residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
.. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. The use of antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present methods.
[0088] The methods include the use of anti-PCSK9 antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present methods include the use of anti-PCSK9 antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
[0089] The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BlAcore TM system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
[0090] The term "KD ", as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.
[0091] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A
single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects.
Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.
[0092] According to certain embodiments, the anti-PCSK9 antibody used in the methods is
residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence.
.. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. The use of antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present methods.
[0088] The methods include the use of anti-PCSK9 antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present methods include the use of anti-PCSK9 antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
[0089] The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BlAcore TM system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
[0090] The term "KD ", as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.
[0091] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A
single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects.
Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.
[0092] According to certain embodiments, the anti-PCSK9 antibody used in the methods is
24 an antibody with pH-dependent binding characteristics. As used herein, the expression "pH-dependent binding" means that the antibody or antigen-binding fragment thereof exhibits "reduced binding to PCSK9 at acidic pH as compared to neutral pH"
(for purposes of the present disclosure, both expressions may be used interchangeably). For the example, "antibodies with pH-dependent binding characteristics" includes antibodies and antigen-binding fragments thereof that bind PCSK9 with higher affinity at neutral pH than at acidic pH. In certain embodiments, the antibodies and antigen-binding fragments bind PCSK9 with at least 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more times higher affinity at neutral pH than at acidic pH.
[0093] According to this aspect, the anti-PCSK9 antibodies with pH-dependent binding characteristics may possess one or more amino acid variations relative to the parental anti-PCSK9 antibody. For example, an anti-PCSK9 antibody with pH-dependent binding characteristics may contain one or more histidine substitutions or insertions, e.g., in one or more CDRs of a parental anti-PCSK9 antibody. Thus, according to certain embodiments, methods are provided comprising administering an anti-PCSK9 antibody which comprises CDR amino acid sequences (e.g., heavy and light chain CDRs) which are identical to the CDR amino acid sequences of a parental anti-PCSK9 antibody, except for the substitution of one or more amino acids of one or more CDRs of the parental antibody with a histidine residue. The anti-PCSK9 antibodies with pH-dependent binding may possess, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or more histidine substitutions, either within a single CDR
of a parental antibody or distributed throughout multiple (e.g., 2, 3, 4, 5, or 6) CDRs of a parental anti-PCSK9 antibody. For example, the present methods include the use of anti-PCSK9 antibodies with pH-dependent binding comprising one or more histidine substitutions in HCDR1, one or more histidine substitutions in HCDR2, one or more histidine substitutions in HCDR3, one or more histidine substitutions in LCDR1, one or more histidine substitutions in LCDR2, and/or one or more histidine substitutions in LCDR3, of a parental anti-PCSK9 antibody.
[0094] As used herein, the expression "acidic pH" means a pH of 6.0 or less (e.g., less than about 6.0, less than about 5.5, less than about 5.0, etc.). The expression "acidic pH"
includes pH values of about 6.0, 5.95, 5.90, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. As used herein, the expression "neutral pH" means a pH of about 7.0 to about 7.4. The expression "neutral pH"
includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0095] Non-limiting examples of anti-PCSK9 antibodies that can be used in the context of the present methods include, e.g., alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, LY3015014, or antigen-binding portions of any of the foregoing antibodies.
Preparation of Human Antibodies [0096] Methods for generating human antibodies in transgenic mice are known in the art.
Any such known methods can be used in the context of the present methods to make human antibodies that specifically bind to human PCSK9.
5 [0097] Using VELOCIMMUNETm technology (see, for example, US 6,596,541, Regeneron Pharmaceuticals) or any other known method for generating monoclonal antibodies, high affinity chimeric antibodies to PCSK9 are initially isolated having a human variable region and a mouse constant region. The VELOCIMMUNE technology involves generation of a transgenic mouse having a genome comprising human heavy and light chain variable 10 regions operably linked to endogenous mouse constant region loci such that the mouse produces an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation. The DNA encoding the variable regions of the heavy and light chains of the antibody are isolated and operably linked to DNA encoding the human heavy and light chain constant regions. The DNA is then expressed in a cell capable of 15 expressing the fully human antibody.
[0098] Generally, a VELOCIMMUNE mouse is challenged with the antigen of interest, and lymphatic cells (such as B-cells) are recovered from the mice that express antibodies.
The lymphatic cells may be fused with a myeloma cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma 20 cell lines that produce antibodies specific to the antigen of interest.
DNA encoding the variable regions of the heavy chain and light chain may be isolated and linked to desirable isotypic constant regions of the heavy chain and light chain. Such an antibody protein may be produced in a cell, such as a CHO cell. Alternatively, DNA encoding the antigen-specific chimeric antibodies or the variable domains of the light and heavy chains may be isolated
(for purposes of the present disclosure, both expressions may be used interchangeably). For the example, "antibodies with pH-dependent binding characteristics" includes antibodies and antigen-binding fragments thereof that bind PCSK9 with higher affinity at neutral pH than at acidic pH. In certain embodiments, the antibodies and antigen-binding fragments bind PCSK9 with at least 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more times higher affinity at neutral pH than at acidic pH.
[0093] According to this aspect, the anti-PCSK9 antibodies with pH-dependent binding characteristics may possess one or more amino acid variations relative to the parental anti-PCSK9 antibody. For example, an anti-PCSK9 antibody with pH-dependent binding characteristics may contain one or more histidine substitutions or insertions, e.g., in one or more CDRs of a parental anti-PCSK9 antibody. Thus, according to certain embodiments, methods are provided comprising administering an anti-PCSK9 antibody which comprises CDR amino acid sequences (e.g., heavy and light chain CDRs) which are identical to the CDR amino acid sequences of a parental anti-PCSK9 antibody, except for the substitution of one or more amino acids of one or more CDRs of the parental antibody with a histidine residue. The anti-PCSK9 antibodies with pH-dependent binding may possess, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or more histidine substitutions, either within a single CDR
of a parental antibody or distributed throughout multiple (e.g., 2, 3, 4, 5, or 6) CDRs of a parental anti-PCSK9 antibody. For example, the present methods include the use of anti-PCSK9 antibodies with pH-dependent binding comprising one or more histidine substitutions in HCDR1, one or more histidine substitutions in HCDR2, one or more histidine substitutions in HCDR3, one or more histidine substitutions in LCDR1, one or more histidine substitutions in LCDR2, and/or one or more histidine substitutions in LCDR3, of a parental anti-PCSK9 antibody.
[0094] As used herein, the expression "acidic pH" means a pH of 6.0 or less (e.g., less than about 6.0, less than about 5.5, less than about 5.0, etc.). The expression "acidic pH"
includes pH values of about 6.0, 5.95, 5.90, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. As used herein, the expression "neutral pH" means a pH of about 7.0 to about 7.4. The expression "neutral pH"
includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0095] Non-limiting examples of anti-PCSK9 antibodies that can be used in the context of the present methods include, e.g., alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, LY3015014, or antigen-binding portions of any of the foregoing antibodies.
Preparation of Human Antibodies [0096] Methods for generating human antibodies in transgenic mice are known in the art.
Any such known methods can be used in the context of the present methods to make human antibodies that specifically bind to human PCSK9.
5 [0097] Using VELOCIMMUNETm technology (see, for example, US 6,596,541, Regeneron Pharmaceuticals) or any other known method for generating monoclonal antibodies, high affinity chimeric antibodies to PCSK9 are initially isolated having a human variable region and a mouse constant region. The VELOCIMMUNE technology involves generation of a transgenic mouse having a genome comprising human heavy and light chain variable 10 regions operably linked to endogenous mouse constant region loci such that the mouse produces an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation. The DNA encoding the variable regions of the heavy and light chains of the antibody are isolated and operably linked to DNA encoding the human heavy and light chain constant regions. The DNA is then expressed in a cell capable of 15 expressing the fully human antibody.
[0098] Generally, a VELOCIMMUNE mouse is challenged with the antigen of interest, and lymphatic cells (such as B-cells) are recovered from the mice that express antibodies.
The lymphatic cells may be fused with a myeloma cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma 20 cell lines that produce antibodies specific to the antigen of interest.
DNA encoding the variable regions of the heavy chain and light chain may be isolated and linked to desirable isotypic constant regions of the heavy chain and light chain. Such an antibody protein may be produced in a cell, such as a CHO cell. Alternatively, DNA encoding the antigen-specific chimeric antibodies or the variable domains of the light and heavy chains may be isolated
25 directly from antigen-specific lymphocytes.
[0099] Initially, high affinity chimeric antibodies are isolated having a human variable region and a mouse constant region. The antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc, using standard procedures known to those skilled in the art. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody, for example wild-type or modified IgG1 or IgG4. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.
[00100]In general, the antibodies that can be used possess high affinities, as described above, when measured by binding to antigen either immobilized on solid phase or in solution phase. The mouse constant regions are replaced with desired human constant regions to generate the fully human antibodies. While the constant region selected may
[0099] Initially, high affinity chimeric antibodies are isolated having a human variable region and a mouse constant region. The antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc, using standard procedures known to those skilled in the art. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody, for example wild-type or modified IgG1 or IgG4. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.
[00100]In general, the antibodies that can be used possess high affinities, as described above, when measured by binding to antigen either immobilized on solid phase or in solution phase. The mouse constant regions are replaced with desired human constant regions to generate the fully human antibodies. While the constant region selected may
26 vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.
[00101]Specific examples of human antibodies or antigen-binding fragments of antibodies that specifically bind PCSK9 which can be used in the context of the methods include any antibody or antigen-binding fragment which comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID
NOs:1 and 11, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. Alternatively, specific examples of human antibodies or antigen-binding fragments of antibodies that specifically bind PCSK9 which can be used in the context of the methods include any antibody or antigen-binding fragment which comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs 37, 45, 53, 61, 69, 77, 85, 93, 101, 109, 117, 125, 133, 141, 149, 157, 165, 173, 181, and 189, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. The antibody or antigen-binding fragment may comprise the three light chain CDRs (LCVR1, LCVR2, LCVR3) contained within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs 6 and 15, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99%
sequence identity. Alternatively, the antibody or antigen-binding fragment may comprise the three light chain CDRs (LCVR1, LCVR2, LCVR3) contained within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ
ID NOs 41, 49, 57, 65, 73, 81, 89, 97, 105, 113, 121, 129, 137, 145, 153, 161, 169, 177, 185, and 193, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[00102]Sequence identity between two amino acids sequences is determined over the entire length of the reference amino acid sequence, i.e. the amino acid sequence identified with a SEQ ID NO, using the best sequence alignment and/or over the region of the best sequence alignment between the two amino acid sequences, wherein the best sequence alignment can be obtained with art known tools, e.g. Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[00103]In certain embodiments, the antibody or antigen-binding protein comprises the six CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3) from the heavy and light .. chain variable region amino acid sequence pairs (HCVR/LCVR) selected from the group consisting of SEQ ID NOs:1/6 and 11/15. Alternatively, in certain embodiments, the antibody or antigen-binding protein comprises the six CDRs (HCDR1, HCDR2, HCDR3,
[00101]Specific examples of human antibodies or antigen-binding fragments of antibodies that specifically bind PCSK9 which can be used in the context of the methods include any antibody or antigen-binding fragment which comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID
NOs:1 and 11, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. Alternatively, specific examples of human antibodies or antigen-binding fragments of antibodies that specifically bind PCSK9 which can be used in the context of the methods include any antibody or antigen-binding fragment which comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs 37, 45, 53, 61, 69, 77, 85, 93, 101, 109, 117, 125, 133, 141, 149, 157, 165, 173, 181, and 189, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity. The antibody or antigen-binding fragment may comprise the three light chain CDRs (LCVR1, LCVR2, LCVR3) contained within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs 6 and 15, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99%
sequence identity. Alternatively, the antibody or antigen-binding fragment may comprise the three light chain CDRs (LCVR1, LCVR2, LCVR3) contained within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ
ID NOs 41, 49, 57, 65, 73, 81, 89, 97, 105, 113, 121, 129, 137, 145, 153, 161, 169, 177, 185, and 193, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[00102]Sequence identity between two amino acids sequences is determined over the entire length of the reference amino acid sequence, i.e. the amino acid sequence identified with a SEQ ID NO, using the best sequence alignment and/or over the region of the best sequence alignment between the two amino acid sequences, wherein the best sequence alignment can be obtained with art known tools, e.g. Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[00103]In certain embodiments, the antibody or antigen-binding protein comprises the six CDRs (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3) from the heavy and light .. chain variable region amino acid sequence pairs (HCVR/LCVR) selected from the group consisting of SEQ ID NOs:1/6 and 11/15. Alternatively, in certain embodiments, the antibody or antigen-binding protein comprises the six CDRs (HCDR1, HCDR2, HCDR3,
27 LCDR1, LCDR2 and LCDR3) from the heavy and light chain variable region amino acid sequence pairs (HCVR/LCVR) selected from the group consisting of SEQ ID
NOs:37/41, 45/49, 53/57, 61/65, 69/73, 77/81, 85/89, 93/97, 101/105, 109/113, 117/121, 125/129, 133/137, 141/145, 149/153, 157/161, 165/169, 173/177, 181/185, and 189/193.
[00104]In certain embodiments, the anti-PCSK9 antibody, or antigen-binding protein, that can be used in the methods has HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 amino acid sequences selected from SEQ ID NOs: 2/3/4/7/8/10 (mAb316P [also referred to as "REGN727," or "alirocuman) and 12/13/14/16/17/18 (mAb300N) (See US Patent App.
Publ No. 2010/0166768) and 12/13/14/16/17/18, wherein SEQ ID NO:16 comprises a substitution of histidine for leucine at amino acid residue 30 (L3OH).
[00105]In certain embodiments, the antibody or antigen-binding protein comprises HCVR/LCVR amino acid sequence pairs selected from the group consisting of SEQ
ID
NOs: 1/6 and 11/15. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID NO: 1 and an LCVR
amino acid sequence of SEQ ID NO: 6. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID NO: 11 and an LCVR amino acid sequence of SEQ ID NO: 15. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID
NO: 11 and an LCVR amino acid sequence of SEQ ID NO: 15 comprising a substitution of histidine for leucine at amino acid residue 30 (L3OH).
Pharmaceutical Compositions and Methods of Administration [00106]The present methods include administering a PCSK9 inhibitor to a patient, wherein the PCSK9 inhibitor is contained within a pharmaceutical composition. The pharmaceutical compositions are formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists:
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTm), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
[00107]Exemplary pharmaceutical formulations comprising anti-PCSK9 antibodies that can be used in the context of the present methods include any of the formulations as set forth in US 8,795,669 (describing, inter alia, exemplary formulations comprising alirocumab), or in
NOs:37/41, 45/49, 53/57, 61/65, 69/73, 77/81, 85/89, 93/97, 101/105, 109/113, 117/121, 125/129, 133/137, 141/145, 149/153, 157/161, 165/169, 173/177, 181/185, and 189/193.
[00104]In certain embodiments, the anti-PCSK9 antibody, or antigen-binding protein, that can be used in the methods has HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 amino acid sequences selected from SEQ ID NOs: 2/3/4/7/8/10 (mAb316P [also referred to as "REGN727," or "alirocuman) and 12/13/14/16/17/18 (mAb300N) (See US Patent App.
Publ No. 2010/0166768) and 12/13/14/16/17/18, wherein SEQ ID NO:16 comprises a substitution of histidine for leucine at amino acid residue 30 (L3OH).
[00105]In certain embodiments, the antibody or antigen-binding protein comprises HCVR/LCVR amino acid sequence pairs selected from the group consisting of SEQ
ID
NOs: 1/6 and 11/15. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID NO: 1 and an LCVR
amino acid sequence of SEQ ID NO: 6. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID NO: 11 and an LCVR amino acid sequence of SEQ ID NO: 15. In certain exemplary embodiments, the antibody or antigen-binding protein comprises an HCVR amino acid sequence of SEQ ID
NO: 11 and an LCVR amino acid sequence of SEQ ID NO: 15 comprising a substitution of histidine for leucine at amino acid residue 30 (L3OH).
Pharmaceutical Compositions and Methods of Administration [00106]The present methods include administering a PCSK9 inhibitor to a patient, wherein the PCSK9 inhibitor is contained within a pharmaceutical composition. The pharmaceutical compositions are formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists:
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTm), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
[00107]Exemplary pharmaceutical formulations comprising anti-PCSK9 antibodies that can be used in the context of the present methods include any of the formulations as set forth in US 8,795,669 (describing, inter alia, exemplary formulations comprising alirocumab), or in
28 W02013/166448, or W02012/168491.
[00108]Various delivery systems are known and can be used to administer the pharmaceutical composition, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
[00109]A pharmaceutical composition can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition.
Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
[00110]Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition. Examples include, but are not limited to AUTOPENTm (Owen Mumford, Inc., Woodstock, UK), DISETRONICTm pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTm pen, HUMALIN 70/3OTM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM I, ll and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM
(Novo Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTm, OPTIPEN PROTM, OPTIPEN STARLETTm, and OPTICLIKTm (sanofi-aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present methods include, but are not limited to the SOLOSTARTm pen (sanofi-aventis), the FLEXPENTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM
Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTm (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATm Pen (Abbott Labs, Abbott Park IL),
[00108]Various delivery systems are known and can be used to administer the pharmaceutical composition, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
[00109]A pharmaceutical composition can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition.
Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
[00110]Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition. Examples include, but are not limited to AUTOPENTm (Owen Mumford, Inc., Woodstock, UK), DISETRONICTm pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTm pen, HUMALIN 70/3OTM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM I, ll and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM
(Novo Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTm, OPTIPEN PROTM, OPTIPEN STARLETTm, and OPTICLIKTm (sanofi-aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present methods include, but are not limited to the SOLOSTARTm pen (sanofi-aventis), the FLEXPENTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM
Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTm (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATm Pen (Abbott Labs, Abbott Park IL),
29 to name only a few.
[00111]In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra;
Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.
[00112]The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.
[00113]Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
Dosage [00114]The amount of PCSK9 inhibitor (e.g., anti-PCSK9 antibody) administered to a patient is, generally, a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" means a dose of PCSK9 inhibitor that results in a detectable reduction (at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more from baseline) in one or more parameters selected from the group consisting of LDL-C, ApoB, ApoB100, non-HDL-C, total cholesterol, VLDL-C, triglycerides, ApoC3, TRL particles, Lp(a) and remnant cholesterol).
[00115]In the case of an anti-PCSK9 antibody, a therapeutically effective amount can be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, 5 about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, 10 about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg, of the anti-PCSK9 antibody. According to certain exemplary embodiments, a therapeutically effective amount of an anti-PCSK9 antibody is
[00111]In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra;
Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.
[00112]The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.
[00113]Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
Dosage [00114]The amount of PCSK9 inhibitor (e.g., anti-PCSK9 antibody) administered to a patient is, generally, a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" means a dose of PCSK9 inhibitor that results in a detectable reduction (at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more from baseline) in one or more parameters selected from the group consisting of LDL-C, ApoB, ApoB100, non-HDL-C, total cholesterol, VLDL-C, triglycerides, ApoC3, TRL particles, Lp(a) and remnant cholesterol).
[00115]In the case of an anti-PCSK9 antibody, a therapeutically effective amount can be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, 5 about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, 10 about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg, of the anti-PCSK9 antibody. According to certain exemplary embodiments, a therapeutically effective amount of an anti-PCSK9 antibody is
30 mg, 40 15 mg or 75 mg (e.g., in the case of alirocumab for patients with body weight less than 50 kg, and/or younger than or equal to 17 years old), 50 mg, 75 mg 0r150 mg (e.g., in the case of alirocumab for patients with body weight greater than or equal to 50 kg, and/or younger than or equal to 17 years old), or 140 mg or 420 mg (e.g., in the case of evolocumab).
Other dosing amounts of PCSK9 inhibitors will be apparent to persons of ordinary skill in 20 the art.
[00116]The amount of anti-PCSK9 antibody contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg). For example, the anti-PCSK9 antibody may be administered to a patient at a dose of about 0.0001 to about 10 mg/kg of body weight.
25 Administration Regimens [00117]According to certain embodiments, multiple doses of a PCSK9 inhibitor (i.e., a pharmaceutical composition comprising a PCSK9 inhibitor) may be administered to a subject over a defined time course (e.g., on top of a daily therapeutic statin regimen or other background LMT). The methods according to this aspect comprise sequentially 30 administering to a subject multiple doses of a PCSK9 inhibitor. As used herein, "sequentially administering" means that each dose of PCSK9 inhibitor is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present methods includes sequentially administering to the patient a single initial dose of a PCSK9 inhibitor, followed by one or more secondary doses of the PCSK9 inhibitor, and optionally followed by one or more tertiary doses of the PCSK9 inhibitor.
Other dosing amounts of PCSK9 inhibitors will be apparent to persons of ordinary skill in 20 the art.
[00116]The amount of anti-PCSK9 antibody contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg). For example, the anti-PCSK9 antibody may be administered to a patient at a dose of about 0.0001 to about 10 mg/kg of body weight.
25 Administration Regimens [00117]According to certain embodiments, multiple doses of a PCSK9 inhibitor (i.e., a pharmaceutical composition comprising a PCSK9 inhibitor) may be administered to a subject over a defined time course (e.g., on top of a daily therapeutic statin regimen or other background LMT). The methods according to this aspect comprise sequentially 30 administering to a subject multiple doses of a PCSK9 inhibitor. As used herein, "sequentially administering" means that each dose of PCSK9 inhibitor is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present methods includes sequentially administering to the patient a single initial dose of a PCSK9 inhibitor, followed by one or more secondary doses of the PCSK9 inhibitor, and optionally followed by one or more tertiary doses of the PCSK9 inhibitor.
31 [00118]The terms "initial dose," "secondary doses," and "tertiary doses,"
refer to the temporal sequence of administration of the individual doses of a pharmaceutical composition comprising a PCSK9 inhibitor. Thus, the "initial dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "secondary doses" are the doses which are administered after the initial dose;
and the "tertiary doses" are the doses which are administered after the secondary doses.
The initial, secondary, and tertiary doses may all contain the same amount of the PCSK9 inhibitor, but generally may differ from one another in terms of frequency of administration.
In certain embodiments, however, the amount of PCSK9 inhibitor contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as "loading doses" followed by subsequent doses that are administered on a less frequent basis (e.g., "maintenance doses").
.. [00119]According to exemplary embodiments, each secondary and/or tertiary dose is administered 1 to 26 (e.g., 1, 11/2, 2, 2%, 3, 3%, 4, 4%, 5, 5%, 6, 6%, 7, 7%, 8, 8%, 9, 91/2 10, 101/2, 11, 11%, 12, 12%, 13, 13%, 14, 14%, 15, 15%, 16, 16%, 17, 17%, 18, 18%, 19, 19%, 20, 20%, 21, 21%, 22, 22%, 23, 23%, 24, 24%, 25, 25%, 26, 26%, or more) weeks after the immediately preceding dose. The phrase "the immediately preceding dose," as used herein, means, in a sequence of multiple administrations, the dose of antigen-binding molecule which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.
[00120]The methods according to this aspect may comprise administering to a patient any number of secondary and/or tertiary doses of a PCSK9 inhibitor. For example, in certain .. embodiments, only a single secondary dose is administered to the patient.
In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.
[00121]In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses.
For example, each tertiary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of
refer to the temporal sequence of administration of the individual doses of a pharmaceutical composition comprising a PCSK9 inhibitor. Thus, the "initial dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "secondary doses" are the doses which are administered after the initial dose;
and the "tertiary doses" are the doses which are administered after the secondary doses.
The initial, secondary, and tertiary doses may all contain the same amount of the PCSK9 inhibitor, but generally may differ from one another in terms of frequency of administration.
In certain embodiments, however, the amount of PCSK9 inhibitor contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as "loading doses" followed by subsequent doses that are administered on a less frequent basis (e.g., "maintenance doses").
.. [00119]According to exemplary embodiments, each secondary and/or tertiary dose is administered 1 to 26 (e.g., 1, 11/2, 2, 2%, 3, 3%, 4, 4%, 5, 5%, 6, 6%, 7, 7%, 8, 8%, 9, 91/2 10, 101/2, 11, 11%, 12, 12%, 13, 13%, 14, 14%, 15, 15%, 16, 16%, 17, 17%, 18, 18%, 19, 19%, 20, 20%, 21, 21%, 22, 22%, 23, 23%, 24, 24%, 25, 25%, 26, 26%, or more) weeks after the immediately preceding dose. The phrase "the immediately preceding dose," as used herein, means, in a sequence of multiple administrations, the dose of antigen-binding molecule which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.
[00120]The methods according to this aspect may comprise administering to a patient any number of secondary and/or tertiary doses of a PCSK9 inhibitor. For example, in certain .. embodiments, only a single secondary dose is administered to the patient.
In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.
[00121]In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses.
For example, each tertiary dose may be administered to the patient 1 to 2, 4, 6, 8 or more weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of
32 the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.
[00122]The present methods include administration regimens comprising an up-titration option (also referred to herein as "dose modification"). As used herein, an "up-titration option" means that, after receiving a particular number of doses of a PCSK9 inhibitor, if a patient has not achieved a specified reduction in one or more defined therapeutic parameters, the dose of the PCSK9 inhibitor is thereafter increased. For example, in the case of a therapeutic regimen comprising administration of 75 mg doses of an anti-PCSK9 antibody to a patient at a frequency of once every two weeks, if after 8 weeks (i.e., 5 doses administered at Week 0, Week 2 and Week 4, Week 6 and Week 8), the patient has not achieved a serum LDL-C concentration of less than 70 mg/dL, then the dose of anti-PCSK9 antibody is increased to e.g., 150 mg administered once every two weeks thereafter (e.g., starting at Week 10 or Week 12, or later).
[00123]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 75 mg at a frequency of once every two weeks. In certain embodiments, the about 75 mg dose is maintained if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses is <70 mg/dL. In certain embodiments, the about 75 mg dose is discontinued if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses remains >70 mg/dL, and the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is subsequently administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
[00124]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 300 mg at a frequency of once every four weeks. In certain embodiments, the about 300 mg dose is maintained if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses is <70 mg/dL. In certain embodiments, the about 300 mg dose is discontinued if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses remains >70 mg/dL, and the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is subsequently administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
[00125]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
[00122]The present methods include administration regimens comprising an up-titration option (also referred to herein as "dose modification"). As used herein, an "up-titration option" means that, after receiving a particular number of doses of a PCSK9 inhibitor, if a patient has not achieved a specified reduction in one or more defined therapeutic parameters, the dose of the PCSK9 inhibitor is thereafter increased. For example, in the case of a therapeutic regimen comprising administration of 75 mg doses of an anti-PCSK9 antibody to a patient at a frequency of once every two weeks, if after 8 weeks (i.e., 5 doses administered at Week 0, Week 2 and Week 4, Week 6 and Week 8), the patient has not achieved a serum LDL-C concentration of less than 70 mg/dL, then the dose of anti-PCSK9 antibody is increased to e.g., 150 mg administered once every two weeks thereafter (e.g., starting at Week 10 or Week 12, or later).
[00123]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 75 mg at a frequency of once every two weeks. In certain embodiments, the about 75 mg dose is maintained if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses is <70 mg/dL. In certain embodiments, the about 75 mg dose is discontinued if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses remains >70 mg/dL, and the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is subsequently administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
[00124]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 300 mg at a frequency of once every four weeks. In certain embodiments, the about 300 mg dose is maintained if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses is <70 mg/dL. In certain embodiments, the about 300 mg dose is discontinued if the patient's LDL-C measured after one or more, two or more, three or more, four or more, or five or more doses remains >70 mg/dL, and the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is subsequently administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
[00125]In certain embodiments, the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 150 mg at a frequency of once every two weeks.
33 [00126]In certain embodiments, when the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is administered to the patient at a dose of about 150 mg at a frequency of once every two weeks, the about 150 mg dose is discontinued if the patient's LDL-C measured after at least one dose or at least two, three, four, or five consecutive doses is < 10, 15, 20, or 25 mg/dL, and the antibody or antigen-binding fragment thereof that specifically binds PCSK9 is subsequently administered to the patient at a dose of about 75 mg at a frequency of once every two weeks. While not wishing to be bound by theory, it is hypothesized that a very low LDL-C level (e.g., <10, 15, 20, 0r25 mg/dL) may aggravate diabetes. In certain embodiments, the about 150 mg dose is administered to the patient as a constant dose. In certain embodiments, the about 150 mg dose is administered to the patient after a dose adjustment as disclosed herein (e.g., from about 75 mg every two week, or from about 300 mg every four weeks).
Combination Therapies [00127]As described elsewhere herein, the methods may comprise administering a inhibitor to a patient in combination with Con top or) the patient's previously prescribed lipid modifying therapy (LMT). LMTs include, but are not limited to statins, fibrates, niacin (e.g., nicotinic acid and its derivatives), bile acid sequestrants, ezetimibe, lomitapide, phytosterols, orlistat, etc. For example, a PCSK9 inhibitor may be administered to a patient in combination with a stable daily therapeutic statin regimen. Exemplary daily therapeutic statin regimens that a PCSK9 inhibitor may be administered in combination with in the context of the present methods include, e.g., atorvastatin (10, 20, 40 or 80 mg daily), (atorvastatin/ezetimibe 10/10 or 40/10 mg daily), rosuvastatin (5, 10 0r20 mg daily), cerivastatin (0.4 or 0.8 mg daily), pitavastatin (1, 2 or 4 mg daily), fluvastatin (20, 40 or 80 mg daily), simvastatin (5, 10, 20, 40 0r80 mg daily), simvastatin/ezetimibe (10/10, 20/10, 40/10 or 80/10 mg daily), lovastatin (10, 20, 40 or 80 mg daily), pravastatin (10, 20, 40 or 80 mg daily), and combinations thereof. In certain embodiments, the statin therapy is a maximally tolerated statin therapy for the patient. Other LMTs that a PCSK9 inhibitor may be administered in combination with in the context of the present methods include, e.g., (1) an agent which inhibits cholesterol uptake and or bile acid re-absorption (e.g., ezetimibe);
(2) an agent which increase lipoprotein catabolism (such as niacin); and/or (3) activators of the LXR transcription factor that plays a role in cholesterol elimination such as 22-hydroxycholesterol.
[00128]According to certain embodiments, methods are provided comprising administering a PCSK9 inhibitor (e.g., an anti-PCSK9 antibody such as alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab or LY3015014) to a patient in combination with an inhibitor of angiopoietin-like protein 3 (e.g., an anti-ANGPTL3 antibody such as REGN1500), an inhibitor of angiopoietin-like protein 4 (e.g., an anti-ANGPTL4 antibody
Combination Therapies [00127]As described elsewhere herein, the methods may comprise administering a inhibitor to a patient in combination with Con top or) the patient's previously prescribed lipid modifying therapy (LMT). LMTs include, but are not limited to statins, fibrates, niacin (e.g., nicotinic acid and its derivatives), bile acid sequestrants, ezetimibe, lomitapide, phytosterols, orlistat, etc. For example, a PCSK9 inhibitor may be administered to a patient in combination with a stable daily therapeutic statin regimen. Exemplary daily therapeutic statin regimens that a PCSK9 inhibitor may be administered in combination with in the context of the present methods include, e.g., atorvastatin (10, 20, 40 or 80 mg daily), (atorvastatin/ezetimibe 10/10 or 40/10 mg daily), rosuvastatin (5, 10 0r20 mg daily), cerivastatin (0.4 or 0.8 mg daily), pitavastatin (1, 2 or 4 mg daily), fluvastatin (20, 40 or 80 mg daily), simvastatin (5, 10, 20, 40 0r80 mg daily), simvastatin/ezetimibe (10/10, 20/10, 40/10 or 80/10 mg daily), lovastatin (10, 20, 40 or 80 mg daily), pravastatin (10, 20, 40 or 80 mg daily), and combinations thereof. In certain embodiments, the statin therapy is a maximally tolerated statin therapy for the patient. Other LMTs that a PCSK9 inhibitor may be administered in combination with in the context of the present methods include, e.g., (1) an agent which inhibits cholesterol uptake and or bile acid re-absorption (e.g., ezetimibe);
(2) an agent which increase lipoprotein catabolism (such as niacin); and/or (3) activators of the LXR transcription factor that plays a role in cholesterol elimination such as 22-hydroxycholesterol.
[00128]According to certain embodiments, methods are provided comprising administering a PCSK9 inhibitor (e.g., an anti-PCSK9 antibody such as alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab or LY3015014) to a patient in combination with an inhibitor of angiopoietin-like protein 3 (e.g., an anti-ANGPTL3 antibody such as REGN1500), an inhibitor of angiopoietin-like protein 4 (e.g., an anti-ANGPTL4 antibody
34 such as the anti-ANGPTL4 antibody referred to in US Patent No. 9,120,851 as "H1H268P"
or "H4H284P"), or an inhibitor of angiopoietin-like protein 8 (e.g., an anti-antibody).
[00129]According to certain embodiments, methods are provided comprising administering a PCSK9 inhibitor (e.g., an anti-PCSK9 antibody such as alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab or LY3015014) to a patient in combination with an a further anti-diabetic therapy in addition to insulin therapy. Exemplary additional anti-diabetic therapies include without limitation:
(a) all drugs mentioned in the Rote Liste 2016, (e.g. all antidiabetics mentioned in the Rote Liste 2014, chapter 12), all weight-reducing agents or appetite suppressants mentioned in the Rote Liste 2016, chapter 06, all lipid-lowering agents mentioned in the Rote Liste 2016, chapter 58, all antihypertensives mentioned in the Rote Liste 2016 chapter 17, all nephroprotectives mentioned in the Rote Liste, or all diuretics mentioned in the Rote Liste 2016, chapter 36;
(b) glucagon like peptide 1 (GLP-1) therapies, including GLP-1, GLP-1 analogues, and GLP-1 receptor agonists, for example: GLP-1(7-37), GLP-1(7-36)amide, lixisenatide (e.g.
Lyxumia ), exenatide (e.g. exendin-4, rExendin-4, Byetta , Bydureon , exenatide NexP), exenatide-LAR, liraglutide (e.g. Victoze), semaglutide, taspoglutide, albiglutide, dulaglutide, albugon, oxyntomodulin, geniproside, ACP-003, CJC-1131, CJC-1134-PC, GSK-2374697, PB-1023, TTP-054, langlenatide (HM-11260C), CM-3, GLP-1 Eligen, AB-201, ORMD-0901, NN9924, NN9926, NN9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, ZP-3022, CAM-2036, DA-3091, DA-15864, ARI-2651, ARI-2255, exenatide-XTEN (VRS-859), exenatide-XTEN + Glucagon-XTEN (VRS-859 + AMX-808) and polymer-bound GLP-1 and GLP-1 analogues;
(c) dual GLP-1/GIP agonists (e.g. RG-7697 (MAR-701), MAR-709, BHM081, BHM089, BHM098); dual GLP-1/glucagon receptor agonists (e.g. BHM-034, OAP-189 (PF-05212389, TKS-1225), TT-401/402, ZP2929, LAPS-HMOXM25, MOD-6030);
(d) dual GLP-1/gastrin agonists (e.g. ZP-3022);
(e) gastrointestinal peptides such as peptide YY 3-36 (PYY3-36) or analogues thereof and pancreatic polypeptide (PP) or analogues thereof;
(f) glucagon receptor agonists or antagonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists or antagonists, ghrelin antagonists or inverse agonists, xenin and analogues thereof;
(g) dipeptidyl peptidase-IV (DPP-4) inhibitors, for example: alogliptin (e.g.
Nesina , Kazano ), linagliptin (e.g. Ondero , Trajenta , Tradjenta , Trayenta ), saxagliptin (e.g.
Onglyza ' Komboglyze XR ), sitagliptin (e.g. Januvia , Xelevia , Tesavel , Janumet , Velmetia , Juvisync , Janumet XR ), anagliptin, teneligliptin (e.g. Tenelia ), trelagliptin, vildagliptin (e.g. Galvus , Galvumee), gemigliptin, omarigliptin, evogliptin, dutogliptin, DA-1229, MK-3102, KM-223, KRP-104, PBL-1427, Pinoxacin hydrochloride, and Ari-2243;
(h) sodium-dependent glucose transporter 2 (SGLT-2) inhibitors, for example:
canagliflozin, dapagliflozin, remogliflozin, remogliflozin etabonate, sergliflozin, empagliflozin, ipragliflozin, 5 tofogliflozin, luseogliflozin, ertugliflozin, EGT-0001442, LIK-066, SBM-TFC-039, and KGA-3235 (DSP-3235);
(i) dual inhibitors of SGLT-2 and SGLT-1 (e.g. LX-4211, LIK066);
(j) SGLT-1 inhibitors (e.g. LX-2761, KGA-3235) or SGLT-1 inhibitors in combination with anti-obesity drugs such as ileal bile acid transfer (IBAT) inhibitors (e.g.
GSK-1614235 +
10 GSK-2330672);
(k) biguanides (e.g. metformin, buformin, phenformin);
(I) thiazolidinediones (e.g. pioglitazone, rosiglitazone), glitazone analogues (e.g.
lobeglitazone);
(m) peroxisome proliferator-activated receptors (PPAR-)(alpha, gamma or alpha/gamma) 15 agonists or modulators (e.g. saroglitazar (e.g. Lipaglye), GFT-505), or PPAR gamma partial agonists (e.g. Int-131);
(n) sulfonylureas (e.g. tolbutamide, glibenclamide, glimepiride, Amaryl , glipizide) and meglitinides (e.g. nateglinide, repaglinide, mitiglinide);
(o) alpha-glucosidase inhibitors (e.g. acarbose, miglitol, voglibose);
20 (q) amylin and amylin analogues (e.g. pramlintide, Symlin );
(p) G-protein coupled receptor 119 (GPR119) agonists (e.g. GSK-1292263, PSN-821, MBX-2982, APD-597, ARRY-981, ZYG-19, DS-8500, HM-47000, YH-Chem1);
(q) GPR40 agonists (e.g. TUG-424, P-1736, P-11187, JTT-851, GW9508, CNX-011-67, AM-1638, AM-5262);
25 (r) GPR120 agonists and GPR142 agonists;
(s) systemic or low-absorbable TGR5 (GPBAR1 = G-protein-coupled bile acid receptor 1) agonists (e.g. INT-777, XL-475, SB756050);
(t) diabetes immunotherapeutics, for example: oral C-C chemokine receptor type 2 (CCR-2) antagonists (e.g. CCX-140, JNJ-41443532 ), interleukin 1 beta (IL-1R) antagonists (e.g. AC-30 201), or oral monoclonal antibodies (MoA) (e.g. methalozamide, VVP808, PAZ-320, P-1736, PF-05175157, PF-04937319);
(v) anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, for example: nuclear factor kappa B inhibitors (e.g. Triolex );
(w) adenosine monophosphate-activated protein kinase (AMPK) stimulants, for example:
or "H4H284P"), or an inhibitor of angiopoietin-like protein 8 (e.g., an anti-antibody).
[00129]According to certain embodiments, methods are provided comprising administering a PCSK9 inhibitor (e.g., an anti-PCSK9 antibody such as alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab or LY3015014) to a patient in combination with an a further anti-diabetic therapy in addition to insulin therapy. Exemplary additional anti-diabetic therapies include without limitation:
(a) all drugs mentioned in the Rote Liste 2016, (e.g. all antidiabetics mentioned in the Rote Liste 2014, chapter 12), all weight-reducing agents or appetite suppressants mentioned in the Rote Liste 2016, chapter 06, all lipid-lowering agents mentioned in the Rote Liste 2016, chapter 58, all antihypertensives mentioned in the Rote Liste 2016 chapter 17, all nephroprotectives mentioned in the Rote Liste, or all diuretics mentioned in the Rote Liste 2016, chapter 36;
(b) glucagon like peptide 1 (GLP-1) therapies, including GLP-1, GLP-1 analogues, and GLP-1 receptor agonists, for example: GLP-1(7-37), GLP-1(7-36)amide, lixisenatide (e.g.
Lyxumia ), exenatide (e.g. exendin-4, rExendin-4, Byetta , Bydureon , exenatide NexP), exenatide-LAR, liraglutide (e.g. Victoze), semaglutide, taspoglutide, albiglutide, dulaglutide, albugon, oxyntomodulin, geniproside, ACP-003, CJC-1131, CJC-1134-PC, GSK-2374697, PB-1023, TTP-054, langlenatide (HM-11260C), CM-3, GLP-1 Eligen, AB-201, ORMD-0901, NN9924, NN9926, NN9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, ZP-3022, CAM-2036, DA-3091, DA-15864, ARI-2651, ARI-2255, exenatide-XTEN (VRS-859), exenatide-XTEN + Glucagon-XTEN (VRS-859 + AMX-808) and polymer-bound GLP-1 and GLP-1 analogues;
(c) dual GLP-1/GIP agonists (e.g. RG-7697 (MAR-701), MAR-709, BHM081, BHM089, BHM098); dual GLP-1/glucagon receptor agonists (e.g. BHM-034, OAP-189 (PF-05212389, TKS-1225), TT-401/402, ZP2929, LAPS-HMOXM25, MOD-6030);
(d) dual GLP-1/gastrin agonists (e.g. ZP-3022);
(e) gastrointestinal peptides such as peptide YY 3-36 (PYY3-36) or analogues thereof and pancreatic polypeptide (PP) or analogues thereof;
(f) glucagon receptor agonists or antagonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists or antagonists, ghrelin antagonists or inverse agonists, xenin and analogues thereof;
(g) dipeptidyl peptidase-IV (DPP-4) inhibitors, for example: alogliptin (e.g.
Nesina , Kazano ), linagliptin (e.g. Ondero , Trajenta , Tradjenta , Trayenta ), saxagliptin (e.g.
Onglyza ' Komboglyze XR ), sitagliptin (e.g. Januvia , Xelevia , Tesavel , Janumet , Velmetia , Juvisync , Janumet XR ), anagliptin, teneligliptin (e.g. Tenelia ), trelagliptin, vildagliptin (e.g. Galvus , Galvumee), gemigliptin, omarigliptin, evogliptin, dutogliptin, DA-1229, MK-3102, KM-223, KRP-104, PBL-1427, Pinoxacin hydrochloride, and Ari-2243;
(h) sodium-dependent glucose transporter 2 (SGLT-2) inhibitors, for example:
canagliflozin, dapagliflozin, remogliflozin, remogliflozin etabonate, sergliflozin, empagliflozin, ipragliflozin, 5 tofogliflozin, luseogliflozin, ertugliflozin, EGT-0001442, LIK-066, SBM-TFC-039, and KGA-3235 (DSP-3235);
(i) dual inhibitors of SGLT-2 and SGLT-1 (e.g. LX-4211, LIK066);
(j) SGLT-1 inhibitors (e.g. LX-2761, KGA-3235) or SGLT-1 inhibitors in combination with anti-obesity drugs such as ileal bile acid transfer (IBAT) inhibitors (e.g.
GSK-1614235 +
10 GSK-2330672);
(k) biguanides (e.g. metformin, buformin, phenformin);
(I) thiazolidinediones (e.g. pioglitazone, rosiglitazone), glitazone analogues (e.g.
lobeglitazone);
(m) peroxisome proliferator-activated receptors (PPAR-)(alpha, gamma or alpha/gamma) 15 agonists or modulators (e.g. saroglitazar (e.g. Lipaglye), GFT-505), or PPAR gamma partial agonists (e.g. Int-131);
(n) sulfonylureas (e.g. tolbutamide, glibenclamide, glimepiride, Amaryl , glipizide) and meglitinides (e.g. nateglinide, repaglinide, mitiglinide);
(o) alpha-glucosidase inhibitors (e.g. acarbose, miglitol, voglibose);
20 (q) amylin and amylin analogues (e.g. pramlintide, Symlin );
(p) G-protein coupled receptor 119 (GPR119) agonists (e.g. GSK-1292263, PSN-821, MBX-2982, APD-597, ARRY-981, ZYG-19, DS-8500, HM-47000, YH-Chem1);
(q) GPR40 agonists (e.g. TUG-424, P-1736, P-11187, JTT-851, GW9508, CNX-011-67, AM-1638, AM-5262);
25 (r) GPR120 agonists and GPR142 agonists;
(s) systemic or low-absorbable TGR5 (GPBAR1 = G-protein-coupled bile acid receptor 1) agonists (e.g. INT-777, XL-475, SB756050);
(t) diabetes immunotherapeutics, for example: oral C-C chemokine receptor type 2 (CCR-2) antagonists (e.g. CCX-140, JNJ-41443532 ), interleukin 1 beta (IL-1R) antagonists (e.g. AC-30 201), or oral monoclonal antibodies (MoA) (e.g. methalozamide, VVP808, PAZ-320, P-1736, PF-05175157, PF-04937319);
(v) anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, for example: nuclear factor kappa B inhibitors (e.g. Triolex );
(w) adenosine monophosphate-activated protein kinase (AMPK) stimulants, for example:
35 Imeglimin (PXL-008), Debio-0930 (MT-63-78), R-118;
(x) inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11-beta-HSD-1) (e.g.
LY2523199, BMS770767, RG-4929, BMS816336, AZD-8329, HSD-016, BI-135585);
(x) inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11-beta-HSD-1) (e.g.
LY2523199, BMS770767, RG-4929, BMS816336, AZD-8329, HSD-016, BI-135585);
36 (y) activators of glucokinase (e.g. PF-04991532, TTP-399 (GK1-399), GKM-001 (ADV-1002401), ARRY-403 (AMG-151), TAK-329, TMG-123, ZYGK1);
(z) inhibitors of diacylglycerol 0-acyltransferase (DGAT) (e.g. pradigastat (LCQ-908)), inhibitors of protein tyrosine phosphatase 1 (e.g. trodusquemine), inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrogenase kinase;
(aa) modulators of glucose transporter-4, somatostatin receptor 3 agonists (e.g. MK-4256);
(bb) one or more lipid lowering agents are also suitable as combination partners, for example: 3-hydroxy-3-methylglutaryl-coenzym-A-reductase (HMG-CoA-reductase) inhibitors such as simvastatin (e.g. Zocor , Inegy , Simcor ), atorvastatin (e.g. Sortis , Caduer), rosuvastatin (e.g. Crestore), pravastatin (e.g. Lipostat , Selipran ), fluvastatin (e.g. Lescon, pitavastatin (e.g. Livazo , Livale), lovastatin (e.g. Mevacor , Advicor ), mevastatin (e.g.
Compactie), rivastatin, cerivastatin (Lipobay ), fibrates such as bezafibrate (e.g. Cedur retard), ciprofibrate (e.g. Hyperlipen ), fenofibrate (e.g. Antara , Lipofen , LipanthyP), gemfibrozil (e.g. Lopid , Gevilon ), etofibrate, simfibrate, ronifibrate, clinofibrate, clofibride, nicotinic acid and derivatives thereof (e.g. niacin, including slow release formulations of niacin), nicotinic acid receptor 1 agonists (e.g. GSK-256073), PPAR-delta agonists, acetyl-CoA-acetyltransferase (ACAT) inhibitors (e.g. avasimibe), cholesterol absorption inhibitors (e.g. ezetimibe, Ezetrol , Zetia , Liptruzet , Vytorin , S-556971), bile acid-binding substances (e.g. cholestyramine, colesevelam), Heal bile acid transport (IBAT) inhibitors (e.g.
GSK-2330672, LUM-002), microsomal triglyceride transfer protein (MTP) inhibitors (e.g.
lomitapide (AEGR-733), SLx-4090, granotapide), modulators of proprotein convertase subtilisin/kexin type 9 (PCSK9) (e.g. alirocumab (REGN727/SAR236553), AMG-145, LGT-209, PF-04950615, MPSK3169A, LY3015014, ALD-306, ALN-PCS, BMS-962476, SPC5001, ISIS-394814, 11320, LGT-210, 1D05, BMS-PCSK9Rx-2, SX-PCK9, RG7652), LDL
receptor up-regulators, for example liver selective thyroid hormone receptor beta agonists (e.g. eprotirome (KB-2115), MB07811, sobetirome (QRX-431), VIA-3196, ZYT1), HDL-raising compounds such as: cholesteryl ester transfer protein (CETP) inhibitors (e.g.
anacetrapib (MK0859), dalcetrapib, evacetrapib, JTT-302, DRL-17822, TA-8995, R-1658, LY-2484595, DS-1442), or dual CETP/PCSK9 inhibitors (e.g. K-312), ATP-binding cassette (ABC1) regulators, lipid metabolism modulators (e.g. BMS-823778, TAP-301, DRL-21994, DRL-21995), phospholipase A2 (PLA2) inhibitors (e.g. darapladib, Tyrisa , varespladib, rilapladib), ApoA-I enhancers (e.g. RVX-208, CER-001, MDCO-216, CSL-112), cholesterol synthesis inhibitors (e.g. ETC-1002), lipid metabolism modulators (e.g. BMS-823778, TAP-301, DRL-21994, DRL-21995) and omega-3 fatty acids and derivatives thereof (e.g.
icosapent ethyl (AMR101), Epanova , AKR-063, NKPL-66, PRC-4016, CAT-2003);
(z) inhibitors of diacylglycerol 0-acyltransferase (DGAT) (e.g. pradigastat (LCQ-908)), inhibitors of protein tyrosine phosphatase 1 (e.g. trodusquemine), inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrogenase kinase;
(aa) modulators of glucose transporter-4, somatostatin receptor 3 agonists (e.g. MK-4256);
(bb) one or more lipid lowering agents are also suitable as combination partners, for example: 3-hydroxy-3-methylglutaryl-coenzym-A-reductase (HMG-CoA-reductase) inhibitors such as simvastatin (e.g. Zocor , Inegy , Simcor ), atorvastatin (e.g. Sortis , Caduer), rosuvastatin (e.g. Crestore), pravastatin (e.g. Lipostat , Selipran ), fluvastatin (e.g. Lescon, pitavastatin (e.g. Livazo , Livale), lovastatin (e.g. Mevacor , Advicor ), mevastatin (e.g.
Compactie), rivastatin, cerivastatin (Lipobay ), fibrates such as bezafibrate (e.g. Cedur retard), ciprofibrate (e.g. Hyperlipen ), fenofibrate (e.g. Antara , Lipofen , LipanthyP), gemfibrozil (e.g. Lopid , Gevilon ), etofibrate, simfibrate, ronifibrate, clinofibrate, clofibride, nicotinic acid and derivatives thereof (e.g. niacin, including slow release formulations of niacin), nicotinic acid receptor 1 agonists (e.g. GSK-256073), PPAR-delta agonists, acetyl-CoA-acetyltransferase (ACAT) inhibitors (e.g. avasimibe), cholesterol absorption inhibitors (e.g. ezetimibe, Ezetrol , Zetia , Liptruzet , Vytorin , S-556971), bile acid-binding substances (e.g. cholestyramine, colesevelam), Heal bile acid transport (IBAT) inhibitors (e.g.
GSK-2330672, LUM-002), microsomal triglyceride transfer protein (MTP) inhibitors (e.g.
lomitapide (AEGR-733), SLx-4090, granotapide), modulators of proprotein convertase subtilisin/kexin type 9 (PCSK9) (e.g. alirocumab (REGN727/SAR236553), AMG-145, LGT-209, PF-04950615, MPSK3169A, LY3015014, ALD-306, ALN-PCS, BMS-962476, SPC5001, ISIS-394814, 11320, LGT-210, 1D05, BMS-PCSK9Rx-2, SX-PCK9, RG7652), LDL
receptor up-regulators, for example liver selective thyroid hormone receptor beta agonists (e.g. eprotirome (KB-2115), MB07811, sobetirome (QRX-431), VIA-3196, ZYT1), HDL-raising compounds such as: cholesteryl ester transfer protein (CETP) inhibitors (e.g.
anacetrapib (MK0859), dalcetrapib, evacetrapib, JTT-302, DRL-17822, TA-8995, R-1658, LY-2484595, DS-1442), or dual CETP/PCSK9 inhibitors (e.g. K-312), ATP-binding cassette (ABC1) regulators, lipid metabolism modulators (e.g. BMS-823778, TAP-301, DRL-21994, DRL-21995), phospholipase A2 (PLA2) inhibitors (e.g. darapladib, Tyrisa , varespladib, rilapladib), ApoA-I enhancers (e.g. RVX-208, CER-001, MDCO-216, CSL-112), cholesterol synthesis inhibitors (e.g. ETC-1002), lipid metabolism modulators (e.g. BMS-823778, TAP-301, DRL-21994, DRL-21995) and omega-3 fatty acids and derivatives thereof (e.g.
icosapent ethyl (AMR101), Epanova , AKR-063, NKPL-66, PRC-4016, CAT-2003);
37 (cc) bromocriptine (e.g. Cycloset , Parlodel ), phentermine and phentermine formulations or combinations (e.g. Adipex-P, lonamin, Qsymia ), benzphetamine (e.g. Didrex ), diethylpropion (e.g. Tenuate ), phendimetrazin (e.g. Adipost , BontriP), bupropion and combinations (e.g. Zyban , Wellbutrin XL , Contrave , Empatie), sibutramine (e.g.
Reductil , Meridia ), topiramat (e.g. Topamax ), zonisamid (e.g. Zonegran ), tesofensine, opioid antagonists such as naltrexone (e.g. Naltrexin , naltrexone +
bupropion), cannabinoid receptor 1 (CBI) antagonists (e.g. TM-38837), melanin-concentrating hormone (MCH-1) antagonists (e.g. BMS-830216, ALB-127158(a)), MC4 receptor agonists and partial agonists (e.g. AZD-2820, RM-493), neuropeptide Y5 (NPY5) or NPY2 antagonists (e.g.
velneperit, S-234462), NPY4 agonists (e.g. PP-1420), beta-3-adrenergic receptor agonists, leptin or leptin mimetics, agonists of the 5-hydroxytryptamine 2c (5HT2c) receptor (e.g.
lorcaserin, Belviq ), pramlintide/metreleptin, lipase inhibitors such as cetilistat (e.g. Cametor ), orlistat (e.g.
Xenical , Calobalie), angiogenesis inhibitors (e.g. ALS-L1023), betahistidin and histamine H3 antagonists (e.g. HPP-404), AgRP (agouti related protein) inhibitors (e.g.
TTP-435), .. serotonin re-uptake inhibitors such as fluoxetine (e.g. Fluctine ), duloxetine (e.g. Cymbalta ), dual or triple monoamine uptake inhibitors (dopamine, norepinephrine and serotonin re-uptake) such as sertraline (e.g. Zolofe), tesofensine, methionine aminopeptidase 2 (MetAP2) inhibitors (e.g. beloranib), and antisense oligonucleotides against production of fibroblast growth factor receptor 4 (FGFR4) (e.g. ISIS-FGFR4Rx) or prohibitin targeting peptide-1 (e.g. Adipotide ); and (dd) nitric oxide donors, ATI antagonists or angiotensin II (AT2) receptor antagonists such as telmisartan (e.g. Kinzal , Micardis ), candesartan (e.g. Atacand , Bloprese), valsartan (e.g. Diovan , Co-Diovan ), losartan (e.g. Cosaar ), eprosartan (e.g. Teveten ), irbesartan (e.g. Aprovel , CoAproven, olmesartan (e.g. Votum , Olmetec ), tasosartan, azilsartan (e.g.
Edarbn, dual angiotensin receptor blockers (dual ARBs), angiotensin converting enzyme (ACE) inhibitors, ACE-2 activators, renin inhibitors, prorenin inhibitors, endothelin converting enzyme (ECE) inhibitors, endothelin receptor (ETI/ETA) blockers, endothelin antagonists, diuretics, aldosterone antagonists, aldosterone synthase inhibitors, alpha-blockers, antagonists of the alpha-2 adrenergic receptor, beta-blockers, mixed alpha-/beta-blockers, calcium antagonists, calcium channel blockers (CCBs), nasal formulations of the calcium channel blocker diltiazem (e.g. CP-404), dual mineralocorticoid/CCBs, centrally acting antihypertensives, inhibitors of neutral endopeptidase, aminopeptidase-A
inhibitors, vasopeptide inhibitors, dual vasopeptide inhibitors such as neprilysin-ACE
inhibitors or neprilysin-ECE inhibitors, dual-acting AT receptor-neprilysin inhibitors, dual ATI/ETA
antagonists, advanced glycation end-product (AGE) breakers, recombinant renalase, blood pressure vaccines such as anti-RAAS (renin-angiotensin-aldosteron-system) vaccines, ATI-or AT2-vaccines, drugs based on hypertension pharmacogenomics such as modulators of
Reductil , Meridia ), topiramat (e.g. Topamax ), zonisamid (e.g. Zonegran ), tesofensine, opioid antagonists such as naltrexone (e.g. Naltrexin , naltrexone +
bupropion), cannabinoid receptor 1 (CBI) antagonists (e.g. TM-38837), melanin-concentrating hormone (MCH-1) antagonists (e.g. BMS-830216, ALB-127158(a)), MC4 receptor agonists and partial agonists (e.g. AZD-2820, RM-493), neuropeptide Y5 (NPY5) or NPY2 antagonists (e.g.
velneperit, S-234462), NPY4 agonists (e.g. PP-1420), beta-3-adrenergic receptor agonists, leptin or leptin mimetics, agonists of the 5-hydroxytryptamine 2c (5HT2c) receptor (e.g.
lorcaserin, Belviq ), pramlintide/metreleptin, lipase inhibitors such as cetilistat (e.g. Cametor ), orlistat (e.g.
Xenical , Calobalie), angiogenesis inhibitors (e.g. ALS-L1023), betahistidin and histamine H3 antagonists (e.g. HPP-404), AgRP (agouti related protein) inhibitors (e.g.
TTP-435), .. serotonin re-uptake inhibitors such as fluoxetine (e.g. Fluctine ), duloxetine (e.g. Cymbalta ), dual or triple monoamine uptake inhibitors (dopamine, norepinephrine and serotonin re-uptake) such as sertraline (e.g. Zolofe), tesofensine, methionine aminopeptidase 2 (MetAP2) inhibitors (e.g. beloranib), and antisense oligonucleotides against production of fibroblast growth factor receptor 4 (FGFR4) (e.g. ISIS-FGFR4Rx) or prohibitin targeting peptide-1 (e.g. Adipotide ); and (dd) nitric oxide donors, ATI antagonists or angiotensin II (AT2) receptor antagonists such as telmisartan (e.g. Kinzal , Micardis ), candesartan (e.g. Atacand , Bloprese), valsartan (e.g. Diovan , Co-Diovan ), losartan (e.g. Cosaar ), eprosartan (e.g. Teveten ), irbesartan (e.g. Aprovel , CoAproven, olmesartan (e.g. Votum , Olmetec ), tasosartan, azilsartan (e.g.
Edarbn, dual angiotensin receptor blockers (dual ARBs), angiotensin converting enzyme (ACE) inhibitors, ACE-2 activators, renin inhibitors, prorenin inhibitors, endothelin converting enzyme (ECE) inhibitors, endothelin receptor (ETI/ETA) blockers, endothelin antagonists, diuretics, aldosterone antagonists, aldosterone synthase inhibitors, alpha-blockers, antagonists of the alpha-2 adrenergic receptor, beta-blockers, mixed alpha-/beta-blockers, calcium antagonists, calcium channel blockers (CCBs), nasal formulations of the calcium channel blocker diltiazem (e.g. CP-404), dual mineralocorticoid/CCBs, centrally acting antihypertensives, inhibitors of neutral endopeptidase, aminopeptidase-A
inhibitors, vasopeptide inhibitors, dual vasopeptide inhibitors such as neprilysin-ACE
inhibitors or neprilysin-ECE inhibitors, dual-acting AT receptor-neprilysin inhibitors, dual ATI/ETA
antagonists, advanced glycation end-product (AGE) breakers, recombinant renalase, blood pressure vaccines such as anti-RAAS (renin-angiotensin-aldosteron-system) vaccines, ATI-or AT2-vaccines, drugs based on hypertension pharmacogenomics such as modulators of
38 genetic polymorphisms with antihypertensive response, thrombocyte aggregation inhibitors, and others; and (ee) combinations thereof that are suitable.
[00130]In certain embodiments, the additional anti-diabetic therapy is a GLP-1 therapy (e.g., lixisenatide). In certain embodiments, the GLP-1 therapy is formulated with methionine (e.g., L-methionine or D-methionine). In certain embodiments, polysorbate (e.g., polysorbate 20, polysorbate 80), poloxamer (e.g., poloxamer 188), benzalkonium chloride, histidine, lysine, and/or EDTA are absent or substantially absent from the formulation of the GLP-1 therapy. In certain embodiments, the formulation of the GLP-1 therapy is free or substantially free of surfactants, such as polyols (e.g., polypropylene glycols, polyethylene glycols, poloxamers, Pluronics, Tetronics), partial and fatty acid esters and ethers of polyhydric alcohols such as those of glycerol and sorbitol (e.g., Span®, Tween®, Myrj®, Brij®, Cremophor.RTM). The formulation of the GLP-1 therapy can comprise a suitable preservative (e.g., phenol, m-cresol, benzyl alcohol, and/or p-hydroxybenzoate esters) and suitable tonicity modifiers (e.g., glycerol, dextrose, lactose, sorbitol, mannitol, glucose, NaCI, calcium or magnesium compounds such as CaCl2). The concentrations of glycerol, dextrose, lactose, sorbitol, mannitol, and glucose are customarily in the range of 100-250 mM, NaCI in a concentration of up to 150 mM.
[00131]In certain embodiments, the insulin therapy that the patient receives is combined with the additional anti-diabetic therapy (e.g., any of the foregoing anti-diabetic therapies which are not insulin therapies). For example, in certain embodiments, the anti-diabetic therapy comprises a combination of an insulin therapy (e.g., insulin glargine) and a GLP-1 therapy (e.g., lixisenatide). These therapies can be provided either separately or in a single pharmaceutical composition. For example, insulin glargine and lixisenatide can be formulated in a single pharmaceutical composition (e.g., Soliqua 100/33) for daily injection.
[00132]In the context of the methods, additional therapeutically active component(s), e.g., any of the agents listed above or derivatives thereof, may be administered just prior to, concurrent with, or shortly after the administration of a PCSK9 inhibitor;
(for purposes of the present disclosure, such administration regimens are considered the administration of a PCSK9 inhibitor "in combination with" an additional therapeutically active component). The present methods include pharmaceutical compositions and methods of use thereof in which a PCSK9 inhibitor is co-formulated with one or more of the additional therapeutically active component(s) as described elsewhere herein.
Administration of a PCSK9 Inhibitor as Add-On Therapy [00133]The present methods of treatment including treating a patient with hypercholesterolemia and diabetes with a PCSK9 inhibitor, such as an antibody or antigen-
[00130]In certain embodiments, the additional anti-diabetic therapy is a GLP-1 therapy (e.g., lixisenatide). In certain embodiments, the GLP-1 therapy is formulated with methionine (e.g., L-methionine or D-methionine). In certain embodiments, polysorbate (e.g., polysorbate 20, polysorbate 80), poloxamer (e.g., poloxamer 188), benzalkonium chloride, histidine, lysine, and/or EDTA are absent or substantially absent from the formulation of the GLP-1 therapy. In certain embodiments, the formulation of the GLP-1 therapy is free or substantially free of surfactants, such as polyols (e.g., polypropylene glycols, polyethylene glycols, poloxamers, Pluronics, Tetronics), partial and fatty acid esters and ethers of polyhydric alcohols such as those of glycerol and sorbitol (e.g., Span®, Tween®, Myrj®, Brij®, Cremophor.RTM). The formulation of the GLP-1 therapy can comprise a suitable preservative (e.g., phenol, m-cresol, benzyl alcohol, and/or p-hydroxybenzoate esters) and suitable tonicity modifiers (e.g., glycerol, dextrose, lactose, sorbitol, mannitol, glucose, NaCI, calcium or magnesium compounds such as CaCl2). The concentrations of glycerol, dextrose, lactose, sorbitol, mannitol, and glucose are customarily in the range of 100-250 mM, NaCI in a concentration of up to 150 mM.
[00131]In certain embodiments, the insulin therapy that the patient receives is combined with the additional anti-diabetic therapy (e.g., any of the foregoing anti-diabetic therapies which are not insulin therapies). For example, in certain embodiments, the anti-diabetic therapy comprises a combination of an insulin therapy (e.g., insulin glargine) and a GLP-1 therapy (e.g., lixisenatide). These therapies can be provided either separately or in a single pharmaceutical composition. For example, insulin glargine and lixisenatide can be formulated in a single pharmaceutical composition (e.g., Soliqua 100/33) for daily injection.
[00132]In the context of the methods, additional therapeutically active component(s), e.g., any of the agents listed above or derivatives thereof, may be administered just prior to, concurrent with, or shortly after the administration of a PCSK9 inhibitor;
(for purposes of the present disclosure, such administration regimens are considered the administration of a PCSK9 inhibitor "in combination with" an additional therapeutically active component). The present methods include pharmaceutical compositions and methods of use thereof in which a PCSK9 inhibitor is co-formulated with one or more of the additional therapeutically active component(s) as described elsewhere herein.
Administration of a PCSK9 Inhibitor as Add-On Therapy [00133]The present methods of treatment including treating a patient with hypercholesterolemia and diabetes with a PCSK9 inhibitor, such as an antibody or antigen-
39 binding fragment thereof that specifically binds PCKS9, wherein the PCSK9 inhibitor can be administered as an add-on to the patients pre-existing insulin therapy and/or LMT (if applicable), such as an add-on to the patient's pre-existing daily therapeutic insulin and/or statin regimen.
[00134]For example, the methods include add-on therapeutic regimens wherein the PCSK9 inhibitor is administered as add-on therapy to the same stable multiple daily insulin regimen and/or daily therapeutic statin regimen (i.e., same dosing amount of statin) that the patient was on prior to receiving the PCSK9 inhibitor. In other embodiments, the PCSK9 inhibitor is administered as add-on therapy to a therapeutic insulin and/or statin regimen comprising an insulin and/or a statin in an amount that is more than or less than the dose of insulin and/or stain the patient was on prior to receiving the PCSK9 inhibitor. For example, after starting a therapeutic regimen comprising a PCSK9 inhibitor administered at a particular dosing frequency and amount, the daily dose of insulin and/or statin administered or prescribed to the patient may (a) stay the same, (b) increase, or (c) decrease (e.g., up-titrate or down-titrate) in comparison to the daily statin dose the patient was taking before starting the PCSK9 inhibitor therapeutic regimen, depending on the therapeutic needs of the patient.
Therapeutic Efficacy [00135]The methods result in the reduction in serum levels of one or more lipid component selected from the group consisting of LDL-C, ApoB, ApoB100, non-HDL-C, total cholesterol, VLDL-C, triglycerides, Lp(a), HDL-C, LDL particle number, LDL
particle size, ApoC3, ApoA-1, triglyceride-rich lipoprotein cholesterol (TRL-C), and remnant cholesterol.
According to certain embodiments, administration of a pharmaceutical composition comprising a PCSK9 inhibitor to a patient will result in a mean percent reduction from baseline in serum low density lipoprotein cholesterol (LDL-C) of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in ApoB of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in ApoB100 of at least about 25%, 30%, 35%,
[00134]For example, the methods include add-on therapeutic regimens wherein the PCSK9 inhibitor is administered as add-on therapy to the same stable multiple daily insulin regimen and/or daily therapeutic statin regimen (i.e., same dosing amount of statin) that the patient was on prior to receiving the PCSK9 inhibitor. In other embodiments, the PCSK9 inhibitor is administered as add-on therapy to a therapeutic insulin and/or statin regimen comprising an insulin and/or a statin in an amount that is more than or less than the dose of insulin and/or stain the patient was on prior to receiving the PCSK9 inhibitor. For example, after starting a therapeutic regimen comprising a PCSK9 inhibitor administered at a particular dosing frequency and amount, the daily dose of insulin and/or statin administered or prescribed to the patient may (a) stay the same, (b) increase, or (c) decrease (e.g., up-titrate or down-titrate) in comparison to the daily statin dose the patient was taking before starting the PCSK9 inhibitor therapeutic regimen, depending on the therapeutic needs of the patient.
Therapeutic Efficacy [00135]The methods result in the reduction in serum levels of one or more lipid component selected from the group consisting of LDL-C, ApoB, ApoB100, non-HDL-C, total cholesterol, VLDL-C, triglycerides, Lp(a), HDL-C, LDL particle number, LDL
particle size, ApoC3, ApoA-1, triglyceride-rich lipoprotein cholesterol (TRL-C), and remnant cholesterol.
According to certain embodiments, administration of a pharmaceutical composition comprising a PCSK9 inhibitor to a patient will result in a mean percent reduction from baseline in serum low density lipoprotein cholesterol (LDL-C) of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in ApoB of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in ApoB100 of at least about 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in non-HDL-C
of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in total cholesterol of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, or greater; a mean percent reduction from baseline in VLDL-C of at least about 5%, 10%, 15%, 20%, 25%, 30%, or greater; a mean percent reduction from baseline in triglycerides of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35% or greater; a mean percentage reduction from baseline in the number of LDL particles of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater; a mean percent reduction from baseline in the size of LDL particles of at least about 1.5%, 2%, 2.5%, 3%, 3.5% or 4% or more; a mean
of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or greater; a mean percent reduction from baseline in total cholesterol of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, or greater; a mean percent reduction from baseline in VLDL-C of at least about 5%, 10%, 15%, 20%, 25%, 30%, or greater; a mean percent reduction from baseline in triglycerides of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35% or greater; a mean percentage reduction from baseline in the number of LDL particles of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50% or greater; a mean percent reduction from baseline in the size of LDL particles of at least about 1.5%, 2%, 2.5%, 3%, 3.5% or 4% or more; a mean
41 percentage reduction from baseline in apolipoprotein C3 (ApoC3) of at least about 5%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 9.0%, 10% or more; a mean percent increase from baseline in HDL-C of at least about 1%, 2%, 3%, 4%, 5% or greater; a mean percent increase from baseline in ApoA-1 of at least about 1%, 2%, 3%, 4%, 5% or greater; a mean 5 percentage reduction from baseline in TRL-C of at least about 5%, 10%, 15%, 20%, 25%, 30%, or greater; and/or a mean percent reduction from baseline in Lp(a) of at least about 5%, 10%, 15%, 20%, 25%, or greater.
[00136]The present methods include treating a patient with hypercholesterolemia and Ti DM that is receiving insulin therapy, the methods comprising administering multiple 10 doses of an anti-PCSK9 antibody or antigen binding fragment thereof to the patient at a dosing amount of about 75 to 150 mg per dose, and a dosing frequency of about once every two weeks or every four weeks, or a dosing regimen in accordance with an up-titration dosing regimen as disclosed herein. After about 8, 10, 12, 14, 16, 18, 20, 22, 24 or more weeks of treatment with the anti-PCSK9 antibody, the patient may exhibit a reduction 15 in LDL-C level from baseline of at least 35%, 50%, or 60%. In certain embodiments, following one or more weeks of treatment with the anti-PCSK9 antibody, the patient exhibits a reduction in LDL-C level from baseline of about 35%, 50%, or 60%, or more.
[00137]The present methods also include treating a patient with hypercholesterolemia and T2DM that is receiving insulin therapy, the methods comprising administering multiple 20 doses of an anti-PCSK9 antibody or antigen binding fragment thereof to the patient at a dosing amount of about 75 to 150 mg per dose, and a dosing frequency of about once every two weeks or every four weeks, or a dosing regimen in accordance with an up-titration dosing regimen as disclosed herein. After about 8, 10, 12, 14, 16, 18, 20, 22, 24 or more weeks of treatment with the anti-PCSK9 antibody, the patient may exhibit a reduction 25 in LDL-C level from baseline of at least 40%, 48%, or 54%. In certain embodiments, following one or more weeks of treatment with the anti-PCSK9 antibody, the patient exhibits a reduction in LDL-C level from baseline of about 40%, 48%, or 54%, or more.
[00138]As disclosed herein, the present methods do not alter the patient's diabetic parameters. For example, in certain embodiments, the method does not affect (e.g., does 30 not change by greater than 1%, 2`)/0, 3`)/0, 4`)/0, 5`)/0, 6`)/0, 7%, 8%, 9%, or 10`)/0) the hemoglobin A1c (HbA1c) level of the patient. In certain embodiments, the method does not affect (e.g., does not change by greater than 2%, 4%, 6%, 8%, 10%, 12%, 15%, 18%, or 20%) the fasting plasma glucose (FPG) level of the patient.
[00139] In further embodiments the present invention relates to uses of an antibody or an 35 antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1DM).
[00140]In yet further embodiments the present invention relates to methods for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM).
[00141]In one embodiment said use and/or method comprises the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00142]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00143]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00144]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00145]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00146]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00147]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014.
[00148]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00149]In one embodiment said use and/or method comprises further the steps:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00150]In one embodiment said use and/or method comprises further the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is
[00136]The present methods include treating a patient with hypercholesterolemia and Ti DM that is receiving insulin therapy, the methods comprising administering multiple 10 doses of an anti-PCSK9 antibody or antigen binding fragment thereof to the patient at a dosing amount of about 75 to 150 mg per dose, and a dosing frequency of about once every two weeks or every four weeks, or a dosing regimen in accordance with an up-titration dosing regimen as disclosed herein. After about 8, 10, 12, 14, 16, 18, 20, 22, 24 or more weeks of treatment with the anti-PCSK9 antibody, the patient may exhibit a reduction 15 in LDL-C level from baseline of at least 35%, 50%, or 60%. In certain embodiments, following one or more weeks of treatment with the anti-PCSK9 antibody, the patient exhibits a reduction in LDL-C level from baseline of about 35%, 50%, or 60%, or more.
[00137]The present methods also include treating a patient with hypercholesterolemia and T2DM that is receiving insulin therapy, the methods comprising administering multiple 20 doses of an anti-PCSK9 antibody or antigen binding fragment thereof to the patient at a dosing amount of about 75 to 150 mg per dose, and a dosing frequency of about once every two weeks or every four weeks, or a dosing regimen in accordance with an up-titration dosing regimen as disclosed herein. After about 8, 10, 12, 14, 16, 18, 20, 22, 24 or more weeks of treatment with the anti-PCSK9 antibody, the patient may exhibit a reduction 25 in LDL-C level from baseline of at least 40%, 48%, or 54%. In certain embodiments, following one or more weeks of treatment with the anti-PCSK9 antibody, the patient exhibits a reduction in LDL-C level from baseline of about 40%, 48%, or 54%, or more.
[00138]As disclosed herein, the present methods do not alter the patient's diabetic parameters. For example, in certain embodiments, the method does not affect (e.g., does 30 not change by greater than 1%, 2`)/0, 3`)/0, 4`)/0, 5`)/0, 6`)/0, 7%, 8%, 9%, or 10`)/0) the hemoglobin A1c (HbA1c) level of the patient. In certain embodiments, the method does not affect (e.g., does not change by greater than 2%, 4%, 6%, 8%, 10%, 12%, 15%, 18%, or 20%) the fasting plasma glucose (FPG) level of the patient.
[00139] In further embodiments the present invention relates to uses of an antibody or an 35 antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1DM).
[00140]In yet further embodiments the present invention relates to methods for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (Ti DM).
[00141]In one embodiment said use and/or method comprises the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00142]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00143]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00144]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00145]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00146]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00147]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014.
[00148]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00149]In one embodiment said use and/or method comprises further the steps:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00150]In one embodiment said use and/or method comprises further the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is
42 lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00151]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00152]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
[00153]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00154]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
[00155]In one embodiment of said use and/or method the LMT is a statin therapy.
[00156]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00157]In one embodiment of said use and/or method the statin therapy is a maximally tolerated statin therapy.
[00158]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00159]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00160]In one embodiment of said use and/or method the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00161]In one embodiment of said use and/or method the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
[00162]In one embodiment of said use and/or method the additional concomitant anti-diabetic therapy is selected from the group consisting of a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-
[00151]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00152]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
[00153]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00154]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
[00155]In one embodiment of said use and/or method the LMT is a statin therapy.
[00156]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00157]In one embodiment of said use and/or method the statin therapy is a maximally tolerated statin therapy.
[00158]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00159]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00160]In one embodiment of said use and/or method the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00161]In one embodiment of said use and/or method the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
[00162]In one embodiment of said use and/or method the additional concomitant anti-diabetic therapy is selected from the group consisting of a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-
43 activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[00163]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or 45%.
[00164]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 25%, 30%, 35%, or 40%.
[00165]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient.
[00166]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00167]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00168]In further embodiments the present inventions relate to uses and/or methods for .. treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1 DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid
[00163]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or 45%.
[00164]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 25%, 30%, 35%, or 40%.
[00165]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient.
[00166]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00167]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00168]In further embodiments the present inventions relate to uses and/or methods for .. treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1 DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid
44 sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[00169]In further embodiments the present inventions relate to uses and/or methods for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00170]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00171]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00172]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00173]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00174]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00175]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
[00176]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00177]In one embodiment of said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00178]In one embodiment of said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the 5 antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00179]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00180]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
10 [00181]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00182]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
15 [00183]In one embodiment of said use and/or method the LMT is a statin therapy.
[00184]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00185]In one embodiment of said use and/or method the statin therapy is a maximally 20 tolerated dose statin therapy.
[00186]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00187]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00188]In one embodiment of said use and/or method the insulin therapy is selected from 25 the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00189]In one embodiment of said use and/or method the patient receives aconcomitant anti-diabetic therapy in addition to insulin therapy.
[00190]In one embodiment of said use and/or method the additional anti-diabetic therapy is 30 selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent 35 glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[00191]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or
[00169]In further embodiments the present inventions relate to uses and/or methods for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00170]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00171]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00172]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00173]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00174]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00175]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
[00176]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00177]In one embodiment of said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00178]In one embodiment of said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the 5 antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00179]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00180]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
10 [00181]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00182]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
15 [00183]In one embodiment of said use and/or method the LMT is a statin therapy.
[00184]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00185]In one embodiment of said use and/or method the statin therapy is a maximally 20 tolerated dose statin therapy.
[00186]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00187]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00188]In one embodiment of said use and/or method the insulin therapy is selected from 25 the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00189]In one embodiment of said use and/or method the patient receives aconcomitant anti-diabetic therapy in addition to insulin therapy.
[00190]In one embodiment of said use and/or method the additional anti-diabetic therapy is 30 selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent 35 glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[00191]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or
45%.
[00192]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 20%, 25%, 30%, or 35%.
[00193]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
[00194]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00195]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00196]In further embodiments the present inventions relate to uses and/or methods for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL,wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ
ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[00197]In further embodiments the present invention relates to uses of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD).
[00198] In yet further embodiments the present invention relates to methods for treating hypercholesterolemia in a patient with T2DM and ASCVD.
[00199]In one embodiment said use and/or method comprises the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00200]In one embodiment of said use and/or method the ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease.
[00201]In one embodiment of said use and/or method the CHD comprises acute myocardial infarction, silent myocardial infarction, and unstable angina.
[00202]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00203]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00204]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00205]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00206]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00207]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
[00208]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00209]In one embodiment said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00210]In one embodiment said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00211]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00212]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
[00213]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00214]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
[00215]In one embodiment of said use and/or method the LMT is a statin therapy.
[00216]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00217]In one embodiment of said use and/or method the statin therapy is a maximally tolerated dose statin therapy.
[00218]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00219]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00220]In one embodiment of said use and/or method the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00221]In one embodiment of said use and/or method the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
[00222]In one embodiment of said use and/or method the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[00223]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or 45%.
[00224]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 20%, 25%, 30%, or 35%.
[00225]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
[00226]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00227]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00228]In further embodiments the present invention relates to uses and/or methods for treating hypercholesterolemia in a patient with T2DM and ASCVD, the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or 5 antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the 10 amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
EXAMPLES
[00229]The following examples are put forth so as to provide those of ordinary skill in the 15 art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, 20 molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
Example 1. Generation of Human Antibodies to Human PCSK9 [00230]Human anti-PCSK9 antibodies were generated as described in US Patent No.
8,062,640. The exemplary PCSK9 inhibitor used in the following Example is the human 25 anti-PCSK9 antibody designated "mAb316P," also known as "REGN727," or "alirocumab."
mAb316P has the following amino acid sequence characteristics: a heavy chain comprising SEQ ID NO:5 and a light chain comprising SEQ ID NO:9; a heavy chain variable region (HCVR) comprising SEQ ID NO:1 and a light chain variable domain (LCVR) comprising SEQ ID NO:6; a heavy chain complementarity determining region 1 (HCDR1) comprising 30 SEQ ID NO:2, a HCDR2 comprising SEQ ID NO:3, a HCDR3 comprising SEQ ID
NO:4, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID
NO:7, a LCDR2 comprising SEQ ID NO:8 and a LCDR3 comprising SEQ ID NO:10.
Example 2: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy INTRODUCTION
[00231]More than 380 million people worldwide have diabetes, most of whom will die from cardiovascular disease (CVD). Compared to people without diabetes, those with diabetes are at higher risk of developing CVD, develop associated clinical complications and at an earlier age, and have shortened life expectancy by about 6 to 7 years. In addition to the high human cost of disease, CVD contributes greatly to the overall healthcare expenditure in these patients.
[00232]This study, named Odyssey DM-Insulin, included adult patients with Type 1 or Type 2 diabetes mellitus on insulin therapy with hypercholesterolemia at high cardiovascular (CV) risk that was not adequately controlled on a maximally tolerated dose of statin with or without other lipid modifying therapy (LMT).
STUDY OBJECTIVES
[00233]The primary objectives of the study were: (a) to evaluate the efficacy of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) after 24 weeks of treatment in high cardiovascular risk patients with diabetes treated with insulin and with hypercholesterolemia not adequately controlled on maximally tolerated LDL-C lowering therapy; and (b) to evaluate the safety and tolerability of alirocumab in patients with diabetes treated with insulin.
[00234]The secondary objectives of the study was to evaluate the efficacy of alirocumab in comparison to placebo on other lipid parameters at Weeks 12 and 24 (e.g., measured LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (Apo B), total cholesterol (TC), lipoprotein a (Lp(a)), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) levels, triglyceride rich lipoproteins (TGRL), apolipoprotein A-1 (Apo A-1), apolipoprotein C3 (ApoC3), and LDL particle number and size.
STUDY DESIGN
[00235]This was a Phase 3b randomized, double-blind, placebo-controlled, multinational and multicenter study to assess the efficacy and safety of alirocumab administered by subcutaneous (SC) injection in insulin treated patients at high CV risk with Type 1 or Type 2 diabetes mellitus and with hypercholesterolemia not adequately controlled on maximally tolerated LDL-C lowering therapy. The study consisted of a screening period of up to 3 weeks, a double-blind treatment period of 24 weeks, and a safety observation period of 8 weeks after the end of the double-blind treatment period.
[00236]Patients, unless they were statin intolerant, were taking a stable, maximally tolerated dose of statin therapy with or without other lipid modifying therapies (LMT). Statin dose and dose regimen as well as dose and dose regimen of other lipid modifying treatment(s) (if applicable) was stable throughout the entire study duration including for 4 weeks prior to the screening period, during the screening period, and from screening to randomization. Patients were on a stable diet for glucose and lipid management throughout the entire study duration from screening to the Week 24 visit. Patients were receiving treatment for diabetes in accordance with local/regional standards of care.
[00237]Patients were stratified by diabetes type (i.e., Type 1 diabetes versus Type 2 diabetes). Recruitment of patients with Type 2 diabetes was completed when approximately 400 patients had been randomized. Recruitment of patients with Type 1 diabetes was completed at the end of the targeted recruitment period.
[00238]Alirocumab was administered subcutaneously with a starting dose of 75 mg Q2W
for 12 weeks with a blinded up-titration to alirocumab 150 mg Q2W at Week 12 if the LDL-C
at the Week 8 visit was 70 mg/dL (1.81 mmol/L). Patients who have an LDL-C <70 mg/dL
(1.81 mmol/L) at the Week 8 visit continued with alirocumab 75 mg Q2W until the end of the treatment period.
[00239]The data on lipid parameters from blood samples were masked after randomization.
No attempts were made by the Investigator or patient to have the patient's lipid values independently evaluated after randomization until after the Week 24 visit, except for the safety of the patient, as per the Investigator's judgment.
[00240]Patients visited the study site at Weeks -3, 0, 8, 12, 20, and 24 with lab work at each visit. In addition, a phone visit was taken at Weeks 4 and 32.
[00241]Adverse events (AEs) that had occurred within 70 days of the last dose of investigational medicinal product (IMP) were documented. Patients with a serious adverse event (SAE) or an adverse event of special interest (AESI) were followed until resolution, stabilization, or death.
PATIENT SELECTION
[00242]The study enrolled a total of 517 patients, including 76 patients with Ti DM and 441 patients with T2DM.
Inclusion Criteria [00243]The patients enrolled in this study satisfied all of the following criteria:
[00244](1) Patient having Type 1 or Type 2 diabetes treated with insulin, and with the levels of LDL-C 70 mg/dL (1.81 mmol/L) not adequately controlled by a stable, maximum dose/regimen of statin that was tolerated by the patient for at least 4 weeks prior to the screening visit (Week -3) with or without other LMT. The maximum dose/regimen of statin that was tolerated by the patient was the highest registered dose/regimen tolerated by the patient based on the Investigator's judgment or concerns. Some examples of acceptable reasons for a patient taking a lower statin dose included, but were not limited to, adverse effects on higher doses, advanced age, low body mass index (BMI), regional practices, local prescribing information, or concomitant medications. Patients may have been on an alternate day dose of statin as long as the dose is consistently taken (e.g., dose every Monday, Wednesday, Friday, etc). Concomitant treatment with more than 1 statin was not permitted. Patients who had documented statin intolerance, as judged by the Investigator, and who were no longer on statin therapy as a result were also eligible for the study. The reason(s) for not being on a maximum dose/regimen of statin (including statin intolerance) were documented in the case report form.
[00245](2) Patients years of age or legal age of majority at screening visit, whichever was greater.
[00246](3) Patients diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (VVeek -3). Patients diagnosed with Type 1 diabetes needed to meet all of the following criteria:
(a) diagnosis prior to the age of 30 years;
(b) treated with a multiple daily injection regimen/basal-prandial insulin regimen or insulin pump regimen within 6 months after diagnosis; and (c) C-peptide <0.2 pmol/mL at the screening visit.
[00247](4) Glycosylated hemoglobin (HbA1c) <10% at the screening visit (Week -3).
Patients with an elevated HbA1c (up to 10%) were eligible provided that there was no plan to target a lower HbA1c during the study, based on the judgment of the Investigator.
[00248](5) Patients with documented history of CVD (including CHD and/or CHD
risk equivalents) and/or at least one additional CV risk factor.
[00249]History of CHD included at least one of the following:
(a) acute myocardial infarction (MI);
(b) silent MI;
(c) unstable angina;
(d) coronary revascularization procedure (e.g., percutaneuous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)); and (e) clinically significant CHD diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging).
[00250]CHD risk equivalents included at least one of the following:
(a) documented peripheral arterial disease satisfying at least one of the following criteria:
(i) current intermittent claudication (muscle discomfort in the lower limb that is both reproducible and produced by exercise and relieved by rest within 10 minutes) of presumed atherosclerotic origin together with ankle-brachial index 0.90 in either leg at rest;
(ii) history of intermittent claudication (muscle discomfort in the lower limb that is both reproducible and produced by exercise and relieved by rest within 10 minutes) together with endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease; and (iii) history of critical limb ischemia together with thrombolysis, endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease; and (b) documented previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, considered as being of atherothrombotic origin.
Computed tomography or magnetic radio imaging must have been performed to rule out hemorrhage .. and non-ischemic neurological disease.
[00251]Cardiovascular risk factors included at least one of the following:
(a) hypertension (established on antihypertensive medicine);
(b) current cigarette smoker;
(c) age N15 years for men and 55 years for women;
.. (d) history of micro/macroalbuminuria;
(e) history of diabetic retinopathy (preproliferative or proliferative);
(f) family history of premature CHD (in father or brother before 55 years of age; in mother or sister before 65 years of age);
(g) low HDL-C (male <40 mg/dL (1.0 mmol/L) and female <50 mg/dL (1.3 mmol/L));
and .. (h) documented chronic kidney disease (CKD) as defined by 15 eGFR <60 mUmin/1.73 m2 for 3 months or more, including the screening visit).
[00252] (6) Signed written informed consent.
Exclusion Criteria [00253]Patients who met all the above inclusion criteria were screened for the following .. exclusion criteria:
[00254](1) Exclusion criteria related to study methodology:
(a) planned to initiate new LMT during the course of the study or to modify the dose of the current LMT;
(b) not on a stable dose of LMT (including statin or other LMT) for at least 4 weeks prior to the screening visit (Week -3) or from screening to randomization, unless statin intolerant, in which case there was no statin for 4 weeks prior to the screening visit/during the screening period;
(c) use of nutraceutical products or over-the-counter therapies that may affect lipids which have not been at a stable dose for at least 4 weeks prior to the screening visit (VVeek -3) or 5 .. between screening and randomization visits;
(d) use of red yeast rice products within 4 weeks of the screening visit (VVeek -3) or between screening and randomization visits;
(e) use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization.
Topical, intra-10 articular, nasal, inhaled and ophthalmic steroid therapies were not considered as "systemic"
and were allowed;
(f) use of continuous hormone replacement therapy unless the regimen has been stable in the past 6 weeks prior to the Screening visit (VVeek -3) and no plans to change the regimen during the study;
15 (g) recent (within 3 months prior to the screening visit (VVeek -3) or between screening and randomization visits) MI, unstable angina leading to hospitalization, uncontrolled cardiac arrhythmia, CABG, PCI, carotid surgery or stenting, stroke, transient ischemic attack (TIA), endovascular procedure or surgical intervention for peripheral vascular disease;
(h) planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during 20 .. the study;
(i) history of New York Heart Association (NYHA) Class III or IV heart failure (see Table 1) within the past 12 months;
(j) systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg at screening or randomization visit;
25 (k) patient who had received plasmapharesis treatment either within 2 months prior to the screening visit (VVeek -3), between screening and randomization, or who has plans to receive it;
(I) known history of hemorrhagic stroke;
(m) known history of loss of function of PCSK9 (i.e., genetic mutation or sequence variation) 30 or known history of homozygous familial hypercholesterolemia;
(n) new cancer or active progression of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
(o) known history of positive HIV test;
(p) patient who had taken any active investigational drugs within 1 month or 5 half-lives, 35 whichever was longer;
(q) patients not previously instructed on a cholesterol lowering diet prior to the screening visit (VVeek -3);
(r) patient who withdrew consent during the screening (starting from signed ICF);
(s) unstable weight defined as a variation of >5 kg within 2 months prior to the screening visit, as judged by the Investigator;
(t) BMI >45 kg/m2 or plans to undergo bariatric surgery, weight loss program, or to initiate weight loss drugs during the course of the study;
(u) recent initiation of weight loss drugs (i.e., within 3 months prior to the screening visit or between screening and randomization) or recent bariatric surgery (within the last 6 months) and in an active weight loss phase, as judged by the Investigator;
(v) patients not treated with insulin for at least 6 months prior to the screening visit or not on a stable insulin regimen (i.e., a change in type of insulin, general timing/frequency of injections, mode or pattern of administration such as basal only (Type 2 diabetes), basal-prandial, etc.) for at least 3 months prior to the screening visit, or likelihood of requiring a change in insulin type/frequency or mode of injection during the study period;
(w) not on a stable insulin dose for at least 3 months prior to screening (i.e., more than a 30% variation in total daily insulin dose as judged by the Investigator), or likelihood of requiring intensification of insulin/antihyperglycemic regimen during the course of the study, as judged by the Investigator (e.g., addition of new agent, plans for titration of insulin dose, etc);
(x) other antihyperglycemic medications taken by the patient had not been stable for at least 3 months before the screening visit;
(y) history of recent decompensation of diabetes within 2 months prior to the screening visit (i.e., diabetic ketoacidosis or hyperosmolar hyperglycemic state (HHS));
(z) receiving or planned to receive renal replacement therapy during the study (e.g., hemodialysis, renal transplant, etc.);
(aa) presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins. Patients on thyroid replacement therapy could be included if the dosage of thyroxin had been stable for at least 3 months prior to screening and the patient's sensitive thyroid stimulating hormone (s-TSH) levels were within 10% of the normal range of the laboratory at the screening visit;
(bb) laboratory findings during the screening period (not including randomization labs, except for pregnancy test):
(i) serum TG >400 mg/dL (4.52 mmol/L) (1 repeat lab is allowed);
(ii) positive serum or urine pregnancy test in women of childbearing potential;
(iii) positive test for Hepatitis B surface antigen or Hepatitis C antibody;
(iv) eGFR <15 mL/min/1.73 m2 according to 4-variable modification in diet of renal disease (MDRD) equation;
(v) ALT or AST >3 x ULN (1 repeat lab is allowed); or (vi) creatine Phosphokinase (CPK) >3 x ULN (1 repeat lab is allowed); or (cc) conditions/situations such as:
(i) patients with short life expectancy;
(ii) requirement for concomitant treatment that could bias primary evaluation;
(iii) impossibility to meet specific protocol requirements (e.g., need for hospitalization, ability to make study visits, etc.);
(iv) patient was the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;
(v) uncooperative or any condition that could make the patient potentially non-compliant to the study procedures;
(vi) any technical/administrative reason that makes it impossible to randomize the patient in the study; or (vii) any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator or Sub-Investigator would preclude safe completion of the study or constrain endpoint assessments such as major systemic diseases, patients with short life expectancy.
Table 1: New York Heart Association (NYHA) functional classification of heart failure Class Patient Symptoms Class I (Normal) No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath).
Class ll (Mild) Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
Class Ill Marked limitation of physical activity. Comfortable at rest, but less than (Moderate) ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
[00255](2) Exclusion criteria related to the active comparator and/or mandatory background therapies: all contraindications to the background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.
[00256](3) Exclusion criteria related to the current knowledge of alirocumab:
(a) hypersensitivity to alirocumab or to any of the ingredients of alirocumab;
(b) pregnant or breastfeeding woman;
(c) woman of childbearing potential not protected by highly-effective method(s) of birth control (as defined in the ICF and/or in a local protocol addendum in case of specific local requirement) and/or who are unwilling or unable to be tested for pregnancy.
Women of childbearing potential must have a confirmed negative pregnancy test at screening and inclusion visits. They must use an effective contraceptive method throughout the entire duration of the study treatment and for at least 10 weeks after the last injection of IMP. The applied methods of contraception had to meet the criteria for a highly effective method of birth control according to the "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. M3(R2):
Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. ICH. 2009 Jun: 1-25." Postmenopausal women must be amenorrheic for at least 12 months.
STUDY TREATMENTS
Investigational medicinal product [00257]Sterile alirocumab drug product was supplied at a concentration of 75 mg/mL and 150 mg/mL in an aqueous buffer, pH 6.0, containing sucrose, histidine, and polysorbate 20, both as 1 mL volume, in an auto-injector (also known as prefilled pen).
Sterile placebo for alirocumab was prepared in the same formulation as alirocumab without the addition of protein as 1 mL volume in a prefilled pen, for the patients to perform injection training, as well as for those in the placebo treatment arm. During the screening period, the patient (or another designated person) had to perform a placebo self-injection training, using a prefilled pen, before the first administration of IMP.
[00258]For the patients randomized to alirocumab, the initial dose was 75 mg administered subcutaneously once Q2W. The dose was increased in a blinded fashion to 150 mg at Week 12 for patients randomized to alirocumab if the Week 8 LDL-C value is 70 mg/dL
(1.81 mmol/L). The patients randomized to placebo were administered their injection subcutaneously Q2W throughout the duration of the 24-week treatment period.
Route and method of administration [00259]A prefilled pen training guide (auto-injector training guide) was provided to the sites and instructions for use (auto-injector for use) were provided to the patient.
Each administration of IMP consisted of lmL subcutaneous injection in the abdomen, thigh, or outer area of upper arm (i.e., deltoid region). If another concomitant drug was being injected at the same site planned for the IMP injection, then the patient was advised to use an alternate location for administration of the IMP.
[00260]The IMP could be administered by self-injection or by another designated person (such as a spouse, relative, etc). In case a designated person was due to inject alirocumab to a patient during the study, it was ensured that this person had been adequately trained prior to administering the injection. Anyone that planned to administer the IMP was trained by the study staff.
[00261]Instructions were provided to the patient (or another designated person (such as spouse, relative, etc.) that would administer the injections) at training and as needed during the course of the study. Close supervision and feedback was given at the first visit, and other visits as needed.
[00262]The used prefilled pen was discarded in a sharps container which was provided to patients. It was recommended that the subcutaneous IMP injections be rotated within an anatomical area (e.g., right thigh, then left thigh or right abdomen, then left abdomen).
Patients also had the option to inject in a different anatomical area (e.g., thigh then abdomen or the outer area of upper arm, etc) during the study.
[00263]Patients were asked to store the IMP in a refrigerator. Prior to administration, the IMP should be set outside in a safe location at room temperature for about 30 to 40 minutes. Thereafter, the IMP should be administered as soon as possible.
Timing of administration [00264]During the screening period, patients or the designated person had to perform a placebo self-injection training using a prefilled pen, before the first IMP
injection.
[00265]At the randomization visit, the first IMP injection was done at the site by the patient or another designated person (such as spouse, relative, etc) under direct site staff supervision. Patients were monitored at the investigational site for at least 30 minutes after this first injection in this study. If the designated person changed during the course of the study, the new designated person was trained with placebo.
[00266]IMP subcutaneous injections were then performed outside of the clinic, Q2W up to the last injection. If the injection was scheduled to take place on the same date as the site visit, then the IMP was administered after the blood sampling had been completed. In exceptional cases, if a patient preferred to have the injection performed at the study site and provisions were able to be made to accommodate the administration of injections at the site, it was also allowed.
[00267]IMP should be administered subcutaneously Q2W, ideally at approximately the same time of the day. However, it was acceptable to have a window period of 3 days.
The time of the day was based upon the patient's preference.
[00268]If by mistake or due to other circumstances an injection was delayed by more than 5 7 days from the missed date or completely missed, then the patient was requested to return to the original schedule of IMP administration without administering delayed injections. If by mistake or due to other circumstances an injection was delayed by less than or equal to 7 days from the missed date, then the patient was requested to administer the delayed injection and then resume the original schedule of IMP administration.
[00269]The following classes of drugs were identified as non-IMP because the medication is either a background therapy or a potential rescue medication:
(a) statins;
(b) cholesterol absorption inhibitors (ezetimibe);
15 (c) bile acid-binding sequestrants (such as cholestyramine, colestipol, colesevelam);
(d) nicotinic acid;
(e) fibrates (such as Fenofibrate);
(f) omega-3 fatty acids 000 mg daily); and (g) insulins.
20 [00270]For background LMT, including statins, sites followed the national product label for the safety monitoring and management of patients. Patients were on stable, maximum dose/regimen of statin therapy that was tolerated by the patient with or without other LMT
during the study. Lipid profile values were blinded from samples obtained after randomization. Nevertheless, for safety reasons, sites were made aware of TG
alerts, in 25 order to make decisions on the patient's background LMT.
[00271]From the screening visit (Week -3) until the Week 24 visit, the background LMT was not changed. No dose adjustment, discontinuation, or initiation of other statins or other LMT took place during this time, unless in exceptional circumstances whereby overriding concerns (including but not limited to a TG alert posted by the central lab) warranted such 30 changes, as per the Investigator's judgment. For a TG alert that had been confirmed by repeat testing, the Investigator performed investigations, managed the patient, and modified the background LMT as per his/her medical judgment.
[00272]All fibrates were allowed at entry if the patient had tolerated the medication and remained on a stable dose. If the patient required the introduction of a fibrate during the 35 course of the study (i.e., as rescue treatment in response to a TG
alert), only fenofibrate was allowed to be added. Background LMT and insulin were provided by the Sponsor.
Patients obtained these medications in compliance with local regulations.
[00273]BLINDING PROCEDURES
[00274]Alirocumab and placebo for alirocumab were provided in identically matched prefilled pens and packaged identically, which included labeling to protect the blind. Each treatment kit was labeled with a number which was generated by a computer program from the sponsor. The treatment kit numbers were obtained by the Investigator at the time of patient randomization and subsequent patient visits scheduled via IVRS/IWRS
that were available 24 hours-a-day, 7 days-a-week.
[00275]In accordance with the double-blind design, study patients, Investigators and study site personnel remained blinded to study treatment and did not have access to the randomization (treatment codes) except under circumstances described below.
Adverse event [00276]The treatment code was unblinded by the Pharmacovigilance Department for reporting to the Health Authority of any Suspected Unexpected Serious Adverse Reaction (SUSAR), i.e., any serious adverse event that was both unexpected (per the specific section of the CIB) and reasonably associated with the use of the IMP
according to the judgment of the Investigator and/or the Sponsor.
Lipid parameters [00277]Lipid parameter values from blood samples obtained after the randomization visit, run by the central lab, were not communicated to the sites so that they were not able to deduce the treatment group of their patients based on LDL-C level attained.
The sponsor's operational team did not have access to lipid parameters associated with patient identification until after the final database lock had occurred. For safety purposes, TG
alerts for TG values 500 mg/dL any time after randomization were sent to the Investigator.
[00278]At the end of the double-blind treatment period (Week 24 visit) the Investigator continued to manage the patient's lipids in accordance with standard practice.
Any lipid values after randomization was redacted in the source documents and not shared with the Sponsor.
Anti-alirocumab antibodies [00279]Patient anti-alirocumab antibody results were not communicated to the sites while the study was ongoing. The sponsor's operational team did not have access to anti-alirocumab antibody results associated with a patient identification number until after the final database lock had occurred. The lab technicians involved in the determination of patient anti-alirocumab antibody titers were excluded from the operations team and a process was set up to prevent any potential unblinding.
Randomization code breaking during the study [00280]In case of an AE, the code was broken in circumstances when knowledge of the IMP was required for treating the patient. If possible, contact was initiated with the Monitoring Team/Study Physician before breaking the code. All calls were documented by the Monitoring Team as appropriate to include date and time of the call, name of the person contacted within the Monitoring Team, patient ID, documentation of the request, and decision for unblinding or not.
[00281]Code breaking could be performed at any time by using the proper module of the interactive voice response system (IVRS)/interactive web response system (IWRS), depending on which system was used for the site, and/or by calling any other phone number provided by the Sponsor for that purpose. However, it was preferable to contact the Study Physician to discuss the case before unblinding the case. If the blind was broken, the Investigator was requested to document the date, time of day, and reason for code breaking, and report this information on the appropriate page of the e-CRF.
When documenting the reason for unblinding, the Investigator did not provide any detail regarding the nature of the IMP. The Investigator did not divulge IMP detail to the Sponsor's representative or to any staff members until database closure. Furthermore, when completing forms (e.g., AE, SAE), the study treatment was not disclosed on the forms.
[00282]The code-breaking material was also kept at the entity responsible for the "24 hour alert system"; but this system should be used in very exceptional cases only (i.e., unavailability of IVR/IWR system or inability to contact Investigator and/or site staff).
However, the preferred option was to unblind using IVRS. The Investigators were informed by the clinical monitoring team about the availability of the local code-breaking material. A
patient card, including the relevant "24 hour alert system" telephone number, was provided to every patient who will participate in the study. Unblinding was also allowed to be performed by the Sponsor for some SAEs in order to conform to regulatory reporting requirements (i.e., for some SAEs that are both related and unexpected).
[00283]If the code was broken, the patient permanently discontinued IMP
administration.
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP
[00284]The randomized list of treatment kit numbers was generated centrally by the sponsor. The IMP (alirocumab 75 or 150 mg kits, or placebo kit) was packaged in accordance with this list.
[00285]The Trial Supply Operations Manager provided the randomized list of treatment kit numbers, and the Study Biostatistician provided the randomization scheme to the .. centralized treatment allocation system provider. Then, this centralized treatment allocation system provider generated the patient randomization list according to which it allocated the treatments to the patients.
[00286]Patients were randomized to receive either placebo or alirocumab during the double-blind treatment period. The randomization ratio alirocumab: placebo was 2:1. For each randomized patient, there were several corresponding treatment kit numbers (resupply visits), which were allocated through the centralized treatment allocation system.
The randomization was stratified by diabetes type (i.e., Type 1 versus Type 2).
[00287]The treatment kit numbers were allocated using the centralized treatment allocation system on randomization visit (Day 1, Week 0), and then at Week 12 as re-supply visits, and at unscheduled visits if needed.
[00288]For patients in the alirocumab treatment arm, the treatment kit allocated at Week 12 was based on their Week 8 LDL-C level following the up-titration rules.
Regular transfer of data was planned between the central laboratory and the centralized treatment allocation system provider in order to proceed in a blinded manner for study sites and sponsor.
[00289]Before randomizing a patient, the Investigator or designee had to contact the centralized treatment allocation system.
[00290]A randomized patient was defined as a patient who was registered and assigned with a treatment kit number from the centralized treatment allocation system, as documented from its log file. A patient could not be randomized more than once in the .. study. If a treatment was used without contacting the centralized treatment allocation system, then the patient was considered as not randomized and withdrawn from the study.
[00291]Two types of centralized treatment allocation systems, the IVRS and the IWRS, were used depending on the choice of the site.
PACKAGING AND LABELING
[00292]For the double-blind treatment period, each double-blind treatment kit, either alirocumab or placebo for alirocumab, was prepared to contain 6 prefilled pens in a child resistant package. In order to protect the blind, all double-blind treatment kit boxes for injection had the same look and feel and therefore will be labeled with a double-blind label.
[00293]In addition to the double-blind treatment kits for injection, a training kit containing 1 placebo for alirocumab prefilled pen was prepared for the purpose of instructing patients on injection administration which was to be performed prior to randomization at screening visit (Week-3, Visit 1). If deemed necessary, a second injection training with placebo for alirocumab was performed using an additional training kit prior to randomization. Injection training with placebo was performed and documented in the CRF, including if the designated person who administered IMP to the patient changed during the course of the study.
[00294]Packaging was in accordance with the administration schedule. The content of the labeling was in accordance with the local regulatory specifications and requirements.
STORAGE CONDITIONS AND SHELF LIFE
[00295]Investigators or other authorized persons (e.g., pharmacists) were responsible for storing the IMP in a secure and safe place in accordance with local regulations, labeling specifications, policies, and procedures. Control of IMP storage conditions, especially control of temperature (e.g., refrigerated storage) and information on in-use stability and instructions for handling the IMP, was managed according to the rules provided by the Sponsor.
[00296]The IMP was stored in a refrigerator between +2 C and +8 C (36 F to 46 F) at the site. The temperature of the site refrigerator was checked daily and recorded on a log sheet. The IMP that was stored at the investigational site was kept in an appropriate locked room, under the responsibility of the Investigator or designee or other authorized person in accordance with the storage conditions indicated on the label.
[00297]After the supply of IMP kits to patients at the study site visits, appropriate provisions were in place for transportation of the IMP kits from the study site to the patient's refrigerator.
STUDY ENDPOINTS
[00298]Baseline characteristics included standard demography (e.g., age, race, weight, .. height, etc.), disease characteristics including medical history, and medication history for each patient.
Primary Efficacy Endpoint [00299]The primary efficacy endpoint was the percent change in LDL-C from baseline to Week 24 in the intent-to-treat (ITT) population, using all LDL-C values regardless of .. adherence to treatment (ITT estimand). The percent change was defined as 100x (calculated LDL-C value at Week 24 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline.
[00300]The baseline calculated LDL-C value was the last LDL-C level obtained before the first double-blind IMP injection. The calculated LDL-C at Week 24 was the LDL-C level obtained within the Week 24 analysis window. All calculated LDL-C values (scheduled or unscheduled, fasting or not fasting) between Weeks 8 to 24 were allowed to be used to provide a value for the primary efficacy endpoint, if appropriate, according to above definition.
Primary safety endpoints [00301]Safety parameters (AEs, laboratory parameters, vital signs) were assessed throughout the study. The observation of safety data was as follows:
(a) pre-treatment period was defined from the signed informed consent up to the first dose of 5 double-blind IMP injection;
(b) treatment emergent adverse event (TEAE) period was defined as the time from the first dose of double-blind IMP injection to the last dose of IMP injection + 70 days (10 weeks) as residual effect of treatment is expected until 10 weeks after the stop of double-blind IMP; and (c) post-treatment period was defined as the time starting the day after the end of the TEAE
10 period up to resolution/stabilization of all SAE and AESI, whichever came last.
[00302]An AE was any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment.
[00303]An SAE was any untoward medical occurrence that at any dose:
15 (a) resulted in death;
(b) was life-threatening. The term "life-threatening" in the definition of "serious" referred to an event in which the patient was at risk of death at the time of the event;
it did not refer to an event which hypothetically might have caused death if it were more severe;
(c) required inpatient hospitalization or prolongation of existing hospitalization;
20 (d) resulted in persistent or significant disability/incapacity;
(e) was a congenital anomaly/birth defect; or (f) was a medically important event.
[00304]Medical and scientific judgment should be exercised in deciding whether expedited reporting was appropriate in other situations, such as important medical events that may 25 not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention (i.e., specific measures or corrective treatment) to prevent one of the other outcomes listed in the definition above.
[00305]The following list of medically important events was intended to serve as a guideline for determining which condition had to be considered as a medically important event. The 30 list was not intended to be exhaustive:
(a) intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias agranulocytosis, aplastic anemia, bone marrow aplasia, myelodysplasia, pancytopenia, etc), or convulsions (seizures, epilepsy, epileptic fit, absence, etc.);
(b) development of drug dependence or drug abuse;
35 (c) ALT >3 x ULN + total bilirubin >2 x ULN or asymptomatic ALT increase >10 x ULN;
(d) suicide attempt or any event suggestive of suicidality;
(e) syncope, loss of consciousness (except if documented as a consequence of blood sampling);
(f) bullous cutaneous eruptions;
(g) cancers diagnosed during the study or aggravated during the study;
(h) chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study;
and (i) suspected transmission of an infectious agent, if any suspected transmission of an infectious agent via a medicinal product (e.g., product contamination).
[00306]An adverse event of special interest (AESI) is an AE (serious or non-serious) that needs to be monitored, documented, and managed in a pre-specified manner. For this study, the AESI were:
(a) increase in ALT: ALT x ULN (if baseline ALT <ULN) Or ALT times the baseline value (if baseline ALT ULN);
(b) allergic events: allergic drug reactions and/or local injection site reactions deemed to be allergic by the Investigator (or have an allergic component), that required consultation with another physician for further evaluation of hypersensitivity/allergy as per the Investigator's medical judgment should be reported as an AESI;
(c) pregnancy: pregnancy occurring in a female patient or the partner of a male patient (if permitted by the female partner and by local regulatory authorities) during the study or within 70 days following the last dose of study drug. Pregnancy was recorded as AESI
in all cases.
Pregnancy was qualified as an SAE only if it fulfilled one or more SAE
criteria. In the event of pregnancy of a female patient included in the study, study product was discontinued. The follow-up of the pregnancy was mandatory until the outcome has been determined;
(d) symptomatic overdose with IMP. An overdose (accidental or intentional) was an event suspected by the Investigator or spontaneously notified by the patient (not based on systematic injection counts) and defined as at least twice of the intended dose within the intended therapeutic interval (i.e., 2 or more injections are administered in <7 calendar days), to be reported using the term "symptomatic OVERDOSE (accidental or intentional), indicating the circumstance in parentheses (e.g., "symptomatic overdose (accidental)" or "symptomatic overdose (intentional)"). The patient was monitored and appropriate symptomatic treatment instituted. The circumstances of the overdose were clearly specified in the verbatim and symptoms, if any, entered on separate AE/SAE forms.
Asymptomatic overdose was requested to be reported as a standard AE;
(e) neurologic events: neurologic events that require additional examinations/procedures and/or referral to a specialist were requested to be reported as an AESI. If the event did not require additional examinations/procedures and/or referral to a specialist, it was requested to be reported as a standard AE; and (f) Neurocognitive events: all neurocognitive events were considered as AESI.
Secondary Efficacy Endpoints [00307]Key secondary endpoints of the present study were as follows:
(a) percent change in calculated LDL-C from baseline to Week 24, using all LDL-C values during the efficacy treatment period (on-treatment estimand);
(b) percent change in measured LDL-C from baseline to Week 24 (ITT estimand);
(c) percent change in calculated LDL-C from baseline to Week 12 (ITT
estimand);
(d) percent change in measured LDL-C from baseline to Weeks 12 (ITT estimand);
(e) percent change in non-HDL-C from baseline to Week 24 (ITT estimand);
(f) percent change in Apo B from baseline to Week 24 (ITT estimand);
(g) percent change in total cholesterol from baseline to Week 24 (ITT
estimand);
(h) the proportion of patients reaching LDL-C <70 mg/dL at Week 24 (on-treatment estimand);
(i) the proportion of patients reaching LDL-C <50 mg/dL at Week 24 (on-treatment estimand);
(j) the proportion of patients reaching non-HDL-C <100 mg/dL at Week 24 (on-treatment estimand);
(k) the proportion of patients reaching non-HDL-C <80 mg/dL at Week 24 (on-treatment estimand);
(I) the percent change in Lp(a) from baseline to Week 24 (ITT estimand);
(m) the percent change in HDL-C from baseline to Week 24 (ITT estimand);
(n) the percent change in TG from baseline to Week 24 (ITT estimand);
(o) the percent change in LDL-C particle number from baseline to Week 24 (ITT
estimand);
and (p) the percent change in LDL-C particle size from baseline to Week 24 (ITT
estimand).
[00308]The following diabetes-related endpoints were also measured in the study:
(a) absolute change in HbA1c from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(b) absolute change in FPG from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(c) absolute change in total daily insulin dose from baseline to Weeks 12 and 24 (ITT and on-treatment estimands); and (d) absolute change in number of glucose-lowering treatments from baseline to Weeks 12 and 24 (ITT and on treatment estimands).
[00309]Other efficacy endpoints of this study included:
.. (a) percent change in calculated LDL-C from baseline to Week 12 (on-treatment estimand);
(b) percent change in measured LDL-C from baseline to Weeks 12 and 24 (on-treatment estimand);
(c) percent change non-HDL, Apo B, total cholesterol, Lp(a), HDL-C, and TG
from baseline to Weeks 12 (ITT and on-treatment estimands) and Week 24 (on-treatment estimand);
(d) proportion of patients reaching calculated LDL-C <50 and also <70 mg/dL at Weeks 12 (ITT and on-treatment estimands) and 24 (ITT estimand);
(e) proportion of patients with 50% or greater reduction from baseline in calculated LDL-C at Weeks 12 and 24 (ITT estimand);
(f) proportion of patients reaching non-HDL-C <80 mg/dL and also <100 mg/dL at Weeks 12 (ITT and on-treatment estimands) and Week 24 (ITT estimand);
(g) proportion of patients reaching Apo B <80 mg/dL at Weeks 12 and 24 (ITT
and on-treatment estimands);
(h) percent change in LDL-C particle number and size from baseline to Week 12 (ITT and on-treatment estimands) and Week 24 (on-treatment estimand);
(i) percent change in TGRL, Apo A-1, and Apo C-III from baseline to Weeks 12 and 24 (ITT
and on treatment estimands);
(j) absolute change in ratio Apo B/Apo A-1 and TC/HDL-C from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(k) proportion of patients reaching calculated LDL-C <70 and <50 mg/dL at Weeks 12 and 24 according to baseline Al c of <8% or 8% (ITT and on-treatment estimands); and (I) proportion of patients reaching calculated LDL-C <70 mg/dL and <50 mg/dL
at Weeks 12 and 24 according to baseline Al c of <median Al c or median Al c (ITT and on-treatment estimands).
STUDY PROCEDURES
[00310]The window period for Week 0 was +3 days. The window period for Weeks 8, 12 and 24 was 3 days. The window period for Weeks 4, 20, and 32 was 7 days. For all visits after Day 1/inclusion visit, if one visit date was changed, then the next visit took place according to the original schedule as outlined in Figure 1.
Blood sampling [00311]All blood sampling, including the blood sampling for determination of lipid parameters (e.g., TC, LDL-C, HDL-C, TG, non-HDL-C, Apo A, Apo B, Apo C-III, Lp(a), LDL
particle size and number) and also for plasma glucose, was performed in the morning, in fasting condition (i.e., overnight, at least 10 to 12 hours fast and refrain from smoking), and before IMP injection for all site visits throughout the study. Alcohol consumption within 48 hours and intense physical exercise within 24 hours preceding the blood sampling were discouraged. If the patient was not in fasting conditions, the blood sample was not collected, and a new appointment was given to the patient for the day after (or as close as possible to this date), with instructions to fast (see above conditions).
Laboratory tests [00312]The laboratory data were collected in accordance with the study schedule outlined in Figure 1 and the following guidelines:
(a) hematology: all visits except Weeks 4 and 20; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator;
(b) chemistry: all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator, except for plasma glucose which should be performed at Week 0 for all patients;
(c) HbA1c: screening and Weeks 0, 12, and 24;
(d) lipid panel: screening and Weeks 0, 8, 12, 20, and 24;
(e) measured LDL-C via beta quantification: Weeks 0, 12, and 24;
(f) other lipid assessments (Apo B, Apo A-1, Apo C-Ill, LDL particle size and number, Lp[a]):
Weeks 0, 12, and 24;
(g) liver panel: all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator. In case of total bilirubin values above the normal range, differentiation into conjugated and non-conjugated bilirubin will occur automatically;
(h) creatine Phosphokinase (CPK): all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator;
(i) Hepatitis B surface antigen: screening only;
(j) hepatitis C antibody: at screening and Week 24; in case of ALT increase during the study, hepatitis C antibody should be determined. If Hepatitis C antibody was positive during the study, reflexive testing was performed;
(k) pregnancy testing (in women of child bearing potential only): serum pregnancy test at screening only, urine pregnancy test at Weeks 0 and 24;
(I) thyroid stimulating hormone: screening only for patients who are taking thyroid hormone replacement;
(m) C-peptide: screening only;
(n) PCSK9 levels only at Week 0; and 5 (o) anti-alirocumab antibodies (VVeek 0, Week 12, and Week 24).
Urine samplings [00313]Urinalysis was performed at screening and Week 24 visits. Dipstick was performed and assess for pH, specific gravity, and for the presence of blood, protein, glucose, ketones, nitrates, leukocyte esterase, uro-bilinogen and bilirubin. If the dipstick was 10 abnormal, standard microscopy was then conducted. Microscopy was evaluate for the presence of red blood cells (RBC), RBC clumps, white blood cells (WBC), WBC
clumps, epithelial cells (transitional, renal tubular, and squamous), casts (hyaline, epithelial, WBC, RBC, granular, fatty, cellular, broad, waxy), crystals (triple phosphate, calcium oxalate, calcium phosphate, calcium carbonate, uric acid, amorphous, ammonium biurate, bilirubin, 15 leucine, tyrosine, cystine), bacteria, yeast- budding, yeast-hyphae, trichomonas, oval fat body, fat, mucous, and sperm.
[00314]Spot urine testing was performed for albumin and creatinine to calculate the albumin:creatinine ratio at the screening and Week 24 visits. Any clinically relevant abnormal laboratory value was immediately rechecked for confirmation before making any 20 decision for the concerned patient.
Physical examination [00315]A general physical examination was performed. If a new clinically significant abnormality or worsening from baseline was detected after inclusion, then an AE was reported and the patient was considered for further clinical investigations and/or specialist 25 consultation, as per the Investigator's medical judgment.
Blood pressure and heart rate [00316]Blood pressure (BP) was measured in sitting position under standardized conditions, approximately at the same time of the day, on the same arm, with the same apparatus (after the patient has rested comfortably in sitting position for at least 5 minutes).
30 Values were recorded in the e-CRF; both systolic BP and diastolic BP
were recorded. At the first screening visit, BP was measured in both arms. The arm with the highest diastolic pressure was determined at this visit, and BP was measured on this arm throughout the study. This highest value was recorded in the e-CRF.
[00317]Heart rate was measured at the time of the measurement of BP.
Body weight and height [00318]Body weight was obtained with the patient wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study.
.. [00319]Height was measured, as self-reported heights were not acceptable.
iTAQ questionnaire [00320]The iTAQ was a patient reported outcome (PRO) measure to assess treatment acceptability over the 4-week period prior to the completion of the questionnaire. It was requested to be completed by the patient at the Weeks 8 and 24 visits.
Insulin loq [00321]Patients were instructed to complete the insulin log in order to record his/her daily insulin dose (for basal insulin and for prandial insulin, as applicable) for at least 7 days prior to each visit, and to bring this information to the next study visit. The patient may record the daily insulin dose for more than 7 days prior to the study visits, however only the information collected for the last 7 days prior to each visit was entered into the CRF.
RESULTS
[00322]A total of 76 patients with Ti DM and 441 patients with T2DM were enrolled.
[00323]All 76 patients randomized with Ti DM were treated and therefore included in the safety population. Two randomized patients with Ti DM (both in the alirocumab group) were not included in the intent-to-treat (ITT) population.
[00324]Out of 441 patients T2DM, 3 were not treated (1 in the alirocumab group and 2 in placebo group) and therefore not included in the safety population. Twelve randomized patients with T2DM (7 in the alirocumab group and 5 in the placebo group) were not included in the ITT population.
[00325]Patients were not included in the ITT population if there was no calculated LDL-C
value available at baseline or within one of the analysis windows up to Week 24.
STUDY PATIENTS
[00326]Six (7.9%) patients with Ti DM discontinued the study treatment prematurely (3 [5.9%] in the alirocumab group (2 patients discontinued due to AE) and 3 [12.0%] in the placebo group (2 patients discontinued due to AE). All 3 patients in the alirocumab group also did not complete the study period, whereas in the placebo group, 2 patients also did not complete the study period and 1 patient remained in the study until the completion of the study period.
Table 2: Disposition of patients with T1DM as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Randomized but not treated 0 0 0 Randomized and treated 25 (100) 51 (100) 76 (100) Completed the study treatment period 22 (88.0) 48 (94.1) 70 (92.1) Did not complete the study treatment 3 (12.0) 3 (5.9) 6 (7.9) period Completed the study period 22 (88.0) 49 (96.1) 71 (93.4) Did not complete the study period 3 (12.0) 2 (3.9) 5 (6.6) Reason for treatment discontinuation Adverse event 2 (8.0) 2 (3.9) 4 (5.3) Subject did not wish to continue 1 (4.0) 1 (2.0) 2 (2.6) Reason for study discontinuation Subject did not wish to continue 3 (12.0) 2 (3.9) 5 (6.6) Status at last study contact Alive 25 (100) 51 (100) 76 (100) Dead 0 0 0 Percentages are calculated using the number of patients randomized as denominator.
[00327]Thirty-nine (8.8%) patients with T2DM discontinued the study treatment prematurely (29 (9.9%) in the alirocumab group and 10(6.8%) in the placebo group. Out of the 29 patients in the alirocumab group, 18 patients also did not complete the study and 11 patients remained in the study until the completion of the study period. In the placebo group, out of the 10 patients, 7 patients also did not complete the study period and 3 patients remained in the study until the completion of the study period.
[00328]
[00329]Table 3: Disposition of patients with T2DM as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Randomized but not treated 2 (1.4) 1 (0.3) 3 (0.7) Reason for not treated Other 2(1.4) 1(0.3) 3(0.7) Randomized and treated 145 (98.6) 293 (99.7) 438 (99.3) Completed the study treatment period 135 (91.8) 264 (89.8) 399 (90.5) Did not complete the study treatment 10 (6.8) 29 (9.9) 39 (8.8) period Completed the study period 138 (93.9) 275 (93.5) 413 (93.7) Did not complete the study period 7 (4.8) 18 (6.1) 25 (5.7) Placebo Alirocumab All (N=147) (N=294) (N=441) Reason for treatment discontinuation Adverse event 2(1.4) 15(5.1) 17(3.9) Subject did not wish to continue 3 (2.0) 8 (2.7) 11(2.5) Poor compliance to study protocol 2 (1.4) 0 2 (0.5) Death 1 (0.7) 0 1 (0.2) Other 2(1.4) 6(2.0) 8(1.8) Reason for study discontinuation Adverse event 0 1 (0.3) 1 (0.2) Death 1 (0.7) 0 1 (0.2) Subject did not wish to continue 4(2.7) 13(4.4) 17(3.9) Lost to follow-up 0 1(0.3) 1(0.2) Poor compliance to study protocol 2 (1.4) 1 (0.3) 3 (0.7) Other 0 2 (0.7) 2 (0.5) Status at last study contact Alive 146 (99.3) 294 (100) 440 (99.8) Dead 1 (0.7) 0 1 (0.2) Percentages are calculated using the number of patients randomized as denominator.
Demociraphics and baseline characteristics [00330]Baseline characteristics were generally similar in the alirocumab and placebo groups. 60.5% of randomized patients with Ti DM were male, whereas 54.2% of randomized patients with T2DM were male. Patients with Ti DM were younger with mean age of 56.1 (SD = 9.5) than patients with T2DM with mean age of 64.0 (SD =
9.1). Mean BMI for patients with Ti DM was 30.0 kg/m2 (SD=5.9) and a mean BMI of 32.6 kg/m2 (SD=5.06) was observed for patients with T2DM.
Table 4: Demographics and patient characteristics at baseline - Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Age (years) Number Mean (SD) 58.5 (7.8) 54.9 (10.1) 56.1 (9.5) Age group (years) [n(%)]
<65 19 (76.0) 42 (82.4) 61 (80.3) >=65 to <75 6(24.0) 8(15.7) 14 (18.4) >=75 0 1(2.0) 1(1.3) Gender [n(%)]
Number Male 17 (68.0) 29 (56.9) 46 (60.5) Female 8 (32.0) 22 (43.1) 30 (39.5) Weight (kg) Placebo Alirocumab All (N=25) (N=51) (N=76) Mean (SD) 86.98 (18.41) 87.93 (18.47) 87.62 (18.33) BMI (kg/m2) Mean (SD) 28.71 (4.82) 30.59 (6.25) 29.97 (5.85) Systolic blood pressure (mmHg) Mean (SD) 126.5 (15.5) 129.9 (14.5) 128.8 (14.8) Diastolic blood pressure (mmHg) Mean (SD) 69.5 (8.5) 74.7 (9.8) 73.0 (9.7) Heart rate (bpm) Mean (SD) 68.4 (9.3) 73.0 (10.9) 71.5 (10.6) BMI: Body Mass Index.
Table 5: Demographics and patient characteristics at baseline - Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Age (years) Number 147 294 441 Mean (SD) 64.0 (9.4) 63.9 (8.9) 64.0 (9.1) Age group (years) [n(%)]
<65 73 (49.7) 143 (48.6) 216 (49.0) >=65 to <75 55 (37.4) 126 (42.9) 181 (41.0) >=75 19 (12.9) 25 (8.5) 44 (10.0) Gender [n(%)]
Number 147 294 441 Male 78 (53.1) 161 (54.8) 239 (54.2) Female 69 (46.9) 133 (45.2) 202 (45.8) Weight (kg) Mean (SD) 92.58 (20.80) 92.45 (18.38) 92.49 (19.20) BMI (kg/m2) Mean (SD) 32.69 (5.50) 32.55 (4.84) 32.60 (5.06) Systolic blood pressure (mmHg) Mean (SD) 132.4 (15.5) 131.7 (16.1) 131.9 (15.9) Diastolic blood pressure (mmHg) Mean (SD) 75.1 (8.2) 76.0 (9.2) 75.7 (8.8) Heart rate (bpm) Mean (SD) 72.5 (10.9) 72.8 (10.6) 72.7 (10.7) BMI: Body Mass Index.
[00331]Calculated LDL-C at baseline was higher in patients with T1DM (mean =
121.0 mg/dL, SD = 51.2) than patient with T2DM (mean = 110.4 mg/dL, SD = 37.3).
Triglycerides at baseline were lower in patients with Ti DM median (Q1: Q3) = 102.0 mg/dL
(76.5: 135.0) than in patients with T2DM median (Q1 : Q3) = 147.0 mg/dL (105.0 : 2i2.0).
Table 6: Lipid parameters at baseline - Quantitative summary in conventional units -Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Calculated LDL-C (mg/dL) Mean (SD) 110.2 (31.2) 126.4 (58.2) 121.0 (51.2) Measured LDL-C (mg/dL) Mean (SD) 109.8 (31.4) 127.7 (58.1) 121.7 (51.1) Non-HDL-C (mg/dL) Mean (SD) 130.7 (34.2) 150.2 (62.9) 143.8 (55.6) Total Cholesterol (mg/dL) Mean (SD) 195.2 (36.0) 205.1 (65.1) 201.9 (57.1) HDL-C (mg/dL) Mean (SD) 64.4 (17.4) 54.9 (13.7) 58.1 (15.6) Triglycerides (mg/dL) Mean (SD) 100.0 (38.1) 119.1 (58.4) 112.8 (53.1) Triglycerides Rich Lipoprotein (mg/dL) Mean (SD) 20.9 (7.6) 23.7 (11.4) 22.8 (10.4) Lipoprotein-(a) (mg/dL) Mean (SD) 24.8 (29.2) 22.8 (23.0) 23.5 (25.1) Apolipoprotein B (mg/dL) Mean (SD) 87.0 (21.0) 99.7 (35.6) 95.4 (31.8) Apolipoprotein Al (mg/dL) Mean (SD) 166.3 (23.8) 152.3 (26.4) 157.0 (26.2) With respect to other lipid parameters, Ti DM patients exhibited a percentage reduction from baseline in LDL-C particle number (LS Mean) of 40.7% at week 12 and 44.4% at week 24 and percentage reduction in LDL-C particle size of 2.3% at week 12 and 2.3% at week 24.
ApoC3 was reduced in these patients by 6.9% at week 12 and 7.5% at week 24.
Table 7: Lipid parameters at baseline - Quantitative summary in conventional units -Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Calculated LDL-C (mg/dL) Mean (SD) 109.6 (39.1) 110.8 (36.5) 110.4 (37.3) Measured LDL-C (mg/dL) Mean (SD) 110.5 (37.4) 112.1 (34.3) 111.6 (35.3) Non-HDL-C (mg/dL) Mean (SD) 144.9 (48.5) 144.7 (42.6) 144.8 (44.6) Placebo Alirocumab All (N=147) (N=294) (N=441) Total Cholesterol (mg/dL) Mean (SD) 189.9 (47.6) 190.2 (42.4) 190.1 (44.1) HDL-C (mg/dL) Mean (SD) 44.9 (13.2) 45.5 (12.5) 45.3 (12.7) Triglycerides (mg/dL) Mean (SD) 189.4 (148.2) 174.6(110.1) 179.5 (124.2) Triglycerides Rich Lipoprotein (mg/dL) Mean (SD) 34.6 (27.4) 33.2 (20.5) 33.7 (23.0) Lipoprotein-(a) (mg/dL) Mean (SD) 29.7 (37.6) 38.9 (49.6) 35.8 (46.1) Apolipoprotein B (mg/dL) Mean (SD) 96.2 (26.8) 97.0 (24.7) 96.7 (25.4) Apolipoprotein Al (mg/dL) Mean (SD) 141.7 (23.8) 141.6 (22.8) 141.6 (23.1) [00332]With respect to other lipid parameters, T2DM patients exhibited a percentage reduction from baseline in LDL-C particle number (LS Mean) of 37.6% at week 12 and 38.3% at week 24 and percentage reduction in LDL-C particle size of 2.6% at week 12 and .. 2.8% at week 24. ApoC3 was reduced in these patients by 6.3% at week 12 and 5.8% at week 24.
[00333]In patients with Ti DM, the mean durations of diabetes and of insulin use were similar between treatment groups. The mean duration of diabetes was 34.92 years (SD=12.67) and the mean duration of insulin use was 34.81 years (SD=12.77). In patients with T2DM, the mean durations of diabetes and of insulin use were similar between treatment groups. The mean duration of diabetes was 16.75 years (SD=8.13) and the mean duration of insulin use was 8.01 years (SD=6.90) in T2DM.
[00334]The duration of hypercholesterolemia was generally similar between treatment groups and between patients with Ti DM and T2DM.
[00335]The proportion of patients with statin intolerance, as was reported by the investigator, was 31.6% in patients with Ti DM and 23.8% in patients with T2DM.
[00336]The proportion of patients receiving fibrates at randomization was 2.6%
in patients with Ti DM and 8.8% in patients with T2DM.
[00337]The proportion of patients on cholesterol absorption inhibitors (including ezetimibe) at randomization was higher in the alirocumab group (13.6%) than in the placebo group (7.6%), especially in patients with T2DM: 45 patients (15.3%) versus 10 patients (6.8%).
[00338]Cardiovascular history and risk factors were generally similar between treatment groups. The following differences were observed between patients with Ti DM
and T2DM:
(1) ASCVD was more frequent in patients with T2DM than in patients with Ti DM
(40.1`)/0 versus 21.1%) with more frequent coronary heart disease (34.7% versus 15.8%) and stroke (8.2% versus 2.6%), and less frequent PAD (4.3% versus 9.2%) in T2DM versus Ti DM
patients.
(2) Among patients without ASCVD, 56.7 % of patients with Ti DM had target organ damage (microalbuminuria, macroalbuminuria) and/or CKD and/or retinopathy versus 39.4 % of patients with T2DM. Still among patients without ASCVD, the following additional cardiovascular risk factors were observed:
(a) More frequently in Ti DM than in T2DM patients: currently smoker (20.0%
versus 14.0%), pre-proliferative diabetic retinopathy (36.7% versus 12.9%) and proliferative diabetic retinopathy (20.0% versus 5.7%).
(b) Less frequently in Ti DM than in T2DM patients: Hypertension (55.0% versus 84.8%), microalbuminuria (10.0% versus 19.7%), low HDL-C (16.7% versus 28.0%).
(3) The presence of 3 or more additional CV risk factors in patients without ASCVD was observed in 45% of patients with Ti DM and 55.7% of patient with T2DM.
[00339]Overall, Ti DM and T2DM patients were treated with high and moderate intensity statins in both treatment groups with a higher proportion of patients were treated with moderate intensity statins (58.9%). Overall, 59.0 % of Ti DM and T2DM patients were only treated with statin.
Table 9: Background lipid modifying therapies at randomization Placebo Alirocumab All (N=172) (N=345) (N=517) Any statin [n (%)] 129 (75.0) 258 (74.8) 387 (74.9) Intensity of statina'c [n (%)]
Number 127 257 384 High 38 (29.5) 102 (39.5) 140 (36.2) Moderate 85 (65.9) 143 (55.4) 228 (58.9) Low 4(3.1) 12(4.7) 16(4.1) Statin alone [n (%)] 100 (58.1) 205 (59.4) 305 (59.0) Any statin in addition to other LMT [n (%)] 29 (16.9) 53 (15.4) 82 (15.9) Other LMT only (without statin) [n (%)] 11(6.4) 32 (9.3) 43 (8.3) Any LMT other than statinsb [n (%)] 40 (23.3) 85 (24.6) 125 (24.2) Fibrates 15(8.7) 26(7.5) 41(7.9) Bile acid sequestrant 0 1 (0.3) 1 (0.2) Cholesterol absorption inhibitor 13(7.6) 47 (13.6) 60 (11.6) Placebo Alirocumab All (N=172) (N=345) (N=517) Nicotinic acid and derivates 2(1.2) 3(0.9) 5(1.0) Omega 3 fatty acids >= 1000mg/day 17 (9.9) 16 (4.6) 33 (6.4) PCSK9 inhibitor 0 0 0 Nutraceuticals impacting lipids/other 4(2.3) 10(2.9) 14(2.7) No LMT (neither statins or other LMT) [n (%)] 32 (18.6) 55 (15.9) 87 (16.8) Note:
a Only for patients who are currently taking statin.
in combination with statins or not.
c High intensity statin corresponds to atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily or sinnvastatin 80nng daily.
Moderate intensity statin corresponds to atorvastatin 10 to 20 mg daily or rosuvastatin 5 to 10 mg daily or sinnvastatin 20 to 40 mg daily or pravastatin 40 to 80 mg daily or lovastatin 40 mg daily or fluvastatin 80 mg daily or pitavastatin 2 to 4 mg daily.
Low intensity statin corresponds to sinnvastatin 10 mg daily or pravastatin 10 to 20 mg daily or lovastatin 20 mg daily or fluvastatin 20 to 40 mg daily or pitavastatin 1 mg daily.
Patients receiving more than one intensity level of statin is counted in the highest intensity level.
% calculated using the number of patients randomized as denominator except for each intensity of statins where % is calculated using the number of patients on statins as denominator and for each daily dose category where % is calculated using the number of patients taking that particular statin as denominator.
[00340]The exposure of the safety population to investigational medicinal product is summarized in Table 10.
Table 10: Exposure to investigational medicinal product - Injection Placebo Alirocumab (N=170) (N=344) Duration of IMP injection exposure (weeks) Mean (SD) 23.31 (3.92) 23.16 (3.90) Duration of IMP injection exposure by category [n (%)]
>=1 day to <4 weeks 0 2 (0.6) >=4 weeks to <8 weeks 5 (2.9) 6 (1.7) >=8 weeks to <12 weeks 1 (0.6) 6 (1.7) >=12 weeks to <16 weeks 3(1.8) 7(2.0) >=16 weeks to <24 weeks 13 (7.6) 34 (9.9) >=24 weeks 148 (87.1) 289 (84.0) Number of IMP injections Mean (SD) 11.3 (2.0) 11.3 (2.1) Titration [n (%)]
Patients up-titrateda NA 77/326 (23.6) Note:
a up-titrated patients according to IVRS Week 12 transaction with at least one injection of alirocunnab 150nng afterwards. Denominator corresponding to patients with at least one injection post W12 IVRS transaction.
Patients are considered in the treatment group they actually received.
The duration of IMP injection exposure in weeks is defined as: (last IMP
injection date + 14 days - first IMP
injection date)/7, regardless of intermittent discontinuations.
EFFICACY
Primary efficacy endpoint [00341]Alirocumab was superior to placebo on percentage of change in calculated LDL-C
from baseline to Week 24 in the ITT population of patients with Ti DM and T2DM
(as shown in Tables 11 and 12, and in Figures 2 and 3). Among the Ti DM patients, the proportion of individuals achieving LDL-C <70 mg/dL (<1.8 mmol/L) was 70.2% in the alirocumab group and 5.1% in the placebo group (P<0.0001), and the proportion of individuals attaining LDL-C of <50 mg/dL (1.3 mmol/L) was 55.1`)/0 in the alirocumab group and 0% in the placebo group (P value not computable). Among the T2DM patients, the proportion of individuals achieving LDL-C <70 mg/dL (<1.8 mmol/L) was 76.4% in the alirocumab group and 7.4% in the placebo group (P<0.0001), and the proportion of individuals attaining LDL-C of <50 mg/dL (1.3 mmol/L) was 50.7% in the alirocumab group and 2.4% in the placebo group (P<0.0001). The sensitivity analysis on the primary efficacy endpoint showed similar results in both populations (data are not shown).
Table 11: Percent change in calculated LDL-C from baseline to Week 24: MMRM -Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab Calculated LDL Cholesterol (N=25) (N=49) Baseline (mmol/L) Number 25 49 Mean (SD) 2.9 (0.8) 3.2 ( 1.2) Median 2.6 3.0 Min : Max 2:5 1:7 Baseline (mg/dL) Number 25 49 Mean (SD) 110.2 (31.2) 122.5 ( 47.8) Median 100.0 114.0 Min : Max 71:180 48:273 Week 24 percent change from baseline (%) LS mean (SE) -3.9 ( 5.3) -51.8 (3.7) LS mean difference (SE) vs placebo -47.8 (6.5) 95% Cl (-60.7 to -35.0) p-value vs placebo <.0001*
Note:
Least-squares (LS) means, standard errors (SE) and p-value taken from MMRM
(mixed-effect model with repeated measures) analysis.
The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline value-by-time point interaction.
MMRM model run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
MMRM model and baseline description run on patients with a baseline value and a post-baseline value in at least one of the analysis windows used in the model.
The p-value is followed by a "' if statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I error rate at the 0.05 level.
Table 12: Percent change in calculated LDL-C from baseline to Week 24: MMRM -Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab Calculated LDL Cholesterol (N=142) (N=297) Baseline (mmol/L) Number 142 287 Mean (SD) 2.8 (1.0) 2.9 (0.9) Median 2.6 2.7 Min : Max 1:8 1:7 Baseline (mg/dL) Number 142 287 Mean (SD) 109.5 (38.7) 110.3 (35.9) Median 102.0 104.0 Min : Max 43: 309 45: 279 Week 24 percent change from baseline (%) LS mean (SE) 0.8 (2.2) -48.2 (1.6) LS mean difference (SE) vs placebo -49.0 (2.7) 95% Cl (-54.4 to -43.6) p-value vs placebo <.0001*
Note:
Least-squares (LS) means, standard errors (SE) and p-value taken from MMRM
(mixed-effect model with repeated measures) analysis.
The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline value-by-time point interaction.
MMRM model run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
MMRM model and baseline description run on patients with a baseline value and a post-baseline value in at least one of the analysis windows used in the model.
The p-value is followed by a "' if statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I error rate at the 0.05 level.
Secondary efficacy endpoints 5 [00342]Alirocumab resulted in significant reductions from baseline to Week 24 (difference versus placebo) in levels of non-HDL-C, ApoB, total cholesterol, and Lp(a), as well as increase in HDL-C in the ITT population of patients with Ti DM and T2DM (as shown in Tables 13 and 14, respectively).
Table 13: Percent change in key secondary efficacy endpoints from baseline -10 Patients with Type 1 Diabetes Selected key secondary efficacy Placebo Alirocumab Difference vs.
endpoints (N=25) (N=49) placebo, %
% change from baseline, mean (SD) [95% C/], P-value Calculated LDL-C (Week 12) -4.5 (5.0) -49.4 (3.5) -44.8 (6.1) [-56.9 to -32.8], P<0.0001 Non-HDL-C (Week 24) -3.2 (4.8) -45.9 (3.3) -42.7 (5.8) [-54.2 to -31.3], P<0.0001 Apo B (Week 24) -0.4 (4.3) -39.4 (3.0) -39.0 (5.3) [-49.4 to -28.7], P<0.0001 Total cholesterol (Week 24) -0.7 (3.6) -29.9 (2.5) -29.2 (4.3) [-37.8 to -20.7], P<0.0001 Lp(a) (Week 24) -4.3 (5.3) -23.0 (3.8) -18.7 (6.5) [-31.4 to -6.0], P<0.0001 HDL-C (Week 24)t 7.3 (3.5) 11.2 (2.4) 3.9 (4.1) [-4.2 to 12.0], P=0.343t Triglycerides (Week 24)t 1.9 (6.7) -13.6 (4.7) -15.5 (8.1) [-31.4 to 0.4], P=0.056t LDL particle numbers (Week 24) -4.4 (4.6) -44.4 (3.2) -40.0 (5.6) [-51.0 to -28.9], P<0.0001t LDL particle size (Week 24) 0.8 (0.5) -2.3 (0.3) -3.0 (0.6) [-4.2 to -1.9], P<0.0001t ApoC3 (Week 24, ITT) 1.6 (5.8) -7.4 (4.0) -9.0 [ 22.7 to 4.8]
ApoA-I (Week 24, ITT) 7.9 (2.6) 10.2 (1.8) 2.3 [ 3.8 to 8.4]
TRL-C (Week 24, ITT) -8.4 (8.1) -24.7 (5.6) -16.3 [-35.4 to 2.8]
TRL-C (Week 24, on-treatment) -4.2 (8.2) -24.3 (5.8) -20.1 [ 39.5 to 0.6]
iHierarchical testing terminated at the endpoint triglycerides in participants with T2D and at the endpoint HDL-C
in participants with Ti D, therefore all subsequent statistical comparisons were not considered statistically significant.
tP-values for descriptive purposes only.
Apo, apolipoprotein; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; non-HDL-C, non-high-density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein cholesterol; SE, standard error; SD, standard deviation.
Table 14: Percent change in key secondary efficacy endpoints from baseline -Patients with Type 2 Diabetes Selected key secondary efficacy Placebo Alirocumab Difference vs.
endpoints (N=142) (N=287) placebo, %
% change from baseline, mean (SD) [95% CU, P-value Calculated LDL-C (Week 12) 1.4 (2.1) -48.8 (1.4) -50.2 (2.5) [ 55.2 to -45.3], P<0.0001 Non-HDL-C (Week 24) 0.7 (2.0) -37.9 (1.4) -38.7 (2.4) [ 43.4 to -33.9], P<0.0001 Apo B (Week 24) 3.3 (1.7) -33.4 (1.3) -36.7 (2.1) [ 40.9 to -32.5], P<0.0001 Total cholesterol (Week 24) 0.8 (1.5) -26.8 (1.0) -27.6 (1.8) [ 31.2 to -24.1], P<0.0001 Lp(a) (Week 24) -0.5 (2.2) -19.0 (1.6) -18.4 (2.7) [ 23.7 to -13.2], P<0.0001 HDL-C (Week 24)t 3.7 (1.4) 8.1 (1.0) 4.4 (1.7) [1.1 to 7.7], P<0.01 Triglycerides (Week 24)t 0.0 (2.7) -5.7 (2.0) -5.7 (3.4) [ 12.3 to 0.9], P=0.0902t LDL particle numbers (Week 24) 1.9 (1.9) -38.3 (1.3) -40.2 (2.3) [ 44.7 to -35.6], P<0.0001t LDL particle size (Week 24) -0.3 (0.2) -2.8 (0.1) -2.5 (0.2) [ 2.9 to 2.0], P<0.0001t ApoC3 (Week 24, ITT) 4.2 (2.3) -5.8 (1.7) -10.0 [ 15.6 to 4.4]
ApoA-I (Week 24, ITT) 4.5 (1.0) 7.4 (0.7) 2.9 [0.5 to 5.4]
TRL-C (Week 24, ITT) 1.4 (3.3) -15.7 (2.3) -17.2 (4.0) [ 25.1 to -9.3]
TRL-C (Week 24, on-treatment) 2.2 (3.4) -16.4 (2.4) -18.6 [ 26.6 to 10.5]
Hierarchical testing terminated at the endpoint triglycerides in participants with T2D and at the endpoint HDL-C
in participants with Ti D, therefore all subsequent statistical comparisons were not considered statistically significant.
tP-values for descriptive purposes only.
Apo, apolipoprotein; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; non-HDL-C, non-high-density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein cholesterol; SE, standard error; SD, standard deviation.
Diabetes-related endpoints [00343]Overall, FPG and HbA1c, and glucose lowering treatments remained stable over time in patients with Ti DM and T2DM in both treatment groups.
[00344]Regarding HbA1c, in the Ti DM cohort, in the alirocumab group the mean HbA1c %
was 7.84% (SD=0.94) at baseline with mean absolute change=-0.03% (0.6), while in the placebo group the mean HbA1c was 7.68 % (0.78) at baseline, with mean absolute change=-0.23% (0.36). In the T2DM cohort, in the alirocumab group the mean HbA1c was 7.52% (0.96) at baseline with mean absolute change=0.18% (0.74), while in the placebo group the mean HbA1c was 7.54% (1.02) at baseline with mean absolute change=0.06%
(0.66).
[00345]Regarding FPG, in the Ti DM cohort, in the alirocumab group the mean FPG was 173 mg/dL (SD=70.6) at baseline with mean absolute change=-0.03 mg/dL (0.6), while in the placebo group the mean FPG was 166.5 mg/dL (75.6) at baseline with mean absolute change=14.6 mg/dL (75.9). In the T2DM cohort, in the alirocumab group the mean FPG
was 154.1 mg/dL (50.1) at baseline with mean absolute change=9.5 mg/dL (61.8), while in the placebo group the mean FPG was 153.5 mg/dL (52.5) at baseline with mean absolute change=10.0 mg/dL (47.0).
Safety [00346]A total of 344 patients (51 Ti DM and 293 T2DM) were exposed to alirocumab and 170 patients (25 T1DM and 145 T2DM) to a placebo.
[00347]Overall, rates of patients with any treatment emergent adverse events (TEAEs) were similar across treatment groups in the safety population of patients with Ti DM or T2DM (see Table 15).
Table 15: Overview of adverse event profile: treatment emergent adverse events Placebo Alirocumab All (N=170) (N=344) (N=514) n(%) n(%) n(%) Patients with any TEAE 109 (64.1) 222 (64.5) 331 (64.4) Patients with any treatment emergent 14 (8.2) 25 (7.3) 39 (7.6) SAE
Patients with any TEAE leading to death 1 (0.6) 0 1 (0.2) Patients with any TEAE leading to 4 (2.4) 17 (4.9) 21(4.1) permanent treatment discontinuation Note:
TEAE: Treatment Emergent Adverse Event; SAE: Serious Adverse Event.
n (%) = number and percentage of patients with at least one TEAE.
[00348]TEAEs were more frequently 10%) reported in the following system organ classes (SOCs):
(a) infections and infestations (21.8% in alirocumab versus 21.8% in placebo);
(b) gastrointestinal disorders (13.1% in alirocumab versus 12.4% in placebo);
(c) musculoskeletal and connective tissue disorders (21.5% in alirocumab versus 15.9% in placebo); and (d) general disorders and administration site conditions (11.0% in alirocumab versus 8.8% in placebo) [00349]At the PT level, the most frequently reported TEAEs 2%) in the alirocumab group and with a difference 0.5% incidence from the placebo group were by decreasing order of frequency in the alirocumab group: myalgia (4.4% versus 1.8%), arthralgia (2.9% versus 1.8%), bronchitis (2.6% versus 0.6%), dizziness (2.6% versus 1.2%), and peripheral oedema (2.0% versus 0.6%). In contrast, the most frequently reported TEAEs 2%) in the placebo group and with a difference 0.5% incidence from the alirocumab group were:
influenza (2.3% versus 2.9%), pain in extremity (1.7% versus 2.9%), hypoglycemia (1.7%
versus 2.4%), cough (1.5% versus 2.9%), musculoskeletal pain (1.2% versus 2.4%), upper respiratory tract infection (0.9% versus 2.4%), hyperglycaemia (0.9% versus 2.4%), and pneumonia (0.6% versus 2.4%).
[00350]Overall, treatment emergent SAEs were reported in 25 patients (7.3%) in the alirocumab group and 14 patients (8.2%) patients in the placebo group. SAEs (at PT level) reported in more than 1 patient in either treatment groups were pneumonia (in 1 patient (0.3%) in the alirocumab group versus 2 patients (1.2%) in the placebo group), vertebral foramina! stenosis (in 2 patients (0.6%) in the alirocumab group versus no patients in the placebo group), and urinary tract infection (in 2 patients (0.6%) versus no patients in placebo group). One death due to myocardial infarction was reported in a T2DM
patient of the placebo group, 1 month after the first IMP dose administration (Visit 3).
Overall, 17 patients (4.9%) in the alirocumab group and 4 patients (2.4%) in the placebo group experienced TEAEs leading to permanent treatment discontinuation. At the PT
level, the proportion of patients with TEAE leading to permanent treatment discontinuation in more than one patient of a treatment group were: headache (2 patients (0.6%) in the alirocumab group versus no patient in the placebo group), cognitive disorder (in 2 patients (0.6%) versus no patient), allergic dermatitis (2 patients (0.6%) versus no patient) and myalgia (3 patients (0.9%) versus 2 patient (1.2%)).
[00351]As to adverse events of special Interest (AESI), increase in ALT
meeting AESI
criteria were defined as ALT n x ULN (if baseline ALT <ULN) or ALT times the baseline value (if baseline ALT l.11_N). These events were reported in 2 patients (0.6%) in the alirocumab group versus 1 patient (0.6%) in the placebo group.
[00352]Allergic drug reactions meeting AESI criteria were defined as allergic events that require consultation with another physician for further evaluation. These events were reported in 5 patients (1.5%) in the alirocumab group versus 4 patients (2.4%) in the placebo group. These reactions were mainly skin and subcutaneous tissue disorders, reported in 3 patients (0.9%) in the alirocumab group (1 allergic dermatitis,1 eczema, and 1 photosensitivity reaction) and in 2 patients (1.2%) in the placebo group (1 dermatitis, 1 drug eruption). The two other AESI allergic drug reactions in the alirocumab group were drug hypersensitivity and eosinophilia.
[00353]Neurologic events meeting AESI criteria were defined as neurologic events that require additional examinations/procedures and/or referral to a specialist.
Such events were reported in 1 patient (0.3%) in the alirocumab group (paraesthesia) versus 1 patient (0.6%) in the placebo group (dysphagia). Both events were reported in T2DM
patients.
[00354]All neurocognitive events were considered as AESI. Neurocognitive events as per sponsor or FDA grouping were reported in 4 patients (1.2%) in the alirocumab group versus no patients in the placebo group. All events were reported in T2DM patients: a cognitive disorder was reported in 2 patients (0.6%), and memory impairment and amnesia in 1 patient (0.3%) each. Of note, the 2 cognitive disorders also led to permanent treatment discontinuation.
[00355]Local injection site reactions meeting AESI criteria were defined as either local injection site reactions that were allergic and required consultation with another physician or 5 local injection site reactions that were non-allergic that were clinically significant (e.g.
reaction of swelling or erythema with a diameter >2.5 cm; reaction that interferes with activity). LISR confirmed per investigator as related to IMP (per eCRF') were reported in 6 patients (1.7%) in the alirocumab group versus 8 patients (4.7%) in the placebo group (injection site reaction of the placebo for alirocumab). No local injection site reactions 10 (LISR) meeting AESI criteria, defined as reactions that require consultation with another physician for further evaluation, were reported.
[00356]There was no report of symptomatic overdose or pregnancy.
[00357]Analyses of liver function tests (ALT, AST, ALP, total bilirubin), CPK
and renal function tests (creatinine, eGFR, BUN) did not reveal differences between the treatment 15 groups in the changes over time for any of the studied parameters. PCSA
analyses did not identify PCSA of ALT increase in any treatment groups during the study. In patients with normal CPK values at baseline, an increase > 3 ULN (and 10 ULN) was reported in 7 patients (2.1%) in the alirocumab group versus 1 patient (0.6%) in the placebo group. All patients were with T2DM. No CPK increase > 10 ULN was reported.
20 [00358]Numerical, minor differences were observed in the proportions of patients with mild, moderate, or severe decrease in glomerular filtration rate (GFR) during the treatment period, regardless of the baseline status: mild, moderate and severe decreases in GFR in 49.7%, 28.1% and 3.8% of patients, respectively in the alirocumab group, and in 50.6%, 24.4% and 3.6% of patients, respectively in the placebo group. Similarly, blood creatinine 25 increases (30% and < 100%) were measured in 13 (3.8%) patients in the alirocumab group versus 5 patients (3.0%) in the placebo group. No patient had increase in blood creatinine >= 100%. There was no meaningful difference in renal function.
[00359]No meaningful differences for vital signs were observed between treatment groups.
Example 3: Analysis of Individuals with Type 2 Diabetes Mellitus and ASCVD
from 30 Odyssey DM-Insulin Clinical Trial [00360]Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and low-density lipoprotein particle number (LDL-PN). Presence of atherosclerotic cardiovascular disease 35 -- (ASCVD) increases the risk of future cardiovascular events.
[00361]In this analysis, we evaluated the efficacy and safety of alirocumab among individuals with T2DM, high LDL-C, or non-HDL-C, and established ASCVD
receiving maximally tolerated statin in the DM-Insulin study. DM-Insulin study participants with ASCVD and Ti DM were not included in this analysis due to the low number of individuals in this group (alirocumab: n=11; placebo: n=5). As used in this Example, ASCVD
was defined as coronary heart disease (CHD; acute and silent myocardial infarction (MI), and unstable angina), ischemic stroke, or peripheral arterial disease.
[00362]Baseline and efficacy data were analyzed according to studies. Efficacy analysis included Week 24 percentage reduction from baseline in non-HDL-C, LDL-C, ApoB, and LDL-PN, and percentage of individuals achieving non-HDL-C <100 mg/dL (<2.59 mmol/L), LDL-C < 70 mg/dL (<1.81 mmol/L), and ApoB <80 mg/dL at Week 24. Intention-to-treat (ITT) analysis included all randomized individuals with a baseline LDL-C value and at least one LDL-C value up to Week 24.
[00363]This analysis included 177 DM-Insulin individuals with established ASCVD and T2DM (Table 16).
Table 16: Baseline characteristics (randomized population) Alirocumab Placebo n=119) (n=58) Age, years, mean (SD) 66.2 (8.7) 64.9 (8.9) Gender, male, n (%) 79 (66.4) 32 (55.2) BMI, kg/m2, mean (SD) 32.6 (4.5) 33.4 (5.8) CHD, n (%) 102 (85.7) Si (87.9) Acute MI 59 (49.6) 18 (31.0) Silent MI 4 (3.4) 4 (6.9) Unstable angina 15 (12.6) 4 (6.9) Coronary revascularization 80 (67.2) 37 (63.8) procedure Other clinical significant CHDt 31 (26.1) 15 (25.9) Ischemic stroke, n (%) 27 (22.7) 9 (15.5) PAD, n (%) 13 (10.9) 6 (10.3) HTN,* n (%) 105 (88.2) 53 (91.4) CKD, n (%) 37 (31.1) i3(22.4) Diabetes target organ damage," n (%) 60 (50.4) 28 (48.3) Statin, n (%) 88 (73.9) 39 (67.2) Any LLT other than statin, n (%) 34 (28.6) 11 (19.0) HbA1c, %, mean (SD) 7.5 (0.9) 7.4 (1.0) FPG, mg/dL [mmol/L], mean (SD) 162.6 (52.5) 146.7 (45.2) [9.0 (2.9)] [8.1 (2.5)]
Alirocumab Placebo n=119) (n=58) Insulin, n (%) 119 (100) 57 (98.3)1 Non-insulin GLT, n (%) Biguanides 57 (47.9) 33 (56.9) Sulfonylureas 11(9.2) 7(12.1) DPP-4 inhibitor 21 (17.6) 7 (12.1) GLP-1 receptor agonist 11(9.2) 8(13.8) SGLT2 inhibitor 10(8.4) 11 (19.0) Lipids, mg/dL [mmol/L], mean (SD) Non-HDL-C 142.8 (41.5) 147.0 (54.9) [3.70 (1.08)] [3.81 (1.42)]
LDL-C 107.2 (35.1) 111.9 (46.4) [2.78 (0.91)] [2.90 (1.20)]
ApoB 96.4 (25.1) 98.7 (32.0) LDL-PN, nmol/L, mean (SD) 1339.5 (408.5) 1425.0 (467.9) # _________________________________________________________________ tDiagnosis by invasive/non-invasive testing. Includes patients with established HTN on anti-HTN medication. Defined as estimated glomerular filtration rate 15-60 mL/min/1.73 m2.
"Defined as microalbuminuria, macroalbuminuria, retinopathy, and/or CKD. lOne individual in the placebo group was not receiving insulin at the time of randomization, and remained without insulin treatment for the duration of the study.
BMI, body mass index; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like petite 1; GLT, glucose-lowering treatment; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HTN, hypertension; SGLT2, sodium/glucose contransporter 2.
[00364]Regardless of treatment allocation, 89.3% of individuals analyzed had a history of hypertension, and 28.2% had chronic kidney disease (CKD), on top of ASCVD. In total, 20.3% demonstrated a history of ischemic stroke, and 10.7% had peripheral arterial -- disease (PAD). At baseline, the mean (standard deviation [SD]) non-HDL-C
level was 144.2 (46.2) mg/dL [3.73 (1.20) mmol/L]; the mean LDL-C level was 108.7 (39.1) mg/dL
[2.82 (1.01) mmol/L], regardless of treatment allocation.
Efficacy [00365]Alirocumab reduced non-HDL-C, ApoB, LDL-PN, and LDL-C from baseline at Week -- 24 versus control (Figure 4). At Week 24, a significantly greater proportion of individuals achieved non-HDL-C <100 mg/dL (<2.59 mmol/L), LDL-C <70 mg/dL (< 1.81 mmol/L), and ApoB < 80 mg/dL versus control (all P<0.0001; Figure 5).
Safety [00366]The safety analysis was conducted in a pooled population of individuals with T2DM, -- high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in the DM-Insulin study, and individuals with Ti DM or T2DM, high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in the DM-Dyslipidemia study (see Chan et al. (2017) Ann Trans! Med. 5(23):477, which is incorporated by reference herein in its entirety). In total, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events (TEAEs; Table 17). The adverse event pattern was similar in both groups. Mean (SD) levels of HbA1c were similar in each treatment group at baseline (alirocumab: 7.3 [0.9]%; control: 7.3 [0.9]%) and Week 24 (alirocumab: 7.6 [1.2]%;
control: 7.5 [1.2]%; safety analysis). FPG levels were also similar regardless of treatment allocation at baseline (alirocumab: 154.2 [47.9] mg/dL, 8.6 [2.7] mmol/L;
control: 149.5 [43.7] mg/dL, 8.3 [2.4] mmol/L) and at Week 24 (alirocumab: 164.7 [54.9]
mg/dL, 9.1 [3.0]
mmol/L; control: 159.4 [48.4] mg/dL, 8.9 [2.7] mmol/L; safety analysis).
Table 17: Safety summary Alrocumab Control n (%) (n=213) (n=104) TEAEs 142 (66.7) 70 (67.3) Treatment-emergent SAEs 28 (13.1) 10 (9.6) TEAEs leading to death 1 (0.5) 1 (1.0) TEAEs leading to permanent treatment 13 (6.1) 2 (2.3) discontinuation TEAEs occurring in >2% of individuals by preferred term Urinary tract infection 8 (3.8) 6 (5.8) Diarrhea 8 (3.8) 6 (5.8) Nasopharyngitis 6 (2.8) 5 (4.8) Influenza 7 (3.3) 4 (3.8) Hypertension 8 (3.8) 4 (3.8) Headache 7(3.3) 1 (1.0) Musculoskeletal pain 7(3.3) 3 (2.9) Arthralgia 3(i.4) 3(2.9) Bronchitis 3 (1.4) 3(2.9) Cough 1 (0.5) 3 (2.9) Fatigue 5 (2.3) 3 (2.9) Hyperglycaemia 0 (0.0) 3 (2.9) Hypotension 2 (0.9) 3 (2.9) Nausea 4 (1.9) 3 (2.9) Pain in extremity 4(1.9) 3(2.9) Back pain 6(2.8) 2(1.9) Dizziness 6 (2.8) 3 (2.9) Cataract 5(2.3) 1(1.0) Myalgia 5(2.3) 1(1.0) SAE, serious adverse event.
Conclusions [00367]Among individuals with T2DM and ASCVD who had high LDL-C levels despite maximally tolerated statins, alirocumab significantly reduced atherogenic cholesterol content and LDL-PN versus control.
[00192]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 20%, 25%, 30%, or 35%.
[00193]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
[00194]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00195]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00196]In further embodiments the present inventions relate to uses and/or methods for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL,wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ
ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
[00197]In further embodiments the present invention relates to uses of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD).
[00198] In yet further embodiments the present invention relates to methods for treating hypercholesterolemia in a patient with T2DM and ASCVD.
[00199]In one embodiment said use and/or method comprises the steps:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
[00200]In one embodiment of said use and/or method the ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease.
[00201]In one embodiment of said use and/or method the CHD comprises acute myocardial infarction, silent myocardial infarction, and unstable angina.
[00202]In one embodiment of said use and/or method the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00203]In one embodiment of said use and/or method the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
[00204]In one embodiment of said use and/or method the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
[00205]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
[00206]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
[00207]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
[00208]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is alirocumab.
[00209]In one embodiment said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00210]In one embodiment said use and/or method further comprises the step:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
[00211]In one embodiment of said use and/or method the threshold level is 70 mg/dL.
[00212]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof is administered subcutaneously.
[00213]In one embodiment of said use and/or method the patient further receives a concomitant lipid-modifying therapy (LMT).
[00214]In one embodiment of said use and/or method the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
[00215]In one embodiment of said use and/or method the LMT is a statin therapy.
[00216]In one embodiment of said use and/or method the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
[00217]In one embodiment of said use and/or method the statin therapy is a maximally tolerated dose statin therapy.
[00218]In one embodiment of said use and/or method the cholesterol absorption inhibitor is ezetimibe.
[00219]In one embodiment of said use and/or method the patient is intolerant to a statin.
[00220]In one embodiment of said use and/or method the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
[00221]In one embodiment of said use and/or method the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
[00222]In one embodiment of said use and/or method the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol 0-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
[00223]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 30%, 35%, 40%, or 45%.
[00224]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 20%, 25%, 30%, or 35%.
[00225]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
[00226]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
[00227]In one embodiment of said use and/or method the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbAl c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
[00228]In further embodiments the present invention relates to uses and/or methods for treating hypercholesterolemia in a patient with T2DM and ASCVD, the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or 5 antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the 10 amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
EXAMPLES
[00229]The following examples are put forth so as to provide those of ordinary skill in the 15 art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, 20 molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
Example 1. Generation of Human Antibodies to Human PCSK9 [00230]Human anti-PCSK9 antibodies were generated as described in US Patent No.
8,062,640. The exemplary PCSK9 inhibitor used in the following Example is the human 25 anti-PCSK9 antibody designated "mAb316P," also known as "REGN727," or "alirocumab."
mAb316P has the following amino acid sequence characteristics: a heavy chain comprising SEQ ID NO:5 and a light chain comprising SEQ ID NO:9; a heavy chain variable region (HCVR) comprising SEQ ID NO:1 and a light chain variable domain (LCVR) comprising SEQ ID NO:6; a heavy chain complementarity determining region 1 (HCDR1) comprising 30 SEQ ID NO:2, a HCDR2 comprising SEQ ID NO:3, a HCDR3 comprising SEQ ID
NO:4, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID
NO:7, a LCDR2 comprising SEQ ID NO:8 and a LCDR3 comprising SEQ ID NO:10.
Example 2: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy INTRODUCTION
[00231]More than 380 million people worldwide have diabetes, most of whom will die from cardiovascular disease (CVD). Compared to people without diabetes, those with diabetes are at higher risk of developing CVD, develop associated clinical complications and at an earlier age, and have shortened life expectancy by about 6 to 7 years. In addition to the high human cost of disease, CVD contributes greatly to the overall healthcare expenditure in these patients.
[00232]This study, named Odyssey DM-Insulin, included adult patients with Type 1 or Type 2 diabetes mellitus on insulin therapy with hypercholesterolemia at high cardiovascular (CV) risk that was not adequately controlled on a maximally tolerated dose of statin with or without other lipid modifying therapy (LMT).
STUDY OBJECTIVES
[00233]The primary objectives of the study were: (a) to evaluate the efficacy of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) after 24 weeks of treatment in high cardiovascular risk patients with diabetes treated with insulin and with hypercholesterolemia not adequately controlled on maximally tolerated LDL-C lowering therapy; and (b) to evaluate the safety and tolerability of alirocumab in patients with diabetes treated with insulin.
[00234]The secondary objectives of the study was to evaluate the efficacy of alirocumab in comparison to placebo on other lipid parameters at Weeks 12 and 24 (e.g., measured LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (Apo B), total cholesterol (TC), lipoprotein a (Lp(a)), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) levels, triglyceride rich lipoproteins (TGRL), apolipoprotein A-1 (Apo A-1), apolipoprotein C3 (ApoC3), and LDL particle number and size.
STUDY DESIGN
[00235]This was a Phase 3b randomized, double-blind, placebo-controlled, multinational and multicenter study to assess the efficacy and safety of alirocumab administered by subcutaneous (SC) injection in insulin treated patients at high CV risk with Type 1 or Type 2 diabetes mellitus and with hypercholesterolemia not adequately controlled on maximally tolerated LDL-C lowering therapy. The study consisted of a screening period of up to 3 weeks, a double-blind treatment period of 24 weeks, and a safety observation period of 8 weeks after the end of the double-blind treatment period.
[00236]Patients, unless they were statin intolerant, were taking a stable, maximally tolerated dose of statin therapy with or without other lipid modifying therapies (LMT). Statin dose and dose regimen as well as dose and dose regimen of other lipid modifying treatment(s) (if applicable) was stable throughout the entire study duration including for 4 weeks prior to the screening period, during the screening period, and from screening to randomization. Patients were on a stable diet for glucose and lipid management throughout the entire study duration from screening to the Week 24 visit. Patients were receiving treatment for diabetes in accordance with local/regional standards of care.
[00237]Patients were stratified by diabetes type (i.e., Type 1 diabetes versus Type 2 diabetes). Recruitment of patients with Type 2 diabetes was completed when approximately 400 patients had been randomized. Recruitment of patients with Type 1 diabetes was completed at the end of the targeted recruitment period.
[00238]Alirocumab was administered subcutaneously with a starting dose of 75 mg Q2W
for 12 weeks with a blinded up-titration to alirocumab 150 mg Q2W at Week 12 if the LDL-C
at the Week 8 visit was 70 mg/dL (1.81 mmol/L). Patients who have an LDL-C <70 mg/dL
(1.81 mmol/L) at the Week 8 visit continued with alirocumab 75 mg Q2W until the end of the treatment period.
[00239]The data on lipid parameters from blood samples were masked after randomization.
No attempts were made by the Investigator or patient to have the patient's lipid values independently evaluated after randomization until after the Week 24 visit, except for the safety of the patient, as per the Investigator's judgment.
[00240]Patients visited the study site at Weeks -3, 0, 8, 12, 20, and 24 with lab work at each visit. In addition, a phone visit was taken at Weeks 4 and 32.
[00241]Adverse events (AEs) that had occurred within 70 days of the last dose of investigational medicinal product (IMP) were documented. Patients with a serious adverse event (SAE) or an adverse event of special interest (AESI) were followed until resolution, stabilization, or death.
PATIENT SELECTION
[00242]The study enrolled a total of 517 patients, including 76 patients with Ti DM and 441 patients with T2DM.
Inclusion Criteria [00243]The patients enrolled in this study satisfied all of the following criteria:
[00244](1) Patient having Type 1 or Type 2 diabetes treated with insulin, and with the levels of LDL-C 70 mg/dL (1.81 mmol/L) not adequately controlled by a stable, maximum dose/regimen of statin that was tolerated by the patient for at least 4 weeks prior to the screening visit (Week -3) with or without other LMT. The maximum dose/regimen of statin that was tolerated by the patient was the highest registered dose/regimen tolerated by the patient based on the Investigator's judgment or concerns. Some examples of acceptable reasons for a patient taking a lower statin dose included, but were not limited to, adverse effects on higher doses, advanced age, low body mass index (BMI), regional practices, local prescribing information, or concomitant medications. Patients may have been on an alternate day dose of statin as long as the dose is consistently taken (e.g., dose every Monday, Wednesday, Friday, etc). Concomitant treatment with more than 1 statin was not permitted. Patients who had documented statin intolerance, as judged by the Investigator, and who were no longer on statin therapy as a result were also eligible for the study. The reason(s) for not being on a maximum dose/regimen of statin (including statin intolerance) were documented in the case report form.
[00245](2) Patients years of age or legal age of majority at screening visit, whichever was greater.
[00246](3) Patients diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (VVeek -3). Patients diagnosed with Type 1 diabetes needed to meet all of the following criteria:
(a) diagnosis prior to the age of 30 years;
(b) treated with a multiple daily injection regimen/basal-prandial insulin regimen or insulin pump regimen within 6 months after diagnosis; and (c) C-peptide <0.2 pmol/mL at the screening visit.
[00247](4) Glycosylated hemoglobin (HbA1c) <10% at the screening visit (Week -3).
Patients with an elevated HbA1c (up to 10%) were eligible provided that there was no plan to target a lower HbA1c during the study, based on the judgment of the Investigator.
[00248](5) Patients with documented history of CVD (including CHD and/or CHD
risk equivalents) and/or at least one additional CV risk factor.
[00249]History of CHD included at least one of the following:
(a) acute myocardial infarction (MI);
(b) silent MI;
(c) unstable angina;
(d) coronary revascularization procedure (e.g., percutaneuous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)); and (e) clinically significant CHD diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging).
[00250]CHD risk equivalents included at least one of the following:
(a) documented peripheral arterial disease satisfying at least one of the following criteria:
(i) current intermittent claudication (muscle discomfort in the lower limb that is both reproducible and produced by exercise and relieved by rest within 10 minutes) of presumed atherosclerotic origin together with ankle-brachial index 0.90 in either leg at rest;
(ii) history of intermittent claudication (muscle discomfort in the lower limb that is both reproducible and produced by exercise and relieved by rest within 10 minutes) together with endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease; and (iii) history of critical limb ischemia together with thrombolysis, endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease; and (b) documented previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, considered as being of atherothrombotic origin.
Computed tomography or magnetic radio imaging must have been performed to rule out hemorrhage .. and non-ischemic neurological disease.
[00251]Cardiovascular risk factors included at least one of the following:
(a) hypertension (established on antihypertensive medicine);
(b) current cigarette smoker;
(c) age N15 years for men and 55 years for women;
.. (d) history of micro/macroalbuminuria;
(e) history of diabetic retinopathy (preproliferative or proliferative);
(f) family history of premature CHD (in father or brother before 55 years of age; in mother or sister before 65 years of age);
(g) low HDL-C (male <40 mg/dL (1.0 mmol/L) and female <50 mg/dL (1.3 mmol/L));
and .. (h) documented chronic kidney disease (CKD) as defined by 15 eGFR <60 mUmin/1.73 m2 for 3 months or more, including the screening visit).
[00252] (6) Signed written informed consent.
Exclusion Criteria [00253]Patients who met all the above inclusion criteria were screened for the following .. exclusion criteria:
[00254](1) Exclusion criteria related to study methodology:
(a) planned to initiate new LMT during the course of the study or to modify the dose of the current LMT;
(b) not on a stable dose of LMT (including statin or other LMT) for at least 4 weeks prior to the screening visit (Week -3) or from screening to randomization, unless statin intolerant, in which case there was no statin for 4 weeks prior to the screening visit/during the screening period;
(c) use of nutraceutical products or over-the-counter therapies that may affect lipids which have not been at a stable dose for at least 4 weeks prior to the screening visit (VVeek -3) or 5 .. between screening and randomization visits;
(d) use of red yeast rice products within 4 weeks of the screening visit (VVeek -3) or between screening and randomization visits;
(e) use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization.
Topical, intra-10 articular, nasal, inhaled and ophthalmic steroid therapies were not considered as "systemic"
and were allowed;
(f) use of continuous hormone replacement therapy unless the regimen has been stable in the past 6 weeks prior to the Screening visit (VVeek -3) and no plans to change the regimen during the study;
15 (g) recent (within 3 months prior to the screening visit (VVeek -3) or between screening and randomization visits) MI, unstable angina leading to hospitalization, uncontrolled cardiac arrhythmia, CABG, PCI, carotid surgery or stenting, stroke, transient ischemic attack (TIA), endovascular procedure or surgical intervention for peripheral vascular disease;
(h) planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during 20 .. the study;
(i) history of New York Heart Association (NYHA) Class III or IV heart failure (see Table 1) within the past 12 months;
(j) systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg at screening or randomization visit;
25 (k) patient who had received plasmapharesis treatment either within 2 months prior to the screening visit (VVeek -3), between screening and randomization, or who has plans to receive it;
(I) known history of hemorrhagic stroke;
(m) known history of loss of function of PCSK9 (i.e., genetic mutation or sequence variation) 30 or known history of homozygous familial hypercholesterolemia;
(n) new cancer or active progression of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
(o) known history of positive HIV test;
(p) patient who had taken any active investigational drugs within 1 month or 5 half-lives, 35 whichever was longer;
(q) patients not previously instructed on a cholesterol lowering diet prior to the screening visit (VVeek -3);
(r) patient who withdrew consent during the screening (starting from signed ICF);
(s) unstable weight defined as a variation of >5 kg within 2 months prior to the screening visit, as judged by the Investigator;
(t) BMI >45 kg/m2 or plans to undergo bariatric surgery, weight loss program, or to initiate weight loss drugs during the course of the study;
(u) recent initiation of weight loss drugs (i.e., within 3 months prior to the screening visit or between screening and randomization) or recent bariatric surgery (within the last 6 months) and in an active weight loss phase, as judged by the Investigator;
(v) patients not treated with insulin for at least 6 months prior to the screening visit or not on a stable insulin regimen (i.e., a change in type of insulin, general timing/frequency of injections, mode or pattern of administration such as basal only (Type 2 diabetes), basal-prandial, etc.) for at least 3 months prior to the screening visit, or likelihood of requiring a change in insulin type/frequency or mode of injection during the study period;
(w) not on a stable insulin dose for at least 3 months prior to screening (i.e., more than a 30% variation in total daily insulin dose as judged by the Investigator), or likelihood of requiring intensification of insulin/antihyperglycemic regimen during the course of the study, as judged by the Investigator (e.g., addition of new agent, plans for titration of insulin dose, etc);
(x) other antihyperglycemic medications taken by the patient had not been stable for at least 3 months before the screening visit;
(y) history of recent decompensation of diabetes within 2 months prior to the screening visit (i.e., diabetic ketoacidosis or hyperosmolar hyperglycemic state (HHS));
(z) receiving or planned to receive renal replacement therapy during the study (e.g., hemodialysis, renal transplant, etc.);
(aa) presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins. Patients on thyroid replacement therapy could be included if the dosage of thyroxin had been stable for at least 3 months prior to screening and the patient's sensitive thyroid stimulating hormone (s-TSH) levels were within 10% of the normal range of the laboratory at the screening visit;
(bb) laboratory findings during the screening period (not including randomization labs, except for pregnancy test):
(i) serum TG >400 mg/dL (4.52 mmol/L) (1 repeat lab is allowed);
(ii) positive serum or urine pregnancy test in women of childbearing potential;
(iii) positive test for Hepatitis B surface antigen or Hepatitis C antibody;
(iv) eGFR <15 mL/min/1.73 m2 according to 4-variable modification in diet of renal disease (MDRD) equation;
(v) ALT or AST >3 x ULN (1 repeat lab is allowed); or (vi) creatine Phosphokinase (CPK) >3 x ULN (1 repeat lab is allowed); or (cc) conditions/situations such as:
(i) patients with short life expectancy;
(ii) requirement for concomitant treatment that could bias primary evaluation;
(iii) impossibility to meet specific protocol requirements (e.g., need for hospitalization, ability to make study visits, etc.);
(iv) patient was the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;
(v) uncooperative or any condition that could make the patient potentially non-compliant to the study procedures;
(vi) any technical/administrative reason that makes it impossible to randomize the patient in the study; or (vii) any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator or Sub-Investigator would preclude safe completion of the study or constrain endpoint assessments such as major systemic diseases, patients with short life expectancy.
Table 1: New York Heart Association (NYHA) functional classification of heart failure Class Patient Symptoms Class I (Normal) No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath).
Class ll (Mild) Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
Class Ill Marked limitation of physical activity. Comfortable at rest, but less than (Moderate) ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
[00255](2) Exclusion criteria related to the active comparator and/or mandatory background therapies: all contraindications to the background therapies or warning/precaution of use (when appropriate) as displayed in the respective National Product Labeling.
[00256](3) Exclusion criteria related to the current knowledge of alirocumab:
(a) hypersensitivity to alirocumab or to any of the ingredients of alirocumab;
(b) pregnant or breastfeeding woman;
(c) woman of childbearing potential not protected by highly-effective method(s) of birth control (as defined in the ICF and/or in a local protocol addendum in case of specific local requirement) and/or who are unwilling or unable to be tested for pregnancy.
Women of childbearing potential must have a confirmed negative pregnancy test at screening and inclusion visits. They must use an effective contraceptive method throughout the entire duration of the study treatment and for at least 10 weeks after the last injection of IMP. The applied methods of contraception had to meet the criteria for a highly effective method of birth control according to the "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. M3(R2):
Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. ICH. 2009 Jun: 1-25." Postmenopausal women must be amenorrheic for at least 12 months.
STUDY TREATMENTS
Investigational medicinal product [00257]Sterile alirocumab drug product was supplied at a concentration of 75 mg/mL and 150 mg/mL in an aqueous buffer, pH 6.0, containing sucrose, histidine, and polysorbate 20, both as 1 mL volume, in an auto-injector (also known as prefilled pen).
Sterile placebo for alirocumab was prepared in the same formulation as alirocumab without the addition of protein as 1 mL volume in a prefilled pen, for the patients to perform injection training, as well as for those in the placebo treatment arm. During the screening period, the patient (or another designated person) had to perform a placebo self-injection training, using a prefilled pen, before the first administration of IMP.
[00258]For the patients randomized to alirocumab, the initial dose was 75 mg administered subcutaneously once Q2W. The dose was increased in a blinded fashion to 150 mg at Week 12 for patients randomized to alirocumab if the Week 8 LDL-C value is 70 mg/dL
(1.81 mmol/L). The patients randomized to placebo were administered their injection subcutaneously Q2W throughout the duration of the 24-week treatment period.
Route and method of administration [00259]A prefilled pen training guide (auto-injector training guide) was provided to the sites and instructions for use (auto-injector for use) were provided to the patient.
Each administration of IMP consisted of lmL subcutaneous injection in the abdomen, thigh, or outer area of upper arm (i.e., deltoid region). If another concomitant drug was being injected at the same site planned for the IMP injection, then the patient was advised to use an alternate location for administration of the IMP.
[00260]The IMP could be administered by self-injection or by another designated person (such as a spouse, relative, etc). In case a designated person was due to inject alirocumab to a patient during the study, it was ensured that this person had been adequately trained prior to administering the injection. Anyone that planned to administer the IMP was trained by the study staff.
[00261]Instructions were provided to the patient (or another designated person (such as spouse, relative, etc.) that would administer the injections) at training and as needed during the course of the study. Close supervision and feedback was given at the first visit, and other visits as needed.
[00262]The used prefilled pen was discarded in a sharps container which was provided to patients. It was recommended that the subcutaneous IMP injections be rotated within an anatomical area (e.g., right thigh, then left thigh or right abdomen, then left abdomen).
Patients also had the option to inject in a different anatomical area (e.g., thigh then abdomen or the outer area of upper arm, etc) during the study.
[00263]Patients were asked to store the IMP in a refrigerator. Prior to administration, the IMP should be set outside in a safe location at room temperature for about 30 to 40 minutes. Thereafter, the IMP should be administered as soon as possible.
Timing of administration [00264]During the screening period, patients or the designated person had to perform a placebo self-injection training using a prefilled pen, before the first IMP
injection.
[00265]At the randomization visit, the first IMP injection was done at the site by the patient or another designated person (such as spouse, relative, etc) under direct site staff supervision. Patients were monitored at the investigational site for at least 30 minutes after this first injection in this study. If the designated person changed during the course of the study, the new designated person was trained with placebo.
[00266]IMP subcutaneous injections were then performed outside of the clinic, Q2W up to the last injection. If the injection was scheduled to take place on the same date as the site visit, then the IMP was administered after the blood sampling had been completed. In exceptional cases, if a patient preferred to have the injection performed at the study site and provisions were able to be made to accommodate the administration of injections at the site, it was also allowed.
[00267]IMP should be administered subcutaneously Q2W, ideally at approximately the same time of the day. However, it was acceptable to have a window period of 3 days.
The time of the day was based upon the patient's preference.
[00268]If by mistake or due to other circumstances an injection was delayed by more than 5 7 days from the missed date or completely missed, then the patient was requested to return to the original schedule of IMP administration without administering delayed injections. If by mistake or due to other circumstances an injection was delayed by less than or equal to 7 days from the missed date, then the patient was requested to administer the delayed injection and then resume the original schedule of IMP administration.
[00269]The following classes of drugs were identified as non-IMP because the medication is either a background therapy or a potential rescue medication:
(a) statins;
(b) cholesterol absorption inhibitors (ezetimibe);
15 (c) bile acid-binding sequestrants (such as cholestyramine, colestipol, colesevelam);
(d) nicotinic acid;
(e) fibrates (such as Fenofibrate);
(f) omega-3 fatty acids 000 mg daily); and (g) insulins.
20 [00270]For background LMT, including statins, sites followed the national product label for the safety monitoring and management of patients. Patients were on stable, maximum dose/regimen of statin therapy that was tolerated by the patient with or without other LMT
during the study. Lipid profile values were blinded from samples obtained after randomization. Nevertheless, for safety reasons, sites were made aware of TG
alerts, in 25 order to make decisions on the patient's background LMT.
[00271]From the screening visit (Week -3) until the Week 24 visit, the background LMT was not changed. No dose adjustment, discontinuation, or initiation of other statins or other LMT took place during this time, unless in exceptional circumstances whereby overriding concerns (including but not limited to a TG alert posted by the central lab) warranted such 30 changes, as per the Investigator's judgment. For a TG alert that had been confirmed by repeat testing, the Investigator performed investigations, managed the patient, and modified the background LMT as per his/her medical judgment.
[00272]All fibrates were allowed at entry if the patient had tolerated the medication and remained on a stable dose. If the patient required the introduction of a fibrate during the 35 course of the study (i.e., as rescue treatment in response to a TG
alert), only fenofibrate was allowed to be added. Background LMT and insulin were provided by the Sponsor.
Patients obtained these medications in compliance with local regulations.
[00273]BLINDING PROCEDURES
[00274]Alirocumab and placebo for alirocumab were provided in identically matched prefilled pens and packaged identically, which included labeling to protect the blind. Each treatment kit was labeled with a number which was generated by a computer program from the sponsor. The treatment kit numbers were obtained by the Investigator at the time of patient randomization and subsequent patient visits scheduled via IVRS/IWRS
that were available 24 hours-a-day, 7 days-a-week.
[00275]In accordance with the double-blind design, study patients, Investigators and study site personnel remained blinded to study treatment and did not have access to the randomization (treatment codes) except under circumstances described below.
Adverse event [00276]The treatment code was unblinded by the Pharmacovigilance Department for reporting to the Health Authority of any Suspected Unexpected Serious Adverse Reaction (SUSAR), i.e., any serious adverse event that was both unexpected (per the specific section of the CIB) and reasonably associated with the use of the IMP
according to the judgment of the Investigator and/or the Sponsor.
Lipid parameters [00277]Lipid parameter values from blood samples obtained after the randomization visit, run by the central lab, were not communicated to the sites so that they were not able to deduce the treatment group of their patients based on LDL-C level attained.
The sponsor's operational team did not have access to lipid parameters associated with patient identification until after the final database lock had occurred. For safety purposes, TG
alerts for TG values 500 mg/dL any time after randomization were sent to the Investigator.
[00278]At the end of the double-blind treatment period (Week 24 visit) the Investigator continued to manage the patient's lipids in accordance with standard practice.
Any lipid values after randomization was redacted in the source documents and not shared with the Sponsor.
Anti-alirocumab antibodies [00279]Patient anti-alirocumab antibody results were not communicated to the sites while the study was ongoing. The sponsor's operational team did not have access to anti-alirocumab antibody results associated with a patient identification number until after the final database lock had occurred. The lab technicians involved in the determination of patient anti-alirocumab antibody titers were excluded from the operations team and a process was set up to prevent any potential unblinding.
Randomization code breaking during the study [00280]In case of an AE, the code was broken in circumstances when knowledge of the IMP was required for treating the patient. If possible, contact was initiated with the Monitoring Team/Study Physician before breaking the code. All calls were documented by the Monitoring Team as appropriate to include date and time of the call, name of the person contacted within the Monitoring Team, patient ID, documentation of the request, and decision for unblinding or not.
[00281]Code breaking could be performed at any time by using the proper module of the interactive voice response system (IVRS)/interactive web response system (IWRS), depending on which system was used for the site, and/or by calling any other phone number provided by the Sponsor for that purpose. However, it was preferable to contact the Study Physician to discuss the case before unblinding the case. If the blind was broken, the Investigator was requested to document the date, time of day, and reason for code breaking, and report this information on the appropriate page of the e-CRF.
When documenting the reason for unblinding, the Investigator did not provide any detail regarding the nature of the IMP. The Investigator did not divulge IMP detail to the Sponsor's representative or to any staff members until database closure. Furthermore, when completing forms (e.g., AE, SAE), the study treatment was not disclosed on the forms.
[00282]The code-breaking material was also kept at the entity responsible for the "24 hour alert system"; but this system should be used in very exceptional cases only (i.e., unavailability of IVR/IWR system or inability to contact Investigator and/or site staff).
However, the preferred option was to unblind using IVRS. The Investigators were informed by the clinical monitoring team about the availability of the local code-breaking material. A
patient card, including the relevant "24 hour alert system" telephone number, was provided to every patient who will participate in the study. Unblinding was also allowed to be performed by the Sponsor for some SAEs in order to conform to regulatory reporting requirements (i.e., for some SAEs that are both related and unexpected).
[00283]If the code was broken, the patient permanently discontinued IMP
administration.
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP
[00284]The randomized list of treatment kit numbers was generated centrally by the sponsor. The IMP (alirocumab 75 or 150 mg kits, or placebo kit) was packaged in accordance with this list.
[00285]The Trial Supply Operations Manager provided the randomized list of treatment kit numbers, and the Study Biostatistician provided the randomization scheme to the .. centralized treatment allocation system provider. Then, this centralized treatment allocation system provider generated the patient randomization list according to which it allocated the treatments to the patients.
[00286]Patients were randomized to receive either placebo or alirocumab during the double-blind treatment period. The randomization ratio alirocumab: placebo was 2:1. For each randomized patient, there were several corresponding treatment kit numbers (resupply visits), which were allocated through the centralized treatment allocation system.
The randomization was stratified by diabetes type (i.e., Type 1 versus Type 2).
[00287]The treatment kit numbers were allocated using the centralized treatment allocation system on randomization visit (Day 1, Week 0), and then at Week 12 as re-supply visits, and at unscheduled visits if needed.
[00288]For patients in the alirocumab treatment arm, the treatment kit allocated at Week 12 was based on their Week 8 LDL-C level following the up-titration rules.
Regular transfer of data was planned between the central laboratory and the centralized treatment allocation system provider in order to proceed in a blinded manner for study sites and sponsor.
[00289]Before randomizing a patient, the Investigator or designee had to contact the centralized treatment allocation system.
[00290]A randomized patient was defined as a patient who was registered and assigned with a treatment kit number from the centralized treatment allocation system, as documented from its log file. A patient could not be randomized more than once in the .. study. If a treatment was used without contacting the centralized treatment allocation system, then the patient was considered as not randomized and withdrawn from the study.
[00291]Two types of centralized treatment allocation systems, the IVRS and the IWRS, were used depending on the choice of the site.
PACKAGING AND LABELING
[00292]For the double-blind treatment period, each double-blind treatment kit, either alirocumab or placebo for alirocumab, was prepared to contain 6 prefilled pens in a child resistant package. In order to protect the blind, all double-blind treatment kit boxes for injection had the same look and feel and therefore will be labeled with a double-blind label.
[00293]In addition to the double-blind treatment kits for injection, a training kit containing 1 placebo for alirocumab prefilled pen was prepared for the purpose of instructing patients on injection administration which was to be performed prior to randomization at screening visit (Week-3, Visit 1). If deemed necessary, a second injection training with placebo for alirocumab was performed using an additional training kit prior to randomization. Injection training with placebo was performed and documented in the CRF, including if the designated person who administered IMP to the patient changed during the course of the study.
[00294]Packaging was in accordance with the administration schedule. The content of the labeling was in accordance with the local regulatory specifications and requirements.
STORAGE CONDITIONS AND SHELF LIFE
[00295]Investigators or other authorized persons (e.g., pharmacists) were responsible for storing the IMP in a secure and safe place in accordance with local regulations, labeling specifications, policies, and procedures. Control of IMP storage conditions, especially control of temperature (e.g., refrigerated storage) and information on in-use stability and instructions for handling the IMP, was managed according to the rules provided by the Sponsor.
[00296]The IMP was stored in a refrigerator between +2 C and +8 C (36 F to 46 F) at the site. The temperature of the site refrigerator was checked daily and recorded on a log sheet. The IMP that was stored at the investigational site was kept in an appropriate locked room, under the responsibility of the Investigator or designee or other authorized person in accordance with the storage conditions indicated on the label.
[00297]After the supply of IMP kits to patients at the study site visits, appropriate provisions were in place for transportation of the IMP kits from the study site to the patient's refrigerator.
STUDY ENDPOINTS
[00298]Baseline characteristics included standard demography (e.g., age, race, weight, .. height, etc.), disease characteristics including medical history, and medication history for each patient.
Primary Efficacy Endpoint [00299]The primary efficacy endpoint was the percent change in LDL-C from baseline to Week 24 in the intent-to-treat (ITT) population, using all LDL-C values regardless of .. adherence to treatment (ITT estimand). The percent change was defined as 100x (calculated LDL-C value at Week 24 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline.
[00300]The baseline calculated LDL-C value was the last LDL-C level obtained before the first double-blind IMP injection. The calculated LDL-C at Week 24 was the LDL-C level obtained within the Week 24 analysis window. All calculated LDL-C values (scheduled or unscheduled, fasting or not fasting) between Weeks 8 to 24 were allowed to be used to provide a value for the primary efficacy endpoint, if appropriate, according to above definition.
Primary safety endpoints [00301]Safety parameters (AEs, laboratory parameters, vital signs) were assessed throughout the study. The observation of safety data was as follows:
(a) pre-treatment period was defined from the signed informed consent up to the first dose of 5 double-blind IMP injection;
(b) treatment emergent adverse event (TEAE) period was defined as the time from the first dose of double-blind IMP injection to the last dose of IMP injection + 70 days (10 weeks) as residual effect of treatment is expected until 10 weeks after the stop of double-blind IMP; and (c) post-treatment period was defined as the time starting the day after the end of the TEAE
10 period up to resolution/stabilization of all SAE and AESI, whichever came last.
[00302]An AE was any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment.
[00303]An SAE was any untoward medical occurrence that at any dose:
15 (a) resulted in death;
(b) was life-threatening. The term "life-threatening" in the definition of "serious" referred to an event in which the patient was at risk of death at the time of the event;
it did not refer to an event which hypothetically might have caused death if it were more severe;
(c) required inpatient hospitalization or prolongation of existing hospitalization;
20 (d) resulted in persistent or significant disability/incapacity;
(e) was a congenital anomaly/birth defect; or (f) was a medically important event.
[00304]Medical and scientific judgment should be exercised in deciding whether expedited reporting was appropriate in other situations, such as important medical events that may 25 not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention (i.e., specific measures or corrective treatment) to prevent one of the other outcomes listed in the definition above.
[00305]The following list of medically important events was intended to serve as a guideline for determining which condition had to be considered as a medically important event. The 30 list was not intended to be exhaustive:
(a) intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias agranulocytosis, aplastic anemia, bone marrow aplasia, myelodysplasia, pancytopenia, etc), or convulsions (seizures, epilepsy, epileptic fit, absence, etc.);
(b) development of drug dependence or drug abuse;
35 (c) ALT >3 x ULN + total bilirubin >2 x ULN or asymptomatic ALT increase >10 x ULN;
(d) suicide attempt or any event suggestive of suicidality;
(e) syncope, loss of consciousness (except if documented as a consequence of blood sampling);
(f) bullous cutaneous eruptions;
(g) cancers diagnosed during the study or aggravated during the study;
(h) chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study;
and (i) suspected transmission of an infectious agent, if any suspected transmission of an infectious agent via a medicinal product (e.g., product contamination).
[00306]An adverse event of special interest (AESI) is an AE (serious or non-serious) that needs to be monitored, documented, and managed in a pre-specified manner. For this study, the AESI were:
(a) increase in ALT: ALT x ULN (if baseline ALT <ULN) Or ALT times the baseline value (if baseline ALT ULN);
(b) allergic events: allergic drug reactions and/or local injection site reactions deemed to be allergic by the Investigator (or have an allergic component), that required consultation with another physician for further evaluation of hypersensitivity/allergy as per the Investigator's medical judgment should be reported as an AESI;
(c) pregnancy: pregnancy occurring in a female patient or the partner of a male patient (if permitted by the female partner and by local regulatory authorities) during the study or within 70 days following the last dose of study drug. Pregnancy was recorded as AESI
in all cases.
Pregnancy was qualified as an SAE only if it fulfilled one or more SAE
criteria. In the event of pregnancy of a female patient included in the study, study product was discontinued. The follow-up of the pregnancy was mandatory until the outcome has been determined;
(d) symptomatic overdose with IMP. An overdose (accidental or intentional) was an event suspected by the Investigator or spontaneously notified by the patient (not based on systematic injection counts) and defined as at least twice of the intended dose within the intended therapeutic interval (i.e., 2 or more injections are administered in <7 calendar days), to be reported using the term "symptomatic OVERDOSE (accidental or intentional), indicating the circumstance in parentheses (e.g., "symptomatic overdose (accidental)" or "symptomatic overdose (intentional)"). The patient was monitored and appropriate symptomatic treatment instituted. The circumstances of the overdose were clearly specified in the verbatim and symptoms, if any, entered on separate AE/SAE forms.
Asymptomatic overdose was requested to be reported as a standard AE;
(e) neurologic events: neurologic events that require additional examinations/procedures and/or referral to a specialist were requested to be reported as an AESI. If the event did not require additional examinations/procedures and/or referral to a specialist, it was requested to be reported as a standard AE; and (f) Neurocognitive events: all neurocognitive events were considered as AESI.
Secondary Efficacy Endpoints [00307]Key secondary endpoints of the present study were as follows:
(a) percent change in calculated LDL-C from baseline to Week 24, using all LDL-C values during the efficacy treatment period (on-treatment estimand);
(b) percent change in measured LDL-C from baseline to Week 24 (ITT estimand);
(c) percent change in calculated LDL-C from baseline to Week 12 (ITT
estimand);
(d) percent change in measured LDL-C from baseline to Weeks 12 (ITT estimand);
(e) percent change in non-HDL-C from baseline to Week 24 (ITT estimand);
(f) percent change in Apo B from baseline to Week 24 (ITT estimand);
(g) percent change in total cholesterol from baseline to Week 24 (ITT
estimand);
(h) the proportion of patients reaching LDL-C <70 mg/dL at Week 24 (on-treatment estimand);
(i) the proportion of patients reaching LDL-C <50 mg/dL at Week 24 (on-treatment estimand);
(j) the proportion of patients reaching non-HDL-C <100 mg/dL at Week 24 (on-treatment estimand);
(k) the proportion of patients reaching non-HDL-C <80 mg/dL at Week 24 (on-treatment estimand);
(I) the percent change in Lp(a) from baseline to Week 24 (ITT estimand);
(m) the percent change in HDL-C from baseline to Week 24 (ITT estimand);
(n) the percent change in TG from baseline to Week 24 (ITT estimand);
(o) the percent change in LDL-C particle number from baseline to Week 24 (ITT
estimand);
and (p) the percent change in LDL-C particle size from baseline to Week 24 (ITT
estimand).
[00308]The following diabetes-related endpoints were also measured in the study:
(a) absolute change in HbA1c from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(b) absolute change in FPG from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(c) absolute change in total daily insulin dose from baseline to Weeks 12 and 24 (ITT and on-treatment estimands); and (d) absolute change in number of glucose-lowering treatments from baseline to Weeks 12 and 24 (ITT and on treatment estimands).
[00309]Other efficacy endpoints of this study included:
.. (a) percent change in calculated LDL-C from baseline to Week 12 (on-treatment estimand);
(b) percent change in measured LDL-C from baseline to Weeks 12 and 24 (on-treatment estimand);
(c) percent change non-HDL, Apo B, total cholesterol, Lp(a), HDL-C, and TG
from baseline to Weeks 12 (ITT and on-treatment estimands) and Week 24 (on-treatment estimand);
(d) proportion of patients reaching calculated LDL-C <50 and also <70 mg/dL at Weeks 12 (ITT and on-treatment estimands) and 24 (ITT estimand);
(e) proportion of patients with 50% or greater reduction from baseline in calculated LDL-C at Weeks 12 and 24 (ITT estimand);
(f) proportion of patients reaching non-HDL-C <80 mg/dL and also <100 mg/dL at Weeks 12 (ITT and on-treatment estimands) and Week 24 (ITT estimand);
(g) proportion of patients reaching Apo B <80 mg/dL at Weeks 12 and 24 (ITT
and on-treatment estimands);
(h) percent change in LDL-C particle number and size from baseline to Week 12 (ITT and on-treatment estimands) and Week 24 (on-treatment estimand);
(i) percent change in TGRL, Apo A-1, and Apo C-III from baseline to Weeks 12 and 24 (ITT
and on treatment estimands);
(j) absolute change in ratio Apo B/Apo A-1 and TC/HDL-C from baseline to Weeks 12 and 24 (ITT and on-treatment estimands);
(k) proportion of patients reaching calculated LDL-C <70 and <50 mg/dL at Weeks 12 and 24 according to baseline Al c of <8% or 8% (ITT and on-treatment estimands); and (I) proportion of patients reaching calculated LDL-C <70 mg/dL and <50 mg/dL
at Weeks 12 and 24 according to baseline Al c of <median Al c or median Al c (ITT and on-treatment estimands).
STUDY PROCEDURES
[00310]The window period for Week 0 was +3 days. The window period for Weeks 8, 12 and 24 was 3 days. The window period for Weeks 4, 20, and 32 was 7 days. For all visits after Day 1/inclusion visit, if one visit date was changed, then the next visit took place according to the original schedule as outlined in Figure 1.
Blood sampling [00311]All blood sampling, including the blood sampling for determination of lipid parameters (e.g., TC, LDL-C, HDL-C, TG, non-HDL-C, Apo A, Apo B, Apo C-III, Lp(a), LDL
particle size and number) and also for plasma glucose, was performed in the morning, in fasting condition (i.e., overnight, at least 10 to 12 hours fast and refrain from smoking), and before IMP injection for all site visits throughout the study. Alcohol consumption within 48 hours and intense physical exercise within 24 hours preceding the blood sampling were discouraged. If the patient was not in fasting conditions, the blood sample was not collected, and a new appointment was given to the patient for the day after (or as close as possible to this date), with instructions to fast (see above conditions).
Laboratory tests [00312]The laboratory data were collected in accordance with the study schedule outlined in Figure 1 and the following guidelines:
(a) hematology: all visits except Weeks 4 and 20; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator;
(b) chemistry: all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator, except for plasma glucose which should be performed at Week 0 for all patients;
(c) HbA1c: screening and Weeks 0, 12, and 24;
(d) lipid panel: screening and Weeks 0, 8, 12, 20, and 24;
(e) measured LDL-C via beta quantification: Weeks 0, 12, and 24;
(f) other lipid assessments (Apo B, Apo A-1, Apo C-Ill, LDL particle size and number, Lp[a]):
Weeks 0, 12, and 24;
(g) liver panel: all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator. In case of total bilirubin values above the normal range, differentiation into conjugated and non-conjugated bilirubin will occur automatically;
(h) creatine Phosphokinase (CPK): all visits except Visits 3 and 6; may be performed at Week 0 as applicable and based on the clinical discretion of the Investigator;
(i) Hepatitis B surface antigen: screening only;
(j) hepatitis C antibody: at screening and Week 24; in case of ALT increase during the study, hepatitis C antibody should be determined. If Hepatitis C antibody was positive during the study, reflexive testing was performed;
(k) pregnancy testing (in women of child bearing potential only): serum pregnancy test at screening only, urine pregnancy test at Weeks 0 and 24;
(I) thyroid stimulating hormone: screening only for patients who are taking thyroid hormone replacement;
(m) C-peptide: screening only;
(n) PCSK9 levels only at Week 0; and 5 (o) anti-alirocumab antibodies (VVeek 0, Week 12, and Week 24).
Urine samplings [00313]Urinalysis was performed at screening and Week 24 visits. Dipstick was performed and assess for pH, specific gravity, and for the presence of blood, protein, glucose, ketones, nitrates, leukocyte esterase, uro-bilinogen and bilirubin. If the dipstick was 10 abnormal, standard microscopy was then conducted. Microscopy was evaluate for the presence of red blood cells (RBC), RBC clumps, white blood cells (WBC), WBC
clumps, epithelial cells (transitional, renal tubular, and squamous), casts (hyaline, epithelial, WBC, RBC, granular, fatty, cellular, broad, waxy), crystals (triple phosphate, calcium oxalate, calcium phosphate, calcium carbonate, uric acid, amorphous, ammonium biurate, bilirubin, 15 leucine, tyrosine, cystine), bacteria, yeast- budding, yeast-hyphae, trichomonas, oval fat body, fat, mucous, and sperm.
[00314]Spot urine testing was performed for albumin and creatinine to calculate the albumin:creatinine ratio at the screening and Week 24 visits. Any clinically relevant abnormal laboratory value was immediately rechecked for confirmation before making any 20 decision for the concerned patient.
Physical examination [00315]A general physical examination was performed. If a new clinically significant abnormality or worsening from baseline was detected after inclusion, then an AE was reported and the patient was considered for further clinical investigations and/or specialist 25 consultation, as per the Investigator's medical judgment.
Blood pressure and heart rate [00316]Blood pressure (BP) was measured in sitting position under standardized conditions, approximately at the same time of the day, on the same arm, with the same apparatus (after the patient has rested comfortably in sitting position for at least 5 minutes).
30 Values were recorded in the e-CRF; both systolic BP and diastolic BP
were recorded. At the first screening visit, BP was measured in both arms. The arm with the highest diastolic pressure was determined at this visit, and BP was measured on this arm throughout the study. This highest value was recorded in the e-CRF.
[00317]Heart rate was measured at the time of the measurement of BP.
Body weight and height [00318]Body weight was obtained with the patient wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study.
.. [00319]Height was measured, as self-reported heights were not acceptable.
iTAQ questionnaire [00320]The iTAQ was a patient reported outcome (PRO) measure to assess treatment acceptability over the 4-week period prior to the completion of the questionnaire. It was requested to be completed by the patient at the Weeks 8 and 24 visits.
Insulin loq [00321]Patients were instructed to complete the insulin log in order to record his/her daily insulin dose (for basal insulin and for prandial insulin, as applicable) for at least 7 days prior to each visit, and to bring this information to the next study visit. The patient may record the daily insulin dose for more than 7 days prior to the study visits, however only the information collected for the last 7 days prior to each visit was entered into the CRF.
RESULTS
[00322]A total of 76 patients with Ti DM and 441 patients with T2DM were enrolled.
[00323]All 76 patients randomized with Ti DM were treated and therefore included in the safety population. Two randomized patients with Ti DM (both in the alirocumab group) were not included in the intent-to-treat (ITT) population.
[00324]Out of 441 patients T2DM, 3 were not treated (1 in the alirocumab group and 2 in placebo group) and therefore not included in the safety population. Twelve randomized patients with T2DM (7 in the alirocumab group and 5 in the placebo group) were not included in the ITT population.
[00325]Patients were not included in the ITT population if there was no calculated LDL-C
value available at baseline or within one of the analysis windows up to Week 24.
STUDY PATIENTS
[00326]Six (7.9%) patients with Ti DM discontinued the study treatment prematurely (3 [5.9%] in the alirocumab group (2 patients discontinued due to AE) and 3 [12.0%] in the placebo group (2 patients discontinued due to AE). All 3 patients in the alirocumab group also did not complete the study period, whereas in the placebo group, 2 patients also did not complete the study period and 1 patient remained in the study until the completion of the study period.
Table 2: Disposition of patients with T1DM as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Randomized but not treated 0 0 0 Randomized and treated 25 (100) 51 (100) 76 (100) Completed the study treatment period 22 (88.0) 48 (94.1) 70 (92.1) Did not complete the study treatment 3 (12.0) 3 (5.9) 6 (7.9) period Completed the study period 22 (88.0) 49 (96.1) 71 (93.4) Did not complete the study period 3 (12.0) 2 (3.9) 5 (6.6) Reason for treatment discontinuation Adverse event 2 (8.0) 2 (3.9) 4 (5.3) Subject did not wish to continue 1 (4.0) 1 (2.0) 2 (2.6) Reason for study discontinuation Subject did not wish to continue 3 (12.0) 2 (3.9) 5 (6.6) Status at last study contact Alive 25 (100) 51 (100) 76 (100) Dead 0 0 0 Percentages are calculated using the number of patients randomized as denominator.
[00327]Thirty-nine (8.8%) patients with T2DM discontinued the study treatment prematurely (29 (9.9%) in the alirocumab group and 10(6.8%) in the placebo group. Out of the 29 patients in the alirocumab group, 18 patients also did not complete the study and 11 patients remained in the study until the completion of the study period. In the placebo group, out of the 10 patients, 7 patients also did not complete the study period and 3 patients remained in the study until the completion of the study period.
[00328]
[00329]Table 3: Disposition of patients with T2DM as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Randomized but not treated 2 (1.4) 1 (0.3) 3 (0.7) Reason for not treated Other 2(1.4) 1(0.3) 3(0.7) Randomized and treated 145 (98.6) 293 (99.7) 438 (99.3) Completed the study treatment period 135 (91.8) 264 (89.8) 399 (90.5) Did not complete the study treatment 10 (6.8) 29 (9.9) 39 (8.8) period Completed the study period 138 (93.9) 275 (93.5) 413 (93.7) Did not complete the study period 7 (4.8) 18 (6.1) 25 (5.7) Placebo Alirocumab All (N=147) (N=294) (N=441) Reason for treatment discontinuation Adverse event 2(1.4) 15(5.1) 17(3.9) Subject did not wish to continue 3 (2.0) 8 (2.7) 11(2.5) Poor compliance to study protocol 2 (1.4) 0 2 (0.5) Death 1 (0.7) 0 1 (0.2) Other 2(1.4) 6(2.0) 8(1.8) Reason for study discontinuation Adverse event 0 1 (0.3) 1 (0.2) Death 1 (0.7) 0 1 (0.2) Subject did not wish to continue 4(2.7) 13(4.4) 17(3.9) Lost to follow-up 0 1(0.3) 1(0.2) Poor compliance to study protocol 2 (1.4) 1 (0.3) 3 (0.7) Other 0 2 (0.7) 2 (0.5) Status at last study contact Alive 146 (99.3) 294 (100) 440 (99.8) Dead 1 (0.7) 0 1 (0.2) Percentages are calculated using the number of patients randomized as denominator.
Demociraphics and baseline characteristics [00330]Baseline characteristics were generally similar in the alirocumab and placebo groups. 60.5% of randomized patients with Ti DM were male, whereas 54.2% of randomized patients with T2DM were male. Patients with Ti DM were younger with mean age of 56.1 (SD = 9.5) than patients with T2DM with mean age of 64.0 (SD =
9.1). Mean BMI for patients with Ti DM was 30.0 kg/m2 (SD=5.9) and a mean BMI of 32.6 kg/m2 (SD=5.06) was observed for patients with T2DM.
Table 4: Demographics and patient characteristics at baseline - Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Age (years) Number Mean (SD) 58.5 (7.8) 54.9 (10.1) 56.1 (9.5) Age group (years) [n(%)]
<65 19 (76.0) 42 (82.4) 61 (80.3) >=65 to <75 6(24.0) 8(15.7) 14 (18.4) >=75 0 1(2.0) 1(1.3) Gender [n(%)]
Number Male 17 (68.0) 29 (56.9) 46 (60.5) Female 8 (32.0) 22 (43.1) 30 (39.5) Weight (kg) Placebo Alirocumab All (N=25) (N=51) (N=76) Mean (SD) 86.98 (18.41) 87.93 (18.47) 87.62 (18.33) BMI (kg/m2) Mean (SD) 28.71 (4.82) 30.59 (6.25) 29.97 (5.85) Systolic blood pressure (mmHg) Mean (SD) 126.5 (15.5) 129.9 (14.5) 128.8 (14.8) Diastolic blood pressure (mmHg) Mean (SD) 69.5 (8.5) 74.7 (9.8) 73.0 (9.7) Heart rate (bpm) Mean (SD) 68.4 (9.3) 73.0 (10.9) 71.5 (10.6) BMI: Body Mass Index.
Table 5: Demographics and patient characteristics at baseline - Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Age (years) Number 147 294 441 Mean (SD) 64.0 (9.4) 63.9 (8.9) 64.0 (9.1) Age group (years) [n(%)]
<65 73 (49.7) 143 (48.6) 216 (49.0) >=65 to <75 55 (37.4) 126 (42.9) 181 (41.0) >=75 19 (12.9) 25 (8.5) 44 (10.0) Gender [n(%)]
Number 147 294 441 Male 78 (53.1) 161 (54.8) 239 (54.2) Female 69 (46.9) 133 (45.2) 202 (45.8) Weight (kg) Mean (SD) 92.58 (20.80) 92.45 (18.38) 92.49 (19.20) BMI (kg/m2) Mean (SD) 32.69 (5.50) 32.55 (4.84) 32.60 (5.06) Systolic blood pressure (mmHg) Mean (SD) 132.4 (15.5) 131.7 (16.1) 131.9 (15.9) Diastolic blood pressure (mmHg) Mean (SD) 75.1 (8.2) 76.0 (9.2) 75.7 (8.8) Heart rate (bpm) Mean (SD) 72.5 (10.9) 72.8 (10.6) 72.7 (10.7) BMI: Body Mass Index.
[00331]Calculated LDL-C at baseline was higher in patients with T1DM (mean =
121.0 mg/dL, SD = 51.2) than patient with T2DM (mean = 110.4 mg/dL, SD = 37.3).
Triglycerides at baseline were lower in patients with Ti DM median (Q1: Q3) = 102.0 mg/dL
(76.5: 135.0) than in patients with T2DM median (Q1 : Q3) = 147.0 mg/dL (105.0 : 2i2.0).
Table 6: Lipid parameters at baseline - Quantitative summary in conventional units -Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab All (N=25) (N=51) (N=76) Calculated LDL-C (mg/dL) Mean (SD) 110.2 (31.2) 126.4 (58.2) 121.0 (51.2) Measured LDL-C (mg/dL) Mean (SD) 109.8 (31.4) 127.7 (58.1) 121.7 (51.1) Non-HDL-C (mg/dL) Mean (SD) 130.7 (34.2) 150.2 (62.9) 143.8 (55.6) Total Cholesterol (mg/dL) Mean (SD) 195.2 (36.0) 205.1 (65.1) 201.9 (57.1) HDL-C (mg/dL) Mean (SD) 64.4 (17.4) 54.9 (13.7) 58.1 (15.6) Triglycerides (mg/dL) Mean (SD) 100.0 (38.1) 119.1 (58.4) 112.8 (53.1) Triglycerides Rich Lipoprotein (mg/dL) Mean (SD) 20.9 (7.6) 23.7 (11.4) 22.8 (10.4) Lipoprotein-(a) (mg/dL) Mean (SD) 24.8 (29.2) 22.8 (23.0) 23.5 (25.1) Apolipoprotein B (mg/dL) Mean (SD) 87.0 (21.0) 99.7 (35.6) 95.4 (31.8) Apolipoprotein Al (mg/dL) Mean (SD) 166.3 (23.8) 152.3 (26.4) 157.0 (26.2) With respect to other lipid parameters, Ti DM patients exhibited a percentage reduction from baseline in LDL-C particle number (LS Mean) of 40.7% at week 12 and 44.4% at week 24 and percentage reduction in LDL-C particle size of 2.3% at week 12 and 2.3% at week 24.
ApoC3 was reduced in these patients by 6.9% at week 12 and 7.5% at week 24.
Table 7: Lipid parameters at baseline - Quantitative summary in conventional units -Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab All (N=147) (N=294) (N=441) Calculated LDL-C (mg/dL) Mean (SD) 109.6 (39.1) 110.8 (36.5) 110.4 (37.3) Measured LDL-C (mg/dL) Mean (SD) 110.5 (37.4) 112.1 (34.3) 111.6 (35.3) Non-HDL-C (mg/dL) Mean (SD) 144.9 (48.5) 144.7 (42.6) 144.8 (44.6) Placebo Alirocumab All (N=147) (N=294) (N=441) Total Cholesterol (mg/dL) Mean (SD) 189.9 (47.6) 190.2 (42.4) 190.1 (44.1) HDL-C (mg/dL) Mean (SD) 44.9 (13.2) 45.5 (12.5) 45.3 (12.7) Triglycerides (mg/dL) Mean (SD) 189.4 (148.2) 174.6(110.1) 179.5 (124.2) Triglycerides Rich Lipoprotein (mg/dL) Mean (SD) 34.6 (27.4) 33.2 (20.5) 33.7 (23.0) Lipoprotein-(a) (mg/dL) Mean (SD) 29.7 (37.6) 38.9 (49.6) 35.8 (46.1) Apolipoprotein B (mg/dL) Mean (SD) 96.2 (26.8) 97.0 (24.7) 96.7 (25.4) Apolipoprotein Al (mg/dL) Mean (SD) 141.7 (23.8) 141.6 (22.8) 141.6 (23.1) [00332]With respect to other lipid parameters, T2DM patients exhibited a percentage reduction from baseline in LDL-C particle number (LS Mean) of 37.6% at week 12 and 38.3% at week 24 and percentage reduction in LDL-C particle size of 2.6% at week 12 and .. 2.8% at week 24. ApoC3 was reduced in these patients by 6.3% at week 12 and 5.8% at week 24.
[00333]In patients with Ti DM, the mean durations of diabetes and of insulin use were similar between treatment groups. The mean duration of diabetes was 34.92 years (SD=12.67) and the mean duration of insulin use was 34.81 years (SD=12.77). In patients with T2DM, the mean durations of diabetes and of insulin use were similar between treatment groups. The mean duration of diabetes was 16.75 years (SD=8.13) and the mean duration of insulin use was 8.01 years (SD=6.90) in T2DM.
[00334]The duration of hypercholesterolemia was generally similar between treatment groups and between patients with Ti DM and T2DM.
[00335]The proportion of patients with statin intolerance, as was reported by the investigator, was 31.6% in patients with Ti DM and 23.8% in patients with T2DM.
[00336]The proportion of patients receiving fibrates at randomization was 2.6%
in patients with Ti DM and 8.8% in patients with T2DM.
[00337]The proportion of patients on cholesterol absorption inhibitors (including ezetimibe) at randomization was higher in the alirocumab group (13.6%) than in the placebo group (7.6%), especially in patients with T2DM: 45 patients (15.3%) versus 10 patients (6.8%).
[00338]Cardiovascular history and risk factors were generally similar between treatment groups. The following differences were observed between patients with Ti DM
and T2DM:
(1) ASCVD was more frequent in patients with T2DM than in patients with Ti DM
(40.1`)/0 versus 21.1%) with more frequent coronary heart disease (34.7% versus 15.8%) and stroke (8.2% versus 2.6%), and less frequent PAD (4.3% versus 9.2%) in T2DM versus Ti DM
patients.
(2) Among patients without ASCVD, 56.7 % of patients with Ti DM had target organ damage (microalbuminuria, macroalbuminuria) and/or CKD and/or retinopathy versus 39.4 % of patients with T2DM. Still among patients without ASCVD, the following additional cardiovascular risk factors were observed:
(a) More frequently in Ti DM than in T2DM patients: currently smoker (20.0%
versus 14.0%), pre-proliferative diabetic retinopathy (36.7% versus 12.9%) and proliferative diabetic retinopathy (20.0% versus 5.7%).
(b) Less frequently in Ti DM than in T2DM patients: Hypertension (55.0% versus 84.8%), microalbuminuria (10.0% versus 19.7%), low HDL-C (16.7% versus 28.0%).
(3) The presence of 3 or more additional CV risk factors in patients without ASCVD was observed in 45% of patients with Ti DM and 55.7% of patient with T2DM.
[00339]Overall, Ti DM and T2DM patients were treated with high and moderate intensity statins in both treatment groups with a higher proportion of patients were treated with moderate intensity statins (58.9%). Overall, 59.0 % of Ti DM and T2DM patients were only treated with statin.
Table 9: Background lipid modifying therapies at randomization Placebo Alirocumab All (N=172) (N=345) (N=517) Any statin [n (%)] 129 (75.0) 258 (74.8) 387 (74.9) Intensity of statina'c [n (%)]
Number 127 257 384 High 38 (29.5) 102 (39.5) 140 (36.2) Moderate 85 (65.9) 143 (55.4) 228 (58.9) Low 4(3.1) 12(4.7) 16(4.1) Statin alone [n (%)] 100 (58.1) 205 (59.4) 305 (59.0) Any statin in addition to other LMT [n (%)] 29 (16.9) 53 (15.4) 82 (15.9) Other LMT only (without statin) [n (%)] 11(6.4) 32 (9.3) 43 (8.3) Any LMT other than statinsb [n (%)] 40 (23.3) 85 (24.6) 125 (24.2) Fibrates 15(8.7) 26(7.5) 41(7.9) Bile acid sequestrant 0 1 (0.3) 1 (0.2) Cholesterol absorption inhibitor 13(7.6) 47 (13.6) 60 (11.6) Placebo Alirocumab All (N=172) (N=345) (N=517) Nicotinic acid and derivates 2(1.2) 3(0.9) 5(1.0) Omega 3 fatty acids >= 1000mg/day 17 (9.9) 16 (4.6) 33 (6.4) PCSK9 inhibitor 0 0 0 Nutraceuticals impacting lipids/other 4(2.3) 10(2.9) 14(2.7) No LMT (neither statins or other LMT) [n (%)] 32 (18.6) 55 (15.9) 87 (16.8) Note:
a Only for patients who are currently taking statin.
in combination with statins or not.
c High intensity statin corresponds to atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily or sinnvastatin 80nng daily.
Moderate intensity statin corresponds to atorvastatin 10 to 20 mg daily or rosuvastatin 5 to 10 mg daily or sinnvastatin 20 to 40 mg daily or pravastatin 40 to 80 mg daily or lovastatin 40 mg daily or fluvastatin 80 mg daily or pitavastatin 2 to 4 mg daily.
Low intensity statin corresponds to sinnvastatin 10 mg daily or pravastatin 10 to 20 mg daily or lovastatin 20 mg daily or fluvastatin 20 to 40 mg daily or pitavastatin 1 mg daily.
Patients receiving more than one intensity level of statin is counted in the highest intensity level.
% calculated using the number of patients randomized as denominator except for each intensity of statins where % is calculated using the number of patients on statins as denominator and for each daily dose category where % is calculated using the number of patients taking that particular statin as denominator.
[00340]The exposure of the safety population to investigational medicinal product is summarized in Table 10.
Table 10: Exposure to investigational medicinal product - Injection Placebo Alirocumab (N=170) (N=344) Duration of IMP injection exposure (weeks) Mean (SD) 23.31 (3.92) 23.16 (3.90) Duration of IMP injection exposure by category [n (%)]
>=1 day to <4 weeks 0 2 (0.6) >=4 weeks to <8 weeks 5 (2.9) 6 (1.7) >=8 weeks to <12 weeks 1 (0.6) 6 (1.7) >=12 weeks to <16 weeks 3(1.8) 7(2.0) >=16 weeks to <24 weeks 13 (7.6) 34 (9.9) >=24 weeks 148 (87.1) 289 (84.0) Number of IMP injections Mean (SD) 11.3 (2.0) 11.3 (2.1) Titration [n (%)]
Patients up-titrateda NA 77/326 (23.6) Note:
a up-titrated patients according to IVRS Week 12 transaction with at least one injection of alirocunnab 150nng afterwards. Denominator corresponding to patients with at least one injection post W12 IVRS transaction.
Patients are considered in the treatment group they actually received.
The duration of IMP injection exposure in weeks is defined as: (last IMP
injection date + 14 days - first IMP
injection date)/7, regardless of intermittent discontinuations.
EFFICACY
Primary efficacy endpoint [00341]Alirocumab was superior to placebo on percentage of change in calculated LDL-C
from baseline to Week 24 in the ITT population of patients with Ti DM and T2DM
(as shown in Tables 11 and 12, and in Figures 2 and 3). Among the Ti DM patients, the proportion of individuals achieving LDL-C <70 mg/dL (<1.8 mmol/L) was 70.2% in the alirocumab group and 5.1% in the placebo group (P<0.0001), and the proportion of individuals attaining LDL-C of <50 mg/dL (1.3 mmol/L) was 55.1`)/0 in the alirocumab group and 0% in the placebo group (P value not computable). Among the T2DM patients, the proportion of individuals achieving LDL-C <70 mg/dL (<1.8 mmol/L) was 76.4% in the alirocumab group and 7.4% in the placebo group (P<0.0001), and the proportion of individuals attaining LDL-C of <50 mg/dL (1.3 mmol/L) was 50.7% in the alirocumab group and 2.4% in the placebo group (P<0.0001). The sensitivity analysis on the primary efficacy endpoint showed similar results in both populations (data are not shown).
Table 11: Percent change in calculated LDL-C from baseline to Week 24: MMRM -Patients with Type 1 Diabetes as per IVRS
Placebo Alirocumab Calculated LDL Cholesterol (N=25) (N=49) Baseline (mmol/L) Number 25 49 Mean (SD) 2.9 (0.8) 3.2 ( 1.2) Median 2.6 3.0 Min : Max 2:5 1:7 Baseline (mg/dL) Number 25 49 Mean (SD) 110.2 (31.2) 122.5 ( 47.8) Median 100.0 114.0 Min : Max 71:180 48:273 Week 24 percent change from baseline (%) LS mean (SE) -3.9 ( 5.3) -51.8 (3.7) LS mean difference (SE) vs placebo -47.8 (6.5) 95% Cl (-60.7 to -35.0) p-value vs placebo <.0001*
Note:
Least-squares (LS) means, standard errors (SE) and p-value taken from MMRM
(mixed-effect model with repeated measures) analysis.
The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline value-by-time point interaction.
MMRM model run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
MMRM model and baseline description run on patients with a baseline value and a post-baseline value in at least one of the analysis windows used in the model.
The p-value is followed by a "' if statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I error rate at the 0.05 level.
Table 12: Percent change in calculated LDL-C from baseline to Week 24: MMRM -Patients with Type 2 Diabetes as per IVRS
Placebo Alirocumab Calculated LDL Cholesterol (N=142) (N=297) Baseline (mmol/L) Number 142 287 Mean (SD) 2.8 (1.0) 2.9 (0.9) Median 2.6 2.7 Min : Max 1:8 1:7 Baseline (mg/dL) Number 142 287 Mean (SD) 109.5 (38.7) 110.3 (35.9) Median 102.0 104.0 Min : Max 43: 309 45: 279 Week 24 percent change from baseline (%) LS mean (SE) 0.8 (2.2) -48.2 (1.6) LS mean difference (SE) vs placebo -49.0 (2.7) 95% Cl (-54.4 to -43.6) p-value vs placebo <.0001*
Note:
Least-squares (LS) means, standard errors (SE) and p-value taken from MMRM
(mixed-effect model with repeated measures) analysis.
The model includes the fixed categorical effects of treatment group, randomization strata as per IVRS, time point, and the interactions treatment group-by-time point, strata-by-time point, treatment group-by-strata and treatment group-by-strata-by-time point, as well as the continuous fixed covariates of baseline calculated LDL-C value and baseline value-by-time point interaction.
MMRM model run on all patients in the ITT population (i.e. Type 1 and Type 2 Diabetes patients).
MMRM model and baseline description run on patients with a baseline value and a post-baseline value in at least one of the analysis windows used in the model.
The p-value is followed by a "' if statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type-I error rate at the 0.05 level.
Secondary efficacy endpoints 5 [00342]Alirocumab resulted in significant reductions from baseline to Week 24 (difference versus placebo) in levels of non-HDL-C, ApoB, total cholesterol, and Lp(a), as well as increase in HDL-C in the ITT population of patients with Ti DM and T2DM (as shown in Tables 13 and 14, respectively).
Table 13: Percent change in key secondary efficacy endpoints from baseline -10 Patients with Type 1 Diabetes Selected key secondary efficacy Placebo Alirocumab Difference vs.
endpoints (N=25) (N=49) placebo, %
% change from baseline, mean (SD) [95% C/], P-value Calculated LDL-C (Week 12) -4.5 (5.0) -49.4 (3.5) -44.8 (6.1) [-56.9 to -32.8], P<0.0001 Non-HDL-C (Week 24) -3.2 (4.8) -45.9 (3.3) -42.7 (5.8) [-54.2 to -31.3], P<0.0001 Apo B (Week 24) -0.4 (4.3) -39.4 (3.0) -39.0 (5.3) [-49.4 to -28.7], P<0.0001 Total cholesterol (Week 24) -0.7 (3.6) -29.9 (2.5) -29.2 (4.3) [-37.8 to -20.7], P<0.0001 Lp(a) (Week 24) -4.3 (5.3) -23.0 (3.8) -18.7 (6.5) [-31.4 to -6.0], P<0.0001 HDL-C (Week 24)t 7.3 (3.5) 11.2 (2.4) 3.9 (4.1) [-4.2 to 12.0], P=0.343t Triglycerides (Week 24)t 1.9 (6.7) -13.6 (4.7) -15.5 (8.1) [-31.4 to 0.4], P=0.056t LDL particle numbers (Week 24) -4.4 (4.6) -44.4 (3.2) -40.0 (5.6) [-51.0 to -28.9], P<0.0001t LDL particle size (Week 24) 0.8 (0.5) -2.3 (0.3) -3.0 (0.6) [-4.2 to -1.9], P<0.0001t ApoC3 (Week 24, ITT) 1.6 (5.8) -7.4 (4.0) -9.0 [ 22.7 to 4.8]
ApoA-I (Week 24, ITT) 7.9 (2.6) 10.2 (1.8) 2.3 [ 3.8 to 8.4]
TRL-C (Week 24, ITT) -8.4 (8.1) -24.7 (5.6) -16.3 [-35.4 to 2.8]
TRL-C (Week 24, on-treatment) -4.2 (8.2) -24.3 (5.8) -20.1 [ 39.5 to 0.6]
iHierarchical testing terminated at the endpoint triglycerides in participants with T2D and at the endpoint HDL-C
in participants with Ti D, therefore all subsequent statistical comparisons were not considered statistically significant.
tP-values for descriptive purposes only.
Apo, apolipoprotein; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; non-HDL-C, non-high-density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein cholesterol; SE, standard error; SD, standard deviation.
Table 14: Percent change in key secondary efficacy endpoints from baseline -Patients with Type 2 Diabetes Selected key secondary efficacy Placebo Alirocumab Difference vs.
endpoints (N=142) (N=287) placebo, %
% change from baseline, mean (SD) [95% CU, P-value Calculated LDL-C (Week 12) 1.4 (2.1) -48.8 (1.4) -50.2 (2.5) [ 55.2 to -45.3], P<0.0001 Non-HDL-C (Week 24) 0.7 (2.0) -37.9 (1.4) -38.7 (2.4) [ 43.4 to -33.9], P<0.0001 Apo B (Week 24) 3.3 (1.7) -33.4 (1.3) -36.7 (2.1) [ 40.9 to -32.5], P<0.0001 Total cholesterol (Week 24) 0.8 (1.5) -26.8 (1.0) -27.6 (1.8) [ 31.2 to -24.1], P<0.0001 Lp(a) (Week 24) -0.5 (2.2) -19.0 (1.6) -18.4 (2.7) [ 23.7 to -13.2], P<0.0001 HDL-C (Week 24)t 3.7 (1.4) 8.1 (1.0) 4.4 (1.7) [1.1 to 7.7], P<0.01 Triglycerides (Week 24)t 0.0 (2.7) -5.7 (2.0) -5.7 (3.4) [ 12.3 to 0.9], P=0.0902t LDL particle numbers (Week 24) 1.9 (1.9) -38.3 (1.3) -40.2 (2.3) [ 44.7 to -35.6], P<0.0001t LDL particle size (Week 24) -0.3 (0.2) -2.8 (0.1) -2.5 (0.2) [ 2.9 to 2.0], P<0.0001t ApoC3 (Week 24, ITT) 4.2 (2.3) -5.8 (1.7) -10.0 [ 15.6 to 4.4]
ApoA-I (Week 24, ITT) 4.5 (1.0) 7.4 (0.7) 2.9 [0.5 to 5.4]
TRL-C (Week 24, ITT) 1.4 (3.3) -15.7 (2.3) -17.2 (4.0) [ 25.1 to -9.3]
TRL-C (Week 24, on-treatment) 2.2 (3.4) -16.4 (2.4) -18.6 [ 26.6 to 10.5]
Hierarchical testing terminated at the endpoint triglycerides in participants with T2D and at the endpoint HDL-C
in participants with Ti D, therefore all subsequent statistical comparisons were not considered statistically significant.
tP-values for descriptive purposes only.
Apo, apolipoprotein; ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; non-HDL-C, non-high-density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein cholesterol; SE, standard error; SD, standard deviation.
Diabetes-related endpoints [00343]Overall, FPG and HbA1c, and glucose lowering treatments remained stable over time in patients with Ti DM and T2DM in both treatment groups.
[00344]Regarding HbA1c, in the Ti DM cohort, in the alirocumab group the mean HbA1c %
was 7.84% (SD=0.94) at baseline with mean absolute change=-0.03% (0.6), while in the placebo group the mean HbA1c was 7.68 % (0.78) at baseline, with mean absolute change=-0.23% (0.36). In the T2DM cohort, in the alirocumab group the mean HbA1c was 7.52% (0.96) at baseline with mean absolute change=0.18% (0.74), while in the placebo group the mean HbA1c was 7.54% (1.02) at baseline with mean absolute change=0.06%
(0.66).
[00345]Regarding FPG, in the Ti DM cohort, in the alirocumab group the mean FPG was 173 mg/dL (SD=70.6) at baseline with mean absolute change=-0.03 mg/dL (0.6), while in the placebo group the mean FPG was 166.5 mg/dL (75.6) at baseline with mean absolute change=14.6 mg/dL (75.9). In the T2DM cohort, in the alirocumab group the mean FPG
was 154.1 mg/dL (50.1) at baseline with mean absolute change=9.5 mg/dL (61.8), while in the placebo group the mean FPG was 153.5 mg/dL (52.5) at baseline with mean absolute change=10.0 mg/dL (47.0).
Safety [00346]A total of 344 patients (51 Ti DM and 293 T2DM) were exposed to alirocumab and 170 patients (25 T1DM and 145 T2DM) to a placebo.
[00347]Overall, rates of patients with any treatment emergent adverse events (TEAEs) were similar across treatment groups in the safety population of patients with Ti DM or T2DM (see Table 15).
Table 15: Overview of adverse event profile: treatment emergent adverse events Placebo Alirocumab All (N=170) (N=344) (N=514) n(%) n(%) n(%) Patients with any TEAE 109 (64.1) 222 (64.5) 331 (64.4) Patients with any treatment emergent 14 (8.2) 25 (7.3) 39 (7.6) SAE
Patients with any TEAE leading to death 1 (0.6) 0 1 (0.2) Patients with any TEAE leading to 4 (2.4) 17 (4.9) 21(4.1) permanent treatment discontinuation Note:
TEAE: Treatment Emergent Adverse Event; SAE: Serious Adverse Event.
n (%) = number and percentage of patients with at least one TEAE.
[00348]TEAEs were more frequently 10%) reported in the following system organ classes (SOCs):
(a) infections and infestations (21.8% in alirocumab versus 21.8% in placebo);
(b) gastrointestinal disorders (13.1% in alirocumab versus 12.4% in placebo);
(c) musculoskeletal and connective tissue disorders (21.5% in alirocumab versus 15.9% in placebo); and (d) general disorders and administration site conditions (11.0% in alirocumab versus 8.8% in placebo) [00349]At the PT level, the most frequently reported TEAEs 2%) in the alirocumab group and with a difference 0.5% incidence from the placebo group were by decreasing order of frequency in the alirocumab group: myalgia (4.4% versus 1.8%), arthralgia (2.9% versus 1.8%), bronchitis (2.6% versus 0.6%), dizziness (2.6% versus 1.2%), and peripheral oedema (2.0% versus 0.6%). In contrast, the most frequently reported TEAEs 2%) in the placebo group and with a difference 0.5% incidence from the alirocumab group were:
influenza (2.3% versus 2.9%), pain in extremity (1.7% versus 2.9%), hypoglycemia (1.7%
versus 2.4%), cough (1.5% versus 2.9%), musculoskeletal pain (1.2% versus 2.4%), upper respiratory tract infection (0.9% versus 2.4%), hyperglycaemia (0.9% versus 2.4%), and pneumonia (0.6% versus 2.4%).
[00350]Overall, treatment emergent SAEs were reported in 25 patients (7.3%) in the alirocumab group and 14 patients (8.2%) patients in the placebo group. SAEs (at PT level) reported in more than 1 patient in either treatment groups were pneumonia (in 1 patient (0.3%) in the alirocumab group versus 2 patients (1.2%) in the placebo group), vertebral foramina! stenosis (in 2 patients (0.6%) in the alirocumab group versus no patients in the placebo group), and urinary tract infection (in 2 patients (0.6%) versus no patients in placebo group). One death due to myocardial infarction was reported in a T2DM
patient of the placebo group, 1 month after the first IMP dose administration (Visit 3).
Overall, 17 patients (4.9%) in the alirocumab group and 4 patients (2.4%) in the placebo group experienced TEAEs leading to permanent treatment discontinuation. At the PT
level, the proportion of patients with TEAE leading to permanent treatment discontinuation in more than one patient of a treatment group were: headache (2 patients (0.6%) in the alirocumab group versus no patient in the placebo group), cognitive disorder (in 2 patients (0.6%) versus no patient), allergic dermatitis (2 patients (0.6%) versus no patient) and myalgia (3 patients (0.9%) versus 2 patient (1.2%)).
[00351]As to adverse events of special Interest (AESI), increase in ALT
meeting AESI
criteria were defined as ALT n x ULN (if baseline ALT <ULN) or ALT times the baseline value (if baseline ALT l.11_N). These events were reported in 2 patients (0.6%) in the alirocumab group versus 1 patient (0.6%) in the placebo group.
[00352]Allergic drug reactions meeting AESI criteria were defined as allergic events that require consultation with another physician for further evaluation. These events were reported in 5 patients (1.5%) in the alirocumab group versus 4 patients (2.4%) in the placebo group. These reactions were mainly skin and subcutaneous tissue disorders, reported in 3 patients (0.9%) in the alirocumab group (1 allergic dermatitis,1 eczema, and 1 photosensitivity reaction) and in 2 patients (1.2%) in the placebo group (1 dermatitis, 1 drug eruption). The two other AESI allergic drug reactions in the alirocumab group were drug hypersensitivity and eosinophilia.
[00353]Neurologic events meeting AESI criteria were defined as neurologic events that require additional examinations/procedures and/or referral to a specialist.
Such events were reported in 1 patient (0.3%) in the alirocumab group (paraesthesia) versus 1 patient (0.6%) in the placebo group (dysphagia). Both events were reported in T2DM
patients.
[00354]All neurocognitive events were considered as AESI. Neurocognitive events as per sponsor or FDA grouping were reported in 4 patients (1.2%) in the alirocumab group versus no patients in the placebo group. All events were reported in T2DM patients: a cognitive disorder was reported in 2 patients (0.6%), and memory impairment and amnesia in 1 patient (0.3%) each. Of note, the 2 cognitive disorders also led to permanent treatment discontinuation.
[00355]Local injection site reactions meeting AESI criteria were defined as either local injection site reactions that were allergic and required consultation with another physician or 5 local injection site reactions that were non-allergic that were clinically significant (e.g.
reaction of swelling or erythema with a diameter >2.5 cm; reaction that interferes with activity). LISR confirmed per investigator as related to IMP (per eCRF') were reported in 6 patients (1.7%) in the alirocumab group versus 8 patients (4.7%) in the placebo group (injection site reaction of the placebo for alirocumab). No local injection site reactions 10 (LISR) meeting AESI criteria, defined as reactions that require consultation with another physician for further evaluation, were reported.
[00356]There was no report of symptomatic overdose or pregnancy.
[00357]Analyses of liver function tests (ALT, AST, ALP, total bilirubin), CPK
and renal function tests (creatinine, eGFR, BUN) did not reveal differences between the treatment 15 groups in the changes over time for any of the studied parameters. PCSA
analyses did not identify PCSA of ALT increase in any treatment groups during the study. In patients with normal CPK values at baseline, an increase > 3 ULN (and 10 ULN) was reported in 7 patients (2.1%) in the alirocumab group versus 1 patient (0.6%) in the placebo group. All patients were with T2DM. No CPK increase > 10 ULN was reported.
20 [00358]Numerical, minor differences were observed in the proportions of patients with mild, moderate, or severe decrease in glomerular filtration rate (GFR) during the treatment period, regardless of the baseline status: mild, moderate and severe decreases in GFR in 49.7%, 28.1% and 3.8% of patients, respectively in the alirocumab group, and in 50.6%, 24.4% and 3.6% of patients, respectively in the placebo group. Similarly, blood creatinine 25 increases (30% and < 100%) were measured in 13 (3.8%) patients in the alirocumab group versus 5 patients (3.0%) in the placebo group. No patient had increase in blood creatinine >= 100%. There was no meaningful difference in renal function.
[00359]No meaningful differences for vital signs were observed between treatment groups.
Example 3: Analysis of Individuals with Type 2 Diabetes Mellitus and ASCVD
from 30 Odyssey DM-Insulin Clinical Trial [00360]Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and low-density lipoprotein particle number (LDL-PN). Presence of atherosclerotic cardiovascular disease 35 -- (ASCVD) increases the risk of future cardiovascular events.
[00361]In this analysis, we evaluated the efficacy and safety of alirocumab among individuals with T2DM, high LDL-C, or non-HDL-C, and established ASCVD
receiving maximally tolerated statin in the DM-Insulin study. DM-Insulin study participants with ASCVD and Ti DM were not included in this analysis due to the low number of individuals in this group (alirocumab: n=11; placebo: n=5). As used in this Example, ASCVD
was defined as coronary heart disease (CHD; acute and silent myocardial infarction (MI), and unstable angina), ischemic stroke, or peripheral arterial disease.
[00362]Baseline and efficacy data were analyzed according to studies. Efficacy analysis included Week 24 percentage reduction from baseline in non-HDL-C, LDL-C, ApoB, and LDL-PN, and percentage of individuals achieving non-HDL-C <100 mg/dL (<2.59 mmol/L), LDL-C < 70 mg/dL (<1.81 mmol/L), and ApoB <80 mg/dL at Week 24. Intention-to-treat (ITT) analysis included all randomized individuals with a baseline LDL-C value and at least one LDL-C value up to Week 24.
[00363]This analysis included 177 DM-Insulin individuals with established ASCVD and T2DM (Table 16).
Table 16: Baseline characteristics (randomized population) Alirocumab Placebo n=119) (n=58) Age, years, mean (SD) 66.2 (8.7) 64.9 (8.9) Gender, male, n (%) 79 (66.4) 32 (55.2) BMI, kg/m2, mean (SD) 32.6 (4.5) 33.4 (5.8) CHD, n (%) 102 (85.7) Si (87.9) Acute MI 59 (49.6) 18 (31.0) Silent MI 4 (3.4) 4 (6.9) Unstable angina 15 (12.6) 4 (6.9) Coronary revascularization 80 (67.2) 37 (63.8) procedure Other clinical significant CHDt 31 (26.1) 15 (25.9) Ischemic stroke, n (%) 27 (22.7) 9 (15.5) PAD, n (%) 13 (10.9) 6 (10.3) HTN,* n (%) 105 (88.2) 53 (91.4) CKD, n (%) 37 (31.1) i3(22.4) Diabetes target organ damage," n (%) 60 (50.4) 28 (48.3) Statin, n (%) 88 (73.9) 39 (67.2) Any LLT other than statin, n (%) 34 (28.6) 11 (19.0) HbA1c, %, mean (SD) 7.5 (0.9) 7.4 (1.0) FPG, mg/dL [mmol/L], mean (SD) 162.6 (52.5) 146.7 (45.2) [9.0 (2.9)] [8.1 (2.5)]
Alirocumab Placebo n=119) (n=58) Insulin, n (%) 119 (100) 57 (98.3)1 Non-insulin GLT, n (%) Biguanides 57 (47.9) 33 (56.9) Sulfonylureas 11(9.2) 7(12.1) DPP-4 inhibitor 21 (17.6) 7 (12.1) GLP-1 receptor agonist 11(9.2) 8(13.8) SGLT2 inhibitor 10(8.4) 11 (19.0) Lipids, mg/dL [mmol/L], mean (SD) Non-HDL-C 142.8 (41.5) 147.0 (54.9) [3.70 (1.08)] [3.81 (1.42)]
LDL-C 107.2 (35.1) 111.9 (46.4) [2.78 (0.91)] [2.90 (1.20)]
ApoB 96.4 (25.1) 98.7 (32.0) LDL-PN, nmol/L, mean (SD) 1339.5 (408.5) 1425.0 (467.9) # _________________________________________________________________ tDiagnosis by invasive/non-invasive testing. Includes patients with established HTN on anti-HTN medication. Defined as estimated glomerular filtration rate 15-60 mL/min/1.73 m2.
"Defined as microalbuminuria, macroalbuminuria, retinopathy, and/or CKD. lOne individual in the placebo group was not receiving insulin at the time of randomization, and remained without insulin treatment for the duration of the study.
BMI, body mass index; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like petite 1; GLT, glucose-lowering treatment; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HTN, hypertension; SGLT2, sodium/glucose contransporter 2.
[00364]Regardless of treatment allocation, 89.3% of individuals analyzed had a history of hypertension, and 28.2% had chronic kidney disease (CKD), on top of ASCVD. In total, 20.3% demonstrated a history of ischemic stroke, and 10.7% had peripheral arterial -- disease (PAD). At baseline, the mean (standard deviation [SD]) non-HDL-C
level was 144.2 (46.2) mg/dL [3.73 (1.20) mmol/L]; the mean LDL-C level was 108.7 (39.1) mg/dL
[2.82 (1.01) mmol/L], regardless of treatment allocation.
Efficacy [00365]Alirocumab reduced non-HDL-C, ApoB, LDL-PN, and LDL-C from baseline at Week -- 24 versus control (Figure 4). At Week 24, a significantly greater proportion of individuals achieved non-HDL-C <100 mg/dL (<2.59 mmol/L), LDL-C <70 mg/dL (< 1.81 mmol/L), and ApoB < 80 mg/dL versus control (all P<0.0001; Figure 5).
Safety [00366]The safety analysis was conducted in a pooled population of individuals with T2DM, -- high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in the DM-Insulin study, and individuals with Ti DM or T2DM, high LDL-C or non-HDL-C, and established ASCVD receiving maximally tolerated statin in the DM-Dyslipidemia study (see Chan et al. (2017) Ann Trans! Med. 5(23):477, which is incorporated by reference herein in its entirety). In total, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment-emergent adverse events (TEAEs; Table 17). The adverse event pattern was similar in both groups. Mean (SD) levels of HbA1c were similar in each treatment group at baseline (alirocumab: 7.3 [0.9]%; control: 7.3 [0.9]%) and Week 24 (alirocumab: 7.6 [1.2]%;
control: 7.5 [1.2]%; safety analysis). FPG levels were also similar regardless of treatment allocation at baseline (alirocumab: 154.2 [47.9] mg/dL, 8.6 [2.7] mmol/L;
control: 149.5 [43.7] mg/dL, 8.3 [2.4] mmol/L) and at Week 24 (alirocumab: 164.7 [54.9]
mg/dL, 9.1 [3.0]
mmol/L; control: 159.4 [48.4] mg/dL, 8.9 [2.7] mmol/L; safety analysis).
Table 17: Safety summary Alrocumab Control n (%) (n=213) (n=104) TEAEs 142 (66.7) 70 (67.3) Treatment-emergent SAEs 28 (13.1) 10 (9.6) TEAEs leading to death 1 (0.5) 1 (1.0) TEAEs leading to permanent treatment 13 (6.1) 2 (2.3) discontinuation TEAEs occurring in >2% of individuals by preferred term Urinary tract infection 8 (3.8) 6 (5.8) Diarrhea 8 (3.8) 6 (5.8) Nasopharyngitis 6 (2.8) 5 (4.8) Influenza 7 (3.3) 4 (3.8) Hypertension 8 (3.8) 4 (3.8) Headache 7(3.3) 1 (1.0) Musculoskeletal pain 7(3.3) 3 (2.9) Arthralgia 3(i.4) 3(2.9) Bronchitis 3 (1.4) 3(2.9) Cough 1 (0.5) 3 (2.9) Fatigue 5 (2.3) 3 (2.9) Hyperglycaemia 0 (0.0) 3 (2.9) Hypotension 2 (0.9) 3 (2.9) Nausea 4 (1.9) 3 (2.9) Pain in extremity 4(1.9) 3(2.9) Back pain 6(2.8) 2(1.9) Dizziness 6 (2.8) 3 (2.9) Cataract 5(2.3) 1(1.0) Myalgia 5(2.3) 1(1.0) SAE, serious adverse event.
Conclusions [00367]Among individuals with T2DM and ASCVD who had high LDL-C levels despite maximally tolerated statins, alirocumab significantly reduced atherogenic cholesterol content and LDL-PN versus control.
Claims (86)
1. A method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
2. The method of claim 1, wherein the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
3. The method of claim 1, wherein the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
4. The method of claim 1, wherein the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
5. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
6. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
7. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab and LY3015014.
8. The method of claim 7, wherein the antibody or antigen-binding fragment thereof is alirocumab.
9. The method of any one of the preceding claims, further comprising:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
10. The method of any one of the preceding claims, further comprising:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
11. The method of claim 9 or 10, wherein the threshold level is 70 mg/dL.
12. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously.
13. The method of any one of the preceding claims, wherein the patient further receives a concomitant lipid-modifying therapy (LMT).
14. The method of claim 13, wherein the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
15. The method of claim 14, wherein the LMT is a statin therapy.
16. The method of claim 15, wherein the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
17. The method of any one of claims 14-16, wherein the statin therapy is a maximally tolerated statin therapy.
18. The method of claim 14, wherein the cholesterol absorption inhibitor is ezetimibe.
19. The method of any one of claims 1-14 and 18, wherein the patient is intolerant to a statin.
20. The method any one of the previous claims, wherein the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
21. The method of any one of the preceding claims, wherein the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
22. The method of claim 21, where the additional concomitant anti-diabetic therapy is selected from the group consisting of a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a GPR142 agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol O-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
23. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 40%.
24. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 35%.
25. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof reduces the apolipoprotein C3 (ApoC3) level of the patient.
26. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
27. The method of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
(a) does not affect the hemoglobin Al c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
28. A method for treating hypercholesterolemia in a patient with type 1 diabetes mellitus (T1DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T1DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
29. A method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
30. The method of claim 29, wherein the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
31. The method of claim 29, wherein the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
32. The method of claim 29, wherein the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
33. The method of any one of claims 29-32, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
34. The method of any one of claims 29-33, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
35. The method of any one of claims 29-32, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
36. The method of claim 35, wherein the antibody or antigen-binding fragment thereof is alirocumab.
37. The method of any one of claims 29-36, further comprising:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
38. The method of any one of claims 29-36, further comprising:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
39. The method of claim 37 or 38, wherein the threshold level is 70 mg/dL.
40. The method of any one of claims 29-39, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously.
41. The method of any one of claims 29-40, wherein the patient further receives a concomitant lipid-modifying therapy (LMT).
42. The method of claim 41, wherein the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
43. The method of claim 42, wherein the LMT is a statin therapy.
44. The method of claim 43, wherein the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
45. The method of any one of claims 42-44, wherein the statin therapy is a maximally tolerated dose statin therapy.
46. The method of claim 42, wherein the cholesterol absorption inhibitor is ezetimibe.
47. The method of any one of claims 29-42 and 46, wherein the patient is intolerant to a statin.
48. The method any one of claims 29-47, wherein the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
49. The method of any one of claims 29-48, wherein the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
50. The method of claim 49, where the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol O-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
51. The method of any one of claims 29-50, wherein the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 40%.
52. The method of any one of claims 29-51, wherein the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 35%.
53. The method of any one of claims 29-52, wherein the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
54. he method of any one of claims 29-53, wherein the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
55. The method of any one of claims 29-54, wherein the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
(a) does not affect the hemoglobin A1c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
56. A method for treating hypercholesterolemia in a patient with type 2 diabetes mellitus (T2DM), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, and (ii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
57. A method for treating hypercholesterolemia in a patient with T2DM and atherosclerotic cardiovascular disease (ASCVD), the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy; and (b) administering to the patient 75 mg, 150 mg or 300mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the patient receives a concomitant insulin therapy.
58. The method of claim 56, wherein the ASCVD is defined as coronary heart disease (CHD), ischemic stroke, or peripheral arterial disease.
59. The method of claim 58, wherein the CHD comprises acute myocardial infarction, silent myocardial infarction, and unstable angina.
60. The method of any one of claims 57-59, wherein the 75 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
61. The method of any one of claims 57-59, wherein the 150 mg of the antibody or antigen binding fragment is administered to the patient every two weeks.
62. The method of any one of claims 57-59, wherein the 300 mg of the antibody or antigen binding fragment is administered to the patient every four weeks.
63. The method of any one of claims 57-62, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs:
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
2, 3, and 4, and the three light chain CDRs set forth in SEQ ID NOs: 7, 8, and 10.
64. The method of any one of claims 57-63, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 6.
65. The method of any one of claims 57-62, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of alirocumab, evolocumab, bococizumab, lodelcizumab, ralpancizumab, and LY3015014.
66. The method of claim 65 wherein the antibody or antigen-binding fragment thereof is alirocumab.
67. The method of any one of claims 57-66, further comprising:
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than the threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
68. The method of any one of claims 57-66, further comprising:
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
(c) administering to the patient one or more following doses of 300 mg of the antibody or antigen-binding fragment thereof about every four weeks if the LDL-C level in the patient is lower than a threshold level, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to the threshold level.
69. The method of claim 67 or 68, wherein the threshold level is 70 mg/dL.
70. The method of any one of claims 57-69, wherein the antibody or antigen-binding fragment thereof is administered subcutaneously.
71. The method of any one of claims 57-70, wherein the patient further receives a concomitant lipid-modifying therapy (LMT).
72. The method of claim 71, wherein the LMT is selected from the group consisting of a statin, a cholesterol absorption inhibitor, a fibrate, niacin, an omega-3 fatty acid, and a bile acid sequestrant.
73. The method of claim 72, wherein the LMT is a statin therapy.
74. The method of claim 73, wherein the statin is selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin, and cerivastatin.
75. The method of any one of claims 72-74, wherein the statin therapy is a maximally tolerated dose statin therapy.
76. The method of claim 72, wherein the cholesterol absorption inhibitor is ezetimibe.
77. The method of any one of claims 57-72 and 76, wherein the patient is intolerant to a statin.
78. The method any one of claims 57-77, wherein the insulin therapy is selected from the group consisting of human insulin, Insulin glargine, insulin glulisine, insulin detemir, insulin lispro, insulin degludec, insulin aspart, and basal insulin.
79. The method of any one of claims 57-78, wherein the patient receives a concomitant anti-diabetic therapy in addition to insulin therapy.
80. The method of claim 79, where the additional anti-diabetic therapy is selected from the group consisting of an a glucagon like peptide 1 (GLP-1) therapy, a gastrointestinal peptide, a glucagon receptor agonist or antagonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist or antagonist, a ghrelin antagonist or inverse agonist, xenin, a xenin analogue, a biguanide, a sulfonylurea, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an alpha-glucosidase inhibitor, a sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, an SGLT-1 inhibitor, a peroxisome proliferator-activated receptor (PPAR-)(alpha, gamma or alpha/gamma) agonist or modulator, amylin, an amylin analogue, a G-protein coupled receptor 119 (GPR119) agonist, a GPR40 agonist, a GPR120 agonist, a agonist, a systemic or low-absorbable TGR5 agonist, a diabetes immunotherapeutic, an anti-inflammatory agents for the treatment of the metabolic syndrome and diabetes, an adenosine monophosphate-activated protein kinase (AMPK) stimulant, an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1, an activator of glucokinase, an inhibitor of diacylglycerol O-acyltransferase (DGAT), a modulator of glucose transporter-4, a somatostatin receptor 3 agonist, a lipid lowering agent, and a combination thereof.
81. The method of any one of claims 57-80, wherein the antibody or antigen-binding fragment thereof reduces the LDL-C level of the patient by at least 40%.
82. The method of any one of claims 57-81, wherein the antibody or antigen-binding fragment thereof reduces the non-HDL-C level of the patient by at least 35%.
83. The method of any one of claims 57-82, wherein the antibody or antigen-binding fragment thereof reduces the ApoC3 level of the patient.
84. The method of any one of claims 57-83, wherein the antibody or antigen-binding fragment thereof reduces the number and/or size of lipoprotein particles in the patient.
85. The method of any one of claims 57-84, wherein the antibody or antigen-binding fragment thereof:
(a) does not affect the hemoglobin Al c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
(a) does not affect the hemoglobin Al c (HbA1c) level of the patient; and/or (b) does not affect the fasting plasma glucose (FPG) level of the patient.
86. A method for treating hypercholesterolemia in a patient with T2DM and ASCVD, the method comprising:
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
(a) selecting a high cardiovascular risk patient receiving insulin therapy that has (i) T2DM, (ii) ASCVD, and (iii) hypercholesterolemia not adequately controlled by maximally tolerated statin therapy;
(b) administering every two weeks to the patient 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (PCSK9); and (c) administering to the patient one or more following doses of 75 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is lower than 70 mg/dL, or administering one or more following doses of 150 mg of the antibody or antigen-binding fragment thereof about every two weeks if the LDL-C level in the patient is greater than or equal to 70 mg/dL, wherein the antibody or antigen-binding fragment thereof comprises an HCVR
having the amino acid sequence of SEQ ID NO: 1 and an LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the patient receives a concomitant insulin therapy.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762517672P | 2017-06-09 | 2017-06-09 | |
US62/517,672 | 2017-06-09 | ||
US201762532162P | 2017-07-13 | 2017-07-13 | |
US62/532,162 | 2017-07-13 | ||
EP18305565.6 | 2018-05-04 | ||
EP18305565 | 2018-05-04 | ||
PCT/IB2018/054182 WO2018225041A1 (en) | 2017-06-09 | 2018-06-09 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3066317A1 true CA3066317A1 (en) | 2018-12-13 |
Family
ID=62815099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3066317A Pending CA3066317A1 (en) | 2017-06-09 | 2018-06-09 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3634469A1 (en) |
JP (2) | JP2020522544A (en) |
KR (1) | KR20200026826A (en) |
CN (1) | CN110913889A (en) |
AU (1) | AU2018280567A1 (en) |
CA (1) | CA3066317A1 (en) |
IL (2) | IL271212B1 (en) |
MX (1) | MX2019014831A (en) |
TW (2) | TW202310872A (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2604139C2 (en) | 2011-01-28 | 2016-12-10 | Санофи Байотекнолоджи | Pharmaceutical compositions containing antibodies to human pcsk9 |
AR087305A1 (en) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
CN113876956B (en) * | 2020-07-01 | 2023-07-04 | 陈敏 | Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation |
CN114525258A (en) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application |
WO2023051822A1 (en) * | 2021-09-30 | 2023-04-06 | 北京安龙生物医药有限公司 | Targeting oligonucleotide for treating diseases associated with pcsk9 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3672B1 (en) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
US20150283236A1 (en) * | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
CN107106678A (en) * | 2014-07-16 | 2017-08-29 | 赛诺菲生物技术公司 | Method for treating the high cardiovascular risk patient with hypercholesterolemia |
EP3677277A1 (en) * | 2014-07-16 | 2020-07-08 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
CA2995645A1 (en) * | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
-
2018
- 2018-06-08 TW TW111142924A patent/TW202310872A/en unknown
- 2018-06-08 TW TW107119851A patent/TW201904608A/en unknown
- 2018-06-09 IL IL271212A patent/IL271212B1/en unknown
- 2018-06-09 EP EP18737034.1A patent/EP3634469A1/en not_active Withdrawn
- 2018-06-09 CA CA3066317A patent/CA3066317A1/en active Pending
- 2018-06-09 JP JP2019567608A patent/JP2020522544A/en active Pending
- 2018-06-09 IL IL314423A patent/IL314423A/en unknown
- 2018-06-09 AU AU2018280567A patent/AU2018280567A1/en active Pending
- 2018-06-09 CN CN201880037888.2A patent/CN110913889A/en not_active Withdrawn
- 2018-06-09 KR KR1020197038159A patent/KR20200026826A/en not_active IP Right Cessation
- 2018-06-09 MX MX2019014831A patent/MX2019014831A/en unknown
-
2023
- 2023-07-07 JP JP2023111915A patent/JP2023123842A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019144346A3 (en) | 2021-10-13 |
TW202310872A (en) | 2023-03-16 |
IL314423A (en) | 2024-09-01 |
KR20200026826A (en) | 2020-03-11 |
JP2020522544A (en) | 2020-07-30 |
IL271212B1 (en) | 2024-08-01 |
MX2019014831A (en) | 2020-02-13 |
RU2019144346A (en) | 2021-07-09 |
AU2018280567A1 (en) | 2020-01-23 |
CN110913889A (en) | 2020-03-24 |
TW201904608A (en) | 2019-02-01 |
IL271212A (en) | 2020-01-30 |
EP3634469A1 (en) | 2020-04-15 |
JP2023123842A (en) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190031774A1 (en) | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor | |
CA3066317A1 (en) | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor | |
AU2020203636B2 (en) | Use of a PCSK9 inhibitor to treat hyperlipidemia | |
JP7141333B2 (en) | Anti-ANGPTL8 antibody and uses thereof | |
JP2022169718A (en) | Methods for preventing or treating allergy by administering an il-4r antagonist | |
KR102482375B1 (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
CA2912101A1 (en) | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations | |
US12090193B2 (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
RU2772712C2 (en) | Methods for treatment of hyperlipidemia in patients with diabetes by injection of pcsk9 inhibitor | |
IL271456A (en) | Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220917 |
|
EEER | Examination request |
Effective date: 20220917 |
|
EEER | Examination request |
Effective date: 20220917 |
|
EEER | Examination request |
Effective date: 20220917 |
|
EEER | Examination request |
Effective date: 20220917 |